

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1p_wp050, Report 1 of 4

Request ID: cder_mpl1p_wp050_cnodes_v02

Request Description: We estimated the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time in the Sentinel Distributed Database (SDD), Canadian Network for Observational Drug Effect Studies (CNODES), Clinical Practice Research Datalink (CPRD), and Danish National Prescription Registry (DNPR). This report only includes the data obtained from CNODES.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, version 10.1.1, with custom programming

Data Source: We distributed this query to CNODES on January 28, 2022. The study period included data from January 1, 2014 through December 31, 2020. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We defined two cohorts—incident and prevalent—to estimate the proportion of ARB utilization over time. For the incident cohort, we identified individuals over 18 years of age with incident use of six ARB products (candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan) and required no use of any ARBs (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan or valsartan) in the 183 days prior to index date (first dispensing date of each ARB). We followed these patients on their exposed time until any of the censoring criteria were met. Using these counts, we estimated the proportion of ARB utilization by age group, monthly and quarterly periods, which is defined as the number of episodes for each individual ARB divided by all ARB episodes occurring during the same month or quarter.

For the prevalent cohort, we identified individuals over 18 years of age with prevalent use of the six ARBs and estimated the proportion of ARB utilization by age group, monthly, and quarterly periods as described above.

To examine the proportion of switching for patients from any of the six primary ARBs to another ARB, angiotensin-converting-enzyme inhibitors (ACEi) or calcium channel blockers (CCB), we first identified the incident and prevalent cohorts for the six ARBs as described above. Then, we defined a switch as a dispensing for another ARB, ACEi, or CCB while the patients were exposed to the index ARB episode (six ARB products).

We estimated proportion of quarterly switching, which is defined as the number of ARB episodes that resulted in a switch from the index ARB to another ARB, ACEi, or CCB, divided by the total number of all ARB index episodes during a given quarter. We also estimated proportion of total switches for each index ARB defined as total switches for each index ARB to another ARB, ACEi, or CCB, divided by the total number of switches for all index ARBs.

For monthly and quarterly assessment, the episodes that cross multiple months or quarters were counted in the relevant month and quarter and the proportions for ARB utilization and switching were calculated using custom programming.

This is a Type 2 analysis using the multiple events Type 2 add-on functionality in the Query Request Package (QRP) documentation. This is report 1 of 3 and contains results for incident and prevalent ARB proportions and switching over time.

Exposures of Interest: For the incident and prevalent cohorts, we captured first qualifying dispensings (index date) of the exposures of interest (candesartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, or any of the above ARBs) using outpatient dispensing data and Drug Identification Numbers (DINs) within CNODES. Cohort re-entry was allowed.

Please see Appendix B for a list of generic and brand names used to define ARBs in this request.

Overview for Request: cder_mpl1p_wp050, Report 1 of 4

Cohort Eligibility Criteria: For both incident and prevalent-cohorts, we required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort. A gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-44, 45-64, and 65+ years. The following sex groups were included in the cohort: male and female.

For the incident cohorts, we excluded patients who were exposed to any of the eight ARBs in the 183 days prior to index date. Additionally, we created prevalent cohorts that did not have this washout requirement.

Follow-up Time: For the incident and prevalent cohorts, we created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 30 days apart and added 30 days to the end of each episode. If dispensings overlapped, we allowed for a maximum of 33% overlap of the previous dispensing's days supply before truncating the previous dispensing's days' supply at the next dispensing date. If there is less than 33% overlap in the dispensings, then the next dispensing date is pushed forward to the end of the previous dispensing.

Follow-up begins on the day of the index dispensing and continues until the first occurrence of any of the following: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; or 4) product discontinuation.

Switching Definitions: Switching is defined using the multiple events Type 2 add-on feature in the QRP, where a "switch" is said to have occurred if a dispensing for the switch product occurs during the length of the incident or prevalent cohorts exposure episodes. The following switches are considered in this request.

For each individual index ARB exposure (candesartan, irbesartan, losartan, olmesartan, telmisartan or valsartan), we evaluated switching from these to each of the following: 1) individual non-index ARBs (six for each ARB); 2) any of the six non-index ARBs; 3) non-combination ACEi drugs; 4) non-combination CCB drugs; and 5) ACEi or CCBs.

Counts for switches to or from azilsartan or eprosartan dispensings were not included in this request due to small cell count. Likewise, switches to ACEi/CCB combination drugs only were not included in this request.

We also obtained counts for exposure to all ARB (azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan) for use as a denominator for proportion calculation.

Please see Appendix B for a list of generic and brand names used to define ARBs in this request. Please see Appendix C for a list of generic and brand names used to define ACEi, CCB, and ACEi/CCB combination drugs.

Baseline Characteristics: We assessed the following characteristics in the 183 days prior to and including the index date of the incident or prevalent cohort index dates: age, calendar year, sex, angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, and stroke. These conditions are defined in any care setting and position using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) diagnosis codes. Please see Appendix D for a list of diagnosis codes used to define baseline characteristics in this request.

Overview for Request: cder_mpl1p_wp050, Report 1 of 4

Please see Appendix E and F for the parameter specifications used in the analyses.

Limitations: Algorithms used to define exposure criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary</u>	Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module
<u>Table 1a</u>	Aggregated Baseline Table for Members Dispensed Any Incident Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and December 31, 2020
<u>Table 1b</u>	Aggregated Baseline Table for Members Dispensed Incident Candesartan between January 1, 2014 and December 31, 2020
<u>Table 1c</u>	Aggregated Baseline Table for Members Dispensed Incident Irbesartan between January 1, 2014 and December 31, 2020
<u>Table 1d</u>	Aggregated Baseline Table for Members Dispensed Incident Losartan between January 1, 2014 and December 31, 2020
<u>Table 1e</u>	Aggregated Baseline Table for Members Dispensed Incident Olmesartan between January 1, 2014 and December 31, 2020
<u>Table 1f</u>	Aggregated Baseline Table for Members Dispensed Incident Telmisartan between January 1, 2014 and December 31, 2020
<u>Table 1g</u>	Aggregated Baseline Table for Members Dispensed Incident Valsartan between January 1, 2014 and December 31, 2020
<u>Table 1h</u>	Aggregated Baseline Table for Members Dispensed Any Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and December 31, 2020
<u>Table 1i</u>	Aggregated Baseline Table for Members Dispensed Prevalent Candesartan between January 1, 2014 and December 31, 2020
<u>Table 1j</u>	Aggregated Baseline Table for Members Dispensed Prevalent Irbesartan between January 1, 2014 and December 31, 2020
<u>Table 1k</u>	Aggregated Baseline Table for Members Dispensed Prevalent Losartan between January 1, 2014 and December 31, 2020
<u>Table 1l</u>	Aggregated Baseline Table for Members Dispensed Prevalent Olmesartan between January 1, 2014 and December 31, 2020
<u>Table 1m</u>	Aggregated Baseline Table for Members Dispensed Prevalent Telmisartan between January 1, 2014 and December 31, 2020
<u>Table 1n</u>	Aggregated Baseline Table for Members Dispensed Prevalent Valsartan between January 1, 2014 and December 31, 2020
<u>Table 2a</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, Overall
<u>Table 2b</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Age Group
<u>Table 2c</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month
<u>Table 2d</u>	Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter
<u>Table 2e</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, Overall

Table of Contents

<u>Table 2f</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Age Group
<u>Table 2g</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month
<u>Table 2h</u>	Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter
<u>Table 3a</u>	Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter (Switching per 1,000 ARB Episodes)
<u>Table 3b</u>	Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter (Switching per 1,000 ARB Episodes)
<u>Table 4a</u>	Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter (Switching per 1,000 ARB Switches)
<u>Table 4b</u>	Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter (Switching per 1,000 ARB Switches)
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 28, 2022)
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request
<u>Appendix C</u>	List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request
<u>Appendix D</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request
<u>Appendix E</u>	Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)
<u>Appendix F</u>	Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Table for Members Dispensed Any Incident Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and December 31, 2020

Characteristic¹	Number	
Number of episodes	536,190	
Number of unique patients	472,599	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.6	11.1
Age	Number	Percent
18-44 years	25,107	4.7%
45-64 years	95,071	17.7%
More than 65 years	416,012	77.6%
Sex		
Female	254,597	53.9%
Male	218,002	46.1%
Race (Unknown)	472,599	100.0%
Year		
2014	68,675	12.8%
2015	66,771	12.5%
2016	70,887	13.2%
2017	76,829	14.3%
2018	85,920	16.0%
2019	90,670	16.9%
2020	76,438	14.3%
Recorded History of:		
Angina	27,708	5.2%
Atrial fibrillation	39,716	7.4%
Diabetes	132,042	24.6%
Heart failure	35,495	6.6%
Hyperlipidemia	29,104	5.4%
Hypertension	294,115	54.9%
Myocardial infarction	11,331	2.1%
Renal disorders	34,126	6.4%
Stroke	13,719	2.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1b. Aggregated Baseline Table for Members Dispensed Incident Candesartan between January 1, 2014 and December 31, 2020

Characteristic	Number	
Number of episodes	144,870	
Number of unique patients	134,250	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.1	11.5
	Number	Percent
Age		
18-44 years	6,587	4.5%
45-64 years	23,733	16.4%
More than 65 years	114,550	79.1%
Sex		
Female	74,477	55.5%
Male	59,773	44.5%
Race (Unknown)	134,250	100.0%
Year		
2014	13,572	9.4%
2015	13,635	9.4%
2016	14,609	10.1%
2017	15,605	10.8%
2018	22,322	15.4%
2019	32,855	22.7%
2020	32,272	22.3%
Recorded History of:		
Angina	9,256	6.4%
Atrial fibrillation	12,524	8.6%
Diabetes	35,714	24.7%
Heart failure	10,333	7.1%
Hyperlipidemia	8,217	5.7%
Hypertension	77,364	53.4%
Myocardial infarction	4,034	2.8%
Renal disorders	11,330	7.8%
Stroke	4,198	2.9%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1c. Aggregated Baseline Table for Members Dispensed Incident Irbesartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	73,135	
Number of unique patients	66,098	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.3	11.4
Age	Number	Percent
18-44 years	4,086	5.6%
45-64 years	15,774	21.6%
More than 65 years	53,275	72.8%
Sex		
Female	35,795	54.2%
Male	30,303	45.8%
Race (Unknown)	66,098	100.0%
Year		
2014	9,832	13.4%
2015	9,363	12.8%
2016	9,406	12.9%
2017	9,641	13.2%
2018	11,045	15.1%
2019	12,446	17.0%
2020	11,402	15.6%
Recorded History of:		
Angina	2,668	3.6%
Atrial fibrillation	3,729	5.1%
Diabetes	19,011	26.0%
Heart failure	2,749	3.8%
Hyperlipidemia	3,261	4.5%
Hypertension	39,631	54.2%
Myocardial infarction	1,002	1.4%
Renal disorders	5,952	8.1%
Stroke	1,759	2.4%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1d. Aggregated Baseline Table for Members Dispensed Incident Losartan between January 1, 2014 and December 31, 2020

Characteristic	Number	
Number of episodes	53,477	
Number of unique patients	48,064	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	68.6	11.5
Age	Number	Percent
18-44 years	3,102	5.8%
45-64 years	11,107	20.8%
More than 65 years	39,268	73.4%
Sex		
Female	26,813	55.8%
Male	21,251	44.2%
Race (Unknown)	48,064	100.0%
Year		
2014	7,773	14.5%
2015	7,551	14.1%
2016	8,010	15.0%
2017	8,523	15.9%
2018	9,973	18.6%
2019	6,427	12.0%
2020	5,220	9.8%
Recorded History of:		
Angina	1,881	3.5%
Atrial fibrillation	2,753	5.1%
Diabetes	12,926	24.2%
Heart failure	1,917	3.6%
Hyperlipidemia	2,767	5.2%
Hypertension	28,511	53.3%
Myocardial infarction	773	1.4%
Renal disorders	3,041	5.7%
Stroke	1,173	2.2%

¹All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1e. Aggregated Baseline Table for Members Dispensed Incident Olmesartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	73,164	
Number of unique patients	65,865	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69	10.8
	Number	Percent
Age		
18-44 years	3,425	4.7%
45-64 years	13,058	17.8%
More than 65 years	56,681	77.5%
Sex		
Female	36,312	55.1%
Male	29,553	44.9%
Race (Unknown)	65,865	100.0%
Year		
2014	12,850	17.6%
2015	12,357	16.9%
2016	13,231	18.1%
2017	11,442	15.6%
2018	11,635	15.9%
2019	7,366	10.1%
2020	4,283	5.9%
Recorded History of:		
Angina	1,885	2.6%
Atrial fibrillation	3,504	4.8%
Diabetes	17,235	23.6%
Heart failure	1,548	2.1%
Hyperlipidemia	4,427	6.1%
Hypertension	45,292	61.9%
Myocardial infarction	534	0.7%
Renal disorders	3,015	4.1%
Stroke	1,401	1.9%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1f. Aggregated Baseline Table for Members Dispensed Incident Telmisartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	108,792	
Number of unique patients	98,398	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.8	10.7
Age	Number	Percent
18-44 years	4,721	4.3%
45-64 years	17,452	16.0%
More than 65 years	86,619	79.6%
Sex		
Female	52,795	53.7%
Male	45,603	46.3%
Race (Unknown)	98,398	100.0%
Year		
2014	12,752	11.7%
2015	12,322	11.3%
2016	13,235	12.2%
2017	14,348	13.2%
2018	18,680	17.2%
2019	22,515	20.7%
2020	14,940	13.7%
Recorded History of:		
Angina	4,725	4.3%
Atrial fibrillation	6,434	5.9%
Diabetes	26,764	24.6%
Heart failure	3,577	3.3%
Hyperlipidemia	5,850	5.4%
Hypertension	60,622	55.7%
Myocardial infarction	1,883	1.7%
Renal disorders	5,835	5.4%
Stroke	2,870	2.6%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1g. Aggregated Baseline Table for Members Dispensed Incident Valsartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	82,354	
Number of unique patients	75,866	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.4	10.9
Age	Number	Percent
18-44 years	3,166	3.8%
45-64 years	13,877	16.9%
More than 65 years	65,311	79.3%
Sex		
Female	37,456	49.4%
Male	38,410	50.6%
Race (Unknown)	75,866	100.0%
Year		
2014	11,824	14.4%
2015	11,466	13.9%
2016	12,336	15.0%
2017	17,212	20.9%
2018	12,202	14.8%
2019	9,008	10.9%
2020	8,306	10.1%
Recorded History of:		
Angina	7,287	8.8%
Atrial fibrillation	10,763	13.1%
Diabetes	20,319	24.7%
Heart failure	15,365	18.7%
Hyperlipidemia	4,571	5.6%
Hypertension	42,502	51.6%
Myocardial infarction	3,102	3.8%
Renal disorders	4,945	6.0%
Stroke	2,312	2.8%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1h. Aggregated Baseline Table for Members Dispensed Any Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product between January 1, 2014 and December 31, 2020

Characteristic	Number	
Number of episodes	1,775,080	
Number of unique patients	798,231	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.4	10.7
	Number	Percent
Age		
18-44 years	61,559	3.5%
45-64 years	312,170	17.6%
More than 65 years	1,401,351	78.9%
Sex		
Female	435,288	54.5%
Male	362,943	45.5%
Race (Unknown)	798,231	100.0%
Year		
2014	238,335	13.4%
2015	237,039	13.4%
2016	238,468	13.4%
2017	247,120	13.9%
2018	262,466	14.8%
2019	279,068	15.7%
2020	272,584	15.4%
Recorded History of:		
Angina	60,765	3.4%
Atrial fibrillation	99,320	5.6%
Diabetes	443,849	25.0%
Heart failure	73,041	4.1%
Hyperlipidemia	83,629	4.7%
Hypertension	817,447	46.1%
Myocardial infarction	20,176	1.1%
Renal disorders	96,232	5.4%
Stroke	32,525	1.8%

^aAll metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1i. Aggregated Baseline Table for Members Dispensed Prevalent Candesartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	487,844	
Number of unique patients	274,514	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	71.3	10.8
Age	Number	Percent
18-44 years	15,168	3.1%
45-64 years	75,556	15.5%
More than 65 years	397,120	81.4%
Sex		
Female	153,875	56.1%
Male	120,639	43.9%
Race (Unknown)	274,514	100.0%
Year		
2014	47,318	9.7%
2015	47,253	9.7%
2016	47,611	9.8%
2017	49,123	10.1%
2018	70,001	14.3%
2019	104,738	21.5%
2020	121,800	25.0%
Recorded History of:		
Angina	20,310	4.2%
Atrial fibrillation	32,232	6.6%
Diabetes	124,373	25.5%
Heart failure	23,751	4.9%
Hyperlipidemia	23,555	4.8%
Hypertension	223,340	45.8%
Myocardial infarction	7,197	1.5%
Renal disorders	32,040	6.6%
Stroke	10,006	2.1%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1j. Aggregated Baseline Table for Members Dispensed Prevalent Irbesartan between January 1, 2014 and December 31, 2020

Characteristic*	Mean	
Number of episodes	324,855	
Number of unique patients	158,462	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.1	10.8
Age	Number	Percent
18-44 years	11,787	3.6%
45-64 years	64,001	19.7%
More than 65 years	249,067	76.7%
Sex		
Female	86,896	54.8%
Male	71,566	45.2%
Race (Unknown)	158,462	100.0%
Year		
2014	43,081	13.3%
2015	41,384	12.7%
2016	40,042	12.3%
2017	39,786	12.2%
2018	45,157	13.9%
2019	53,873	16.6%
2020	61,532	18.9%
Recorded History of:		
Angina	9,047	2.8%
Atrial fibrillation	14,855	4.6%
Diabetes	88,229	27.2%
Heart failure	9,318	2.9%
Hyperlipidemia	12,879	4.0%
Hypertension	143,570	44.2%
Myocardial infarction	2,712	0.8%
Renal disorders	20,274	6.2%
Stroke	5,721	1.8%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1k. Aggregated Baseline Table for Members Dispensed Prevalent Losartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	201,565	
Number of unique patients	97,927	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.2	11.1
Age	Number	Percent
18-44 years	7,817	3.9%
45-64 years	39,377	19.5%
More than 65 years	154,371	76.6%
Sex		
Female	55,797	57.0%
Male	42,130	43.0%
Race (Unknown)	97,927	100.0%
Year		
2014	30,162	15.0%
2015	29,166	14.5%
2016	28,667	14.2%
2017	28,964	14.4%
2018	33,814	16.8%
2019	27,976	13.9%
2020	22,816	11.3%
Recorded History of:		
Angina	5,224	2.6%
Atrial fibrillation	9,515	4.7%
Diabetes	49,965	24.8%
Heart failure	5,608	2.8%
Hyperlipidemia	9,107	4.5%
Hypertension	91,035	45.2%
Myocardial infarction	1,646	0.8%
Renal disorders	9,864	4.9%
Stroke	3,268	1.6%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 11. Aggregated Baseline Table for Members Dispensed Prevalent Olmesartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	217,392	
Number of unique patients	106,348	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	69.3	10.6
Age	Number	Percent
18-44 years	8,873	4.1%
45-64 years	40,723	18.7%
More than 65 years	167,796	77.2%
Sex		
Female	58,622	55.1%
Male	47,726	44.9%
Race (Unknown)	106,348	100.0%
Year		
2014	29,065	13.4%
2015	30,823	14.2%
2016	33,594	15.5%
2017	33,227	15.3%
2018	37,617	17.3%
2019	31,942	14.7%
2020	21,124	9.7%
Recorded History of:		
Angina	4,661	2.1%
Atrial fibrillation	9,002	4.1%
Diabetes	52,999	24.4%
Heart failure	4,064	1.9%
Hyperlipidemia	11,749	5.4%
Hypertension	113,455	52.2%
Myocardial infarction	1,210	0.6%
Renal disorders	9,237	4.2%
Stroke	3,173	1.5%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1m. Aggregated Baseline Table for Members Dispensed Prevalent Telmisartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	374,239	
Number of unique patients	188,840	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	70.6	10.3
	Number	Percent
Age		
18-44 years	12,137	3.2%
45-64 years	60,237	16.1%
More than 65 years	301,865	80.7%
Sex		
Female	102,129	54.1%
Male	86,711	45.9%
Race (Unknown)	188,840	100.0%
Year		
2014	42,741	11.4%
2015	42,867	11.5%
2016	43,459	11.6%
2017	45,337	12.1%
2018	58,914	15.7%
2019	77,310	20.7%
2020	63,611	17.0%
Recorded History of:		
Angina	11,594	3.1%
Atrial fibrillation	18,207	4.9%
Diabetes	93,528	25.0%
Heart failure	9,608	2.6%
Hyperlipidemia	17,668	4.7%
Hypertension	171,586	45.8%
Myocardial infarction	3,684	1.0%
Renal disorders	17,777	4.8%
Stroke	6,868	1.8%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 1n. Aggregated Baseline Table for Members Dispensed Prevalent Valsartan between January 1, 2014 and December 31, 2020

Characteristic*	Number	
Number of episodes	290,191	
Number of unique patients	148,284	
Demographic Characteristics	Mean	Standard Deviation
Age (Years)	71.1	10.5
Age	Number	Percent
18-44 years	7,973	2.7%
45-64 years	49,346	17.0%
More than 65 years	232,872	80.2%
Sex		
Female	78,135	52.7%
Male	70,149	47.3%
Race (Unknown)	148,284	100.0%
Year		
2014	47,985	16.5%
2015	47,245	16.3%
2016	47,009	16.2%
2017	52,508	18.1%
2018	39,986	13.8%
2019	28,212	9.7%
2020	27,246	9.4%
Recorded History of:		
Angina	13,773	4.7%
Atrial fibrillation	22,984	7.9%
Diabetes	71,247	24.6%
Heart failure	26,026	9.0%
Hyperlipidemia	13,667	4.7%
Hypertension	131,639	45.4%
Myocardial infarction	5,004	1.7%
Renal disorders	14,154	4.9%
Stroke	5,839	2.0%

*All metrics are based on total number of episodes per group, except for sex, race, and Hispanic origin which are based on total number of unique patients

Table 2a. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, Overall

	New Users	Eligible Members ¹	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member Years ¹	Proportion of All ARB Use ²
ARB												
<i>Incident ARB episodes</i>	472,599	6,710,290	536,190	276,766,039	757,744.1	7,628,875	7,672,264	259,499,849	272,634,323	10,809,601,643	29,595,076.4	1.00
Candesartan												
<i>Incident Candesartan episodes</i>	134,250	6,710,290	144,870	65,647,401	179,732.8	1,865,046	1,885,939	61,156,758	63,655,830	10,809,601,643	29,595,076.4	0.27
Irbesartan												
<i>Incident Irbesartan episodes</i>	66,098	6,710,290	73,135	36,536,728	100,032.1	959,996	965,430	33,966,307	34,947,701	10,809,601,643	29,595,076.4	0.14
Losartan												
<i>Incident Losartan episodes</i>	48,064	6,710,290	53,477	24,308,032	66,551.8	608,333	612,866	22,204,411	23,296,743	10,809,601,643	29,595,076.4	0.10
Olmesartan												
<i>Incident Olmesartan episodes</i>	65,865	6,710,290	73,164	36,235,414	99,207.2	916,223	917,010	33,324,930	33,619,831	10,809,601,643	29,595,076.4	0.14
Telmisartan												
<i>Incident Telmisartan episodes</i>	98,398	6,710,290	108,792	50,908,786	139,380.7	1,299,132	1,300,032	47,237,372	46,725,487	10,809,601,643	29,595,076.4	0.20
Valsartan												
<i>Incident Valsartan episodes</i>	75,866	6,710,290	82,354	36,378,787	99,599.7	1,025,464	1,030,950	33,405,248	40,696,324	10,809,601,643	29,595,076.4	0.15

¹ Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

² Proportion of ARB use estimated as number of episodes for each individual ARB divided by all ARB episodes

Table 2b. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Age Group

Age Group	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
18-44 years	22,108	2,185,193	25,107	9,880,583	27,051.6	292,801	294,479	8,810,798	9,140,939	2,770,466,004	7,585,122.5	1.00
45-64 years	84,947	1,503,727	95,071	48,526,749	132,859.0	1,428,968	1,436,521	44,745,634	46,361,220	2,118,767,361	5,800,868.9	1.00
More than 65 years	367,950	3,603,980	416,012	218,358,707	597,833.6	5,907,106	5,941,264	205,943,417	217,132,164	5,920,368,278	16,209,085.0	1.00
Candesartan												
<i>Incident Candesartan episodes</i>												
18-44 years	6,141	2,185,193	6,587	2,230,534	6,106.9	68,513	69,404	1,977,311	2,078,280	2,770,466,004	7,585,122.5	0.26
45-64 years	22,206	1,503,727	23,733	10,493,435	28,729.5	320,550	324,269	9,620,794	9,976,657	2,118,767,361	5,800,868.9	0.25
More than 65 years	106,244	3,603,980	114,550	52,923,432	144,896.5	1,475,983	1,492,266	49,558,653	51,600,893	5,920,368,278	16,209,085.0	0.28
Irbesartan												
<i>Incident Irbesartan episodes</i>												
18-44 years	3,672	2,185,193	4,086	1,624,798	4,448.5	45,432	45,688	1,445,782	1,476,393	2,770,466,004	7,585,122.5	0.16
45-64 years	14,326	1,503,727	15,774	7,686,786	21,045.3	211,108	212,241	7,057,935	7,195,389	2,118,767,361	5,800,868.9	0.17
More than 65 years	48,422	3,603,980	53,275	27,225,144	74,538.4	703,456	707,501	25,462,590	26,275,920	5,920,368,278	16,209,085.0	0.13
Losartan												
<i>Incident Losartan episodes</i>												
18-44 years	2,790	2,185,193	3,102	1,141,383	3,124.9	30,878	31,046	997,523	1,025,252	2,770,466,004	7,585,122.5	0.12
45-64 years	10,124	1,503,727	11,107	5,118,959	14,014.9	133,993	134,669	4,604,001	4,751,419	2,118,767,361	5,800,868.9	0.12
More than 65 years	35,350	3,603,980	39,268	18,047,690	49,411.9	443,462	447,151	16,602,887	17,520,072	5,920,368,278	16,209,085.0	0.09
Olmesartan												
<i>Incident Olmesartan episodes</i>												
18-44 years	3,055	2,185,193	3,425	1,251,924	3,427.6	37,796	37,826	1,086,625	1,090,662	2,770,466,004	7,585,122.5	0.14
45-64 years	11,873	1,503,727	13,058	6,384,311	17,479.3	193,404	193,631	5,775,802	5,778,915	2,118,767,361	5,800,868.9	0.14
More than 65 years	51,177	3,603,980	56,681	28,599,179	78,300.3	685,023	685,553	26,462,503	26,750,254	5,920,368,278	16,209,085.0	0.14
Telmisartan												
<i>Incident Telmisartan episodes</i>												
18-44 years	4,240	2,185,193	4,721	1,647,342	4,510.2	48,464	48,512	1,456,846	1,436,985	2,770,466,004	7,585,122.5	0.19
45-64 years	15,845	1,503,727	17,452	7,836,555	21,455.3	218,668	218,747	7,160,790	7,074,242	2,118,767,361	5,800,868.9	0.18
More than 65 years	78,669	3,603,980	86,619	41,424,889	113,415.2	1,032,000	1,032,773	38,619,736	38,214,260	5,920,368,278	16,209,085.0	0.21

Table 2b. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Age Group

Age Group	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Incident Valsartan episodes</i>												
18-44 years	2,876	2,185,193	3,166	1,164,928	3,189.4	32,530	32,688	1,018,606	1,180,069	2,770,466,004	7,585,122.5	0.13
45-64 years	12,842	1,503,727	13,877	6,256,711	17,129.9	184,706	185,709	5,640,139	6,528,894	2,118,767,361	5,800,868.9	0.15
More than 65 years	60,365	3,603,980	65,311	28,957,148	79,280.4	808,228	812,553	26,746,503	32,987,361	5,920,368,278	16,209,085.0	0.16

¹Total number of users by age group may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in specified age group divided by all ARB episodes in the same age group

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
<i>2014</i>												
January	5,829	3,897,370	5,829	4,798,772	13,138.3	132,361	132,996	4,533,141	4,638,796	120,378,135	329,577.4	1.00
February	11,074	3,891,646	11,074	4,347,689	11,903.3	125,983	126,923	4,106,999	4,218,876	108,658,404	297,490.5	1.00
March	16,935	3,891,232	16,935	4,689,904	12,840.3	127,496	128,204	4,420,085	4,527,159	120,270,640	329,283.1	1.00
April	22,603	3,912,584	22,603	5,353,825	14,658.0	138,468	139,182	5,064,577	5,176,429	116,967,074	320,238.4	1.00
May	28,099	3,910,095	28,099	5,174,005	14,165.7	135,946	136,781	4,883,523	4,998,956	120,847,157	330,861.5	1.00
June	32,266	3,903,251	32,266	4,737,772	12,971.3	127,819	128,124	4,468,541	4,594,232	116,767,748	319,692.7	1.00
July	35,963	3,921,603	35,963	4,629,079	12,673.7	121,733	122,298	4,367,869	4,508,251	121,113,484	331,590.6	1.00
August	38,468	3,920,557	38,468	3,620,252	9,911.7	101,605	102,750	3,411,452	3,483,578	121,150,545	331,692.1	1.00
September	41,382	3,915,378	41,382	4,176,763	11,435.4	115,913	116,682	3,939,566	4,053,627	117,143,645	320,721.8	1.00
October	44,895	3,954,085	44,895	4,762,760	13,039.7	127,370	128,307	4,489,571	4,621,182	122,143,428	334,410.5	1.00
November	47,671	3,947,378	47,671	4,061,514	11,119.8	107,417	108,669	3,824,388	3,927,819	118,088,007	323,307.3	1.00
December	50,144	4,035,199	50,144	3,841,100	10,516.4	104,458	104,903	3,615,735	3,692,644	121,919,441	333,797.2	1.00
<i>2015</i>												
January	52,874	3,977,814	52,874	4,113,302	11,261.6	108,869	109,543	3,874,480	3,955,300	122,856,260	336,362.1	1.00
February	54,741	3,971,081	54,741	3,560,700	9,748.7	99,212	100,047	3,353,806	3,446,849	110,546,414	302,659.6	1.00
March	57,739	3,958,182	57,739	4,171,344	11,420.5	114,691	115,449	3,928,418	4,033,445	122,339,281	334,946.7	1.00
April	61,061	3,994,408	61,061	5,092,222	13,941.7	135,171	135,609	4,806,231	4,940,903	119,424,477	326,966.4	1.00
May	63,990	3,991,068	63,990	4,374,563	11,976.9	112,721	113,164	4,120,570	4,235,423	123,359,288	337,739.3	1.00
June	66,529	3,984,059	66,529	4,356,153	11,926.5	115,007	116,193	4,108,797	4,177,601	119,193,678	326,334.5	1.00
July	68,480	4,010,800	68,480	3,817,899	10,452.8	102,533	103,154	3,588,351	3,680,299	123,891,882	339,197.5	1.00
August	69,697	4,008,896	69,697	3,296,341	9,024.9	85,037	85,444	3,105,432	3,184,231	123,891,294	339,195.9	1.00
September	71,569	4,003,250	71,569	3,679,030	10,072.6	103,388	104,227	3,463,973	3,542,993	119,789,102	327,964.7	1.00
October	74,040	4,039,478	74,040	4,203,464	11,508.5	109,626	110,122	3,963,923	4,062,924	124,790,972	341,659.1	1.00
November	76,262	4,031,998	76,262	3,884,134	10,634.2	101,873	102,222	3,651,058	3,782,259	120,629,470	330,265.5	1.00
December	78,375	4,117,723	78,375	3,755,131	10,281.0	100,948	101,525	3,541,811	3,624,138	124,547,867	340,993.5	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
January	80,851	4,062,262	80,851	4,113,631	11,262.5	107,968	108,577	3,878,073	3,959,977	125,490,045	343,573.0	1.00
February	82,675	4,056,572	82,675	3,662,378	10,027.0	103,984	104,766	3,451,963	3,548,098	117,308,826	321,174.1	1.00
March	85,520	4,055,992	85,520	4,091,132	11,200.9	115,532	116,357	3,846,564	3,958,238	125,357,995	343,211.5	1.00
April	88,203	4,093,102	88,203	4,647,133	12,723.2	116,515	117,247	4,379,888	4,511,056	122,442,996	335,230.7	1.00
May	91,151	4,089,844	91,151	4,514,273	12,359.4	119,994	120,616	4,256,115	4,376,270	126,424,947	346,132.6	1.00
June	93,407	4,083,023	93,407	4,177,724	11,438.0	108,056	108,899	3,933,381	4,046,999	122,166,862	334,474.6	1.00
July	94,742	4,111,988	94,742	3,579,339	9,799.7	96,915	97,783	3,368,010	3,447,687	127,083,483	347,935.6	1.00
August	96,231	4,112,457	96,231	3,459,687	9,472.1	94,207	94,516	3,253,178	3,319,787	127,078,360	347,921.6	1.00
September	97,724	4,107,785	97,724	3,520,051	9,637.4	93,229	94,022	3,311,908	3,396,366	122,921,663	336,541.2	1.00
October	99,569	4,145,779	99,569	3,836,526	10,503.8	104,707	105,212	3,601,764	3,712,418	128,072,234	350,642.7	1.00
November	101,739	4,140,062	101,739	3,842,683	10,520.7	100,652	101,128	3,609,485	3,725,171	123,854,935	339,096.3	1.00
December	103,340	4,223,583	103,340	3,355,219	9,186.1	90,159	90,498	3,152,191	3,238,636	127,910,903	350,201.0	1.00
2017												
January	105,132	4,171,811	105,132	3,668,493	10,043.8	94,667	95,197	3,453,878	3,539,074	128,861,537	352,803.7	1.00
February	106,633	4,166,346	106,633	3,304,703	9,047.8	89,945	90,784	3,103,746	3,199,941	116,333,737	318,504.4	1.00
March	109,290	4,166,395	109,290	3,810,468	10,432.5	105,506	106,063	3,579,192	3,670,206	128,774,973	352,566.7	1.00
April	111,298	4,202,135	111,298	3,940,899	10,789.6	103,023	103,609	3,706,940	3,868,652	125,658,584	344,034.5	1.00
May	114,754	4,199,855	114,754	4,669,933	12,785.6	135,289	135,857	4,397,781	5,045,908	129,810,535	355,401.9	1.00
June	117,620	4,192,375	117,620	4,535,112	12,416.5	140,484	141,356	4,275,276	5,125,317	125,417,553	343,374.5	1.00
July	119,355	4,223,214	119,355	3,678,962	10,072.4	101,185	101,642	3,456,387	3,947,852	130,447,938	357,147.0	1.00
August	120,975	4,221,159	120,975	3,461,615	9,477.4	92,590	93,107	3,255,802	3,669,410	130,447,348	357,145.4	1.00
September	122,293	4,215,600	122,293	3,305,244	9,049.3	96,623	97,220	3,105,047	3,372,999	126,137,671	345,346.1	1.00
October	123,973	4,255,290	123,973	3,565,985	9,763.1	100,363	101,194	3,343,515	3,605,489	131,472,312	359,951.6	1.00
November	126,287	4,248,890	126,287	3,759,542	10,293.1	105,208	105,780	3,530,791	3,786,077	127,107,293	348,000.8	1.00
December	127,589	4,331,104	127,589	2,978,406	8,154.4	82,934	83,456	2,786,203	3,043,122	131,200,902	359,208.5	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2018</i>												
January	129,707	4,283,694	129,707	3,600,909	9,858.8	100,443	100,837	3,389,461	3,610,185	132,312,321	362,251.4	1.00
February	131,037	4,276,832	131,037	3,026,816	8,287.0	86,153	86,425	2,836,095	3,015,199	119,400,020	326,899.4	1.00
March	133,593	4,276,339	133,593	3,425,597	9,378.8	101,144	101,789	3,213,644	3,433,579	132,158,682	361,830.8	1.00
April	136,292	4,335,267	136,292	4,026,311	11,023.4	105,934	106,645	3,786,086	4,038,527	129,593,413	354,807.4	1.00
May	139,895	4,316,054	139,895	4,095,300	11,212.3	112,365	113,221	3,846,016	4,089,466	133,402,524	365,236.2	1.00
June	141,940	4,307,951	141,940	3,463,750	9,483.2	97,589	97,810	3,251,860	3,478,197	128,882,112	352,860.0	1.00
July	144,836	4,524,921	144,836	3,892,644	10,657.5	109,506	109,994	3,643,662	3,808,098	139,358,582	381,543.0	1.00
August	146,836	4,522,472	146,836	3,138,178	8,591.9	88,571	89,052	2,926,014	3,086,973	139,745,700	382,602.9	1.00
September	148,063	4,509,048	148,063	2,857,362	7,823.0	79,622	79,990	2,659,999	2,799,314	134,911,121	369,366.5	1.00
October	149,758	4,550,816	149,758	3,374,058	9,237.7	91,413	91,915	3,142,769	3,337,575	140,592,626	384,921.6	1.00
November	152,208	4,544,969	152,208	3,356,146	9,188.6	93,025	93,464	3,129,921	3,351,247	135,947,974	372,205.3	1.00
December	153,345	4,686,840	153,345	2,729,510	7,473.0	79,409	79,819	2,536,905	2,720,205	140,438,162	384,498.7	1.00
<i>2019</i>												
January	155,414	4,578,064	155,414	2,992,447	8,192.9	84,113	84,540	2,780,874	2,980,280	141,400,648	387,133.9	1.00
February	156,696	4,573,799	156,696	2,525,711	6,915.0	74,017	74,401	2,344,063	2,513,306	127,698,813	349,620.3	1.00
March	159,549	4,575,557	159,549	2,959,040	8,101.4	84,066	84,359	2,739,031	2,946,497	141,386,404	387,094.9	1.00
April	162,300	4,471,456	162,300	3,339,180	9,142.2	92,717	93,151	3,102,185	3,369,894	133,649,309	365,911.9	1.00
May	165,584	4,467,437	165,584	3,200,585	8,762.7	90,817	91,213	2,964,823	3,193,175	138,069,018	378,012.4	1.00
June	167,209	4,458,874	167,209	2,645,285	7,242.4	76,372	76,765	2,444,926	2,623,705	133,392,174	365,207.9	1.00
July	168,602	4,471,134	168,602	2,443,618	6,690.3	70,808	71,386	2,249,070	2,456,684	138,086,832	378,061.1	1.00
August	169,439	4,468,836	169,439	2,116,375	5,794.3	61,629	61,803	1,942,271	2,114,164	138,107,214	378,116.9	1.00
September	170,626	4,463,007	170,626	2,223,169	6,086.7	66,337	66,637	2,048,683	2,244,046	133,533,748	365,595.5	1.00
October	172,910	4,495,572	172,910	2,527,021	6,918.6	72,834	73,157	2,320,577	2,529,335	138,885,668	380,248.2	1.00
November	174,926	4,488,234	174,926	2,166,895	5,932.6	64,513	64,735	1,986,567	2,165,852	134,244,281	367,540.8	1.00
December	175,940	4,604,657	175,940	1,780,185	4,873.9	54,493	54,757	1,625,753	1,770,219	138,667,704	379,651.5	1.00

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2020</i>												
January	177,565	4,493,846	177,565	1,878,040	5,141.8	56,837	57,098	1,713,351	1,875,361	138,826,148	380,085.3	1.00
February	177,576	4,487,264	177,576	1,481,600	4,056.4	45,661	45,850	1,348,407	1,481,432	129,775,896	355,307.0	1.00
March	177,674	4,486,857	177,674	1,403,056	3,841.4	42,959	43,220	1,269,497	1,377,705	138,678,094	379,679.9	1.00
April	175,226	4,528,175	175,226	968,770	2,652.3	28,256	28,350	874,184	935,635	135,480,505	370,925.4	1.00
May	174,029	4,526,073	174,029	913,973	2,502.3	25,852	25,946	829,566	887,329	139,906,223	383,042.4	1.00
June	173,026	4,520,879	173,026	941,108	2,576.6	25,914	25,975	858,265	918,448	135,254,130	370,305.6	1.00
July	172,326	4,560,189	172,326	849,495	2,325.8	23,929	24,038	768,837	828,553	140,876,944	385,700.1	1.00
August	172,088	4,563,755	172,088	713,644	1,953.9	21,956	22,045	647,647	702,518	141,007,873	386,058.5	1.00
September	175,024	4,561,471	175,024	692,725	1,896.6	21,836	21,908	635,284	682,151	136,464,652	373,619.9	1.00
October	178,825	4,595,920	178,825	575,678	1,576.1	19,806	19,890	531,286	571,685	142,020,010	388,829.6	1.00
November	181,059	4,587,818	181,059	340,765	933.0	14,224	14,271	318,965	342,400	137,251,792	375,774.9	1.00
December	182,945	4,700,304	182,945	124,237	340.1	8,375	8,404	123,930	132,720	141,703,001	387,961.7	1.00
Candesartan												
<i>Incident Candesartan episodes</i>												
<i>2014</i>												
January	1,093	3,897,370	1,093	927,961	2,540.6	27,699	27,802	876,741	913,327	120,378,135	329,577.4	0.19
February	2,095	3,891,646	2,095	785,148	2,149.6	21,689	22,277	737,403	779,877	108,658,404	297,490.5	0.19
March	3,218	3,891,232	3,218	873,705	2,392.1	23,366	23,785	819,461	853,430	120,270,640	329,283.1	0.19
April	4,334	3,912,584	4,334	1,046,541	2,865.3	28,129	28,495	985,540	1,005,469	116,967,074	320,238.4	0.19
May	5,478	3,910,095	5,478	1,009,603	2,764.1	28,123	28,531	945,920	980,316	120,847,157	330,861.5	0.19
June	6,244	3,903,251	6,244	845,676	2,315.3	23,283	23,460	793,709	839,099	116,767,748	319,692.7	0.19
July	7,010	3,921,603	7,010	944,305	2,585.4	25,805	25,985	889,750	946,805	121,113,484	331,590.6	0.19
August	7,528	3,920,557	7,528	731,835	2,003.7	24,081	24,961	688,048	726,462	121,150,545	331,692.1	0.20
September	8,176	3,915,378	8,176	893,965	2,447.5	25,761	26,160	841,517	871,782	117,143,645	320,721.8	0.20
October	8,878	3,954,085	8,878	898,509	2,460.0	23,919	24,237	843,141	889,706	122,143,428	334,410.5	0.20
November	9,435	3,947,378	9,435	857,784	2,348.5	24,455	24,951	806,682	833,761	118,088,007	323,307.3	0.20
December	9,941	4,035,199	9,941	776,056	2,124.7	23,681	23,842	728,681	762,994	121,919,441	333,797.2	0.20

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2015</i>												
January	10,479	3,977,814	10,479	779,071	2,133.0	22,593	22,937	731,094	757,682	122,856,260	336,362.1	0.20
February	10,847	3,971,081	10,847	705,006	1,930.2	21,807	22,211	661,699	686,137	110,546,414	302,659.6	0.20
March	11,459	3,958,182	11,459	862,818	2,362.3	25,293	25,470	809,515	841,989	122,339,281	334,946.7	0.20
April	12,178	3,994,408	12,178	1,077,931	2,951.2	29,444	29,547	1,013,491	1,043,841	119,424,477	326,966.4	0.20
May	12,866	3,991,068	12,866	910,787	2,493.6	23,496	23,734	856,546	900,522	123,359,288	337,739.3	0.20
June	13,426	3,984,059	13,426	939,849	2,573.2	25,385	25,960	882,555	903,436	119,193,678	326,334.5	0.20
July	13,833	4,010,800	13,833	748,947	2,050.5	20,903	21,096	700,287	733,331	123,891,882	339,197.5	0.20
August	14,122	4,008,896	14,122	706,353	1,933.9	18,614	18,856	664,386	700,747	123,891,294	339,195.9	0.20
September	14,423	4,003,250	14,423	714,799	1,957.0	21,475	22,075	670,771	702,328	119,789,102	327,964.7	0.20
October	14,943	4,039,478	14,943	831,866	2,277.5	21,879	22,215	782,489	822,039	124,790,972	341,659.1	0.20
November	15,360	4,031,998	15,360	801,352	2,194.0	19,547	19,638	753,216	789,940	120,629,470	330,265.5	0.20
December	15,788	4,117,723	15,788	778,622	2,131.8	20,545	20,673	731,826	767,203	124,547,867	340,993.5	0.20
<i>2016</i>												
January	16,339	4,062,262	16,339	871,682	2,386.5	23,371	23,636	816,524	846,037	125,490,045	343,573.0	0.20
February	16,697	4,056,572	16,697	714,031	1,954.9	22,763	23,098	670,265	702,037	117,308,826	321,174.1	0.20
March	17,336	4,055,992	17,336	842,041	2,305.4	24,838	25,164	789,831	829,026	125,357,995	343,211.5	0.20
April	17,914	4,093,102	17,914	949,029	2,598.3	24,933	25,314	894,176	941,303	122,442,996	335,230.7	0.20
May	18,501	4,089,844	18,501	941,638	2,578.1	25,053	25,134	885,712	929,265	126,424,947	346,132.6	0.20
June	18,954	4,083,023	18,954	849,117	2,324.8	24,283	24,808	796,559	843,811	122,166,862	334,474.6	0.20
July	19,192	4,111,988	19,192	714,224	1,955.4	19,675	19,943	669,246	693,902	127,083,483	347,935.6	0.20
August	19,457	4,112,457	19,457	675,810	1,850.3	17,754	17,790	630,465	645,780	127,078,360	347,921.6	0.20
September	19,740	4,107,785	19,740	727,831	1,992.7	21,223	21,613	680,865	707,716	122,921,663	336,541.2	0.20
October	20,102	4,145,779	20,102	761,315	2,084.4	22,444	22,722	712,282	747,046	128,072,234	350,642.7	0.20
November	20,645	4,140,062	20,645	833,732	2,282.6	21,984	22,190	778,115	815,545	123,854,935	339,096.3	0.20
December	21,034	4,223,583	21,034	716,026	1,960.4	20,514	20,655	669,000	690,441	127,910,903	350,201.0	0.20

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2017</i>												
January	21,422	4,171,811	21,422	728,660	1,995.0	18,829	19,288	680,965	712,463	128,861,537	352,803.7	0.20
February	21,677	4,166,346	21,677	671,985	1,839.8	19,355	19,659	629,830	653,240	116,333,737	318,504.4	0.20
March	22,240	4,166,395	22,240	808,301	2,213.0	22,813	23,140	754,621	781,241	128,774,973	352,566.7	0.20
April	22,579	4,202,135	22,579	797,324	2,183.0	21,877	22,292	747,030	772,623	125,658,584	344,034.5	0.20
May	23,088	4,199,855	23,088	848,958	2,324.3	23,482	23,686	794,841	842,497	129,810,535	355,401.9	0.20
June	23,516	4,192,375	23,516	829,123	2,270.0	23,379	23,760	775,539	809,007	125,417,553	343,374.5	0.20
July	23,785	4,223,214	23,785	679,970	1,861.7	19,340	19,462	632,694	666,733	130,447,938	357,147.0	0.20
August	24,121	4,221,159	24,121	690,414	1,890.3	19,003	19,242	644,131	676,585	130,447,348	357,145.4	0.20
September	24,446	4,215,600	24,446	677,777	1,855.7	20,204	20,575	631,078	651,936	126,137,671	345,346.1	0.20
October	24,858	4,255,290	24,858	774,445	2,120.3	22,380	22,773	721,898	744,474	131,472,312	359,951.6	0.20
November	25,429	4,248,890	25,429	807,792	2,211.6	24,119	24,216	752,562	777,484	127,107,293	348,000.8	0.20
December	25,775	4,331,104	25,775	651,120	1,782.7	17,615	17,972	606,363	642,510	131,200,902	359,208.5	0.20
<i>2018</i>												
January	26,248	4,283,694	26,248	742,233	2,032.1	19,686	19,770	692,422	726,364	132,312,321	362,251.4	0.20
February	26,561	4,276,832	26,561	662,975	1,815.1	20,555	20,645	616,095	635,274	119,400,020	326,899.4	0.20
March	27,096	4,276,339	27,096	728,549	1,994.7	23,203	23,599	677,955	699,732	132,158,682	361,830.8	0.20
April	27,657	4,335,267	27,657	849,904	2,326.9	22,260	22,496	792,887	824,229	129,593,413	354,807.4	0.20
May	28,530	4,316,054	28,530	896,463	2,454.4	23,665	23,951	834,818	869,898	133,402,524	365,236.2	0.20
June	29,083	4,307,951	29,083	753,314	2,062.5	21,902	21,989	700,109	723,731	128,882,112	352,860.0	0.20
July	30,439	4,524,921	30,439	1,229,047	3,364.9	36,741	36,999	1,145,928	1,173,697	139,358,582	381,543.0	0.21
August	31,544	4,522,472	31,544	1,030,415	2,821.1	29,611	29,995	961,152	996,628	139,745,700	382,602.9	0.21
September	32,351	4,509,048	32,351	873,016	2,390.2	26,315	26,560	809,107	825,729	134,911,121	369,366.5	0.22
October	33,359	4,550,816	33,359	1,022,298	2,798.9	27,598	27,899	951,132	975,099	140,592,626	384,921.6	0.22
November	34,448	4,544,969	34,448	1,006,198	2,754.8	27,578	27,822	935,096	968,888	135,947,974	372,205.3	0.23
December	35,111	4,686,840	35,111	839,951	2,299.7	24,438	24,607	779,008	804,200	140,438,162	384,498.7	0.23

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2019</i>												
January	36,069	4,578,064	36,069	956,444	2,618.6	26,860	27,126	887,216	921,833	141,400,648	387,133.9	0.23
February	36,743	4,573,799	36,743	792,627	2,170.1	23,339	23,651	732,513	761,234	127,698,813	349,620.3	0.23
March	38,017	4,575,557	38,017	991,757	2,715.3	28,280	28,396	918,605	958,796	141,386,404	387,094.9	0.24
April	39,439	4,471,456	39,439	1,154,133	3,159.8	30,869	31,072	1,069,756	1,126,706	133,649,309	365,911.9	0.24
May	41,065	4,467,437	41,065	1,114,593	3,051.6	31,010	31,220	1,029,505	1,050,515	138,069,018	378,012.4	0.25
June	42,217	4,458,874	42,217	957,125	2,620.5	26,576	26,833	884,842	912,326	133,392,174	365,207.9	0.25
July	43,334	4,471,134	43,334	905,749	2,479.8	25,739	26,050	831,642	870,281	138,086,832	378,061.1	0.26
August	44,211	4,468,836	44,211	782,221	2,141.6	22,287	22,361	714,688	743,265	138,107,214	378,116.9	0.26
September	45,340	4,463,007	45,340	843,313	2,308.9	24,638	24,802	773,254	807,377	133,533,748	365,595.5	0.27
October	47,040	4,495,572	47,040	1,025,979	2,809.0	28,747	28,966	939,347	974,864	138,885,668	380,248.2	0.27
November	48,587	4,488,234	48,587	892,127	2,442.5	26,442	26,580	815,104	850,006	134,244,281	367,540.8	0.28
December	50,056	4,604,657	50,056	824,657	2,257.8	25,412	25,565	750,485	783,035	138,667,704	379,651.5	0.28
<i>2020</i>												
January	52,026	4,493,846	52,026	918,919	2,515.9	27,058	27,218	834,656	879,173	138,826,148	380,085.3	0.29
February	53,042	4,487,264	53,042	706,215	1,933.5	21,326	21,442	641,701	671,557	129,775,896	355,307.0	0.30
March	53,924	4,486,857	53,924	646,518	1,770.1	20,469	20,667	583,054	608,194	138,678,094	379,679.9	0.30
April	53,306	4,528,175	53,306	410,685	1,124.4	12,502	12,560	372,574	385,834	135,480,505	370,925.4	0.30
May	53,112	4,526,073	53,112	380,041	1,040.5	10,860	10,911	346,162	355,207	139,906,223	383,042.4	0.31
June	52,981	4,520,879	52,981	398,796	1,091.8	11,571	11,605	364,993	372,813	135,254,130	370,305.6	0.31
July	52,970	4,560,189	52,970	337,807	924.9	10,155	10,201	307,160	317,937	140,876,944	385,700.1	0.31
August	53,083	4,563,755	53,083	279,399	765.0	9,201	9,247	253,980	262,431	141,007,873	386,058.5	0.31
September	54,350	4,561,471	54,350	266,775	730.4	8,667	8,719	242,901	249,766	136,464,652	373,619.9	0.31
October	56,085	4,595,920	56,085	232,689	637.1	8,207	8,265	213,295	217,030	142,020,010	388,829.6	0.31
November	57,133	4,587,818	57,133	133,865	366.5	5,701	5,730	125,036	127,131	137,251,792	375,774.9	0.32
December	58,175	4,700,304	58,175	49,770	136.3	3,375	3,390	49,520	50,128	141,703,001	387,961.7	0.32

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Incident Irbesartan episodes</i>												
2014												
January	901	3,897,370	901	713,536	1,953.6	18,740	18,783	669,568	684,096	120,378,135	329,577.4	0.15
February	1,640	3,891,646	1,640	607,810	1,664.1	17,327	17,469	572,485	589,622	108,658,404	297,490.5	0.15
March	2,501	3,891,232	2,501	698,772	1,913.1	18,886	18,919	654,159	663,207	120,270,640	329,283.1	0.15
April	3,332	3,912,584	3,332	808,112	2,212.5	19,827	19,969	760,925	784,865	116,967,074	320,238.4	0.15
May	4,144	3,910,095	4,144	739,886	2,025.7	18,599	18,619	694,992	720,014	120,847,157	330,861.5	0.15
June	4,706	3,903,251	4,706	680,678	1,863.6	18,736	18,762	639,639	657,618	116,767,748	319,692.7	0.15
July	5,252	3,921,603	5,252	646,788	1,770.8	14,771	14,833	607,087	630,542	121,113,484	331,590.6	0.15
August	5,620	3,920,557	5,620	505,718	1,384.6	13,614	13,775	472,284	473,639	121,150,545	331,692.1	0.15
September	5,924	3,915,378	5,924	511,895	1,401.5	13,397	13,430	480,747	504,256	117,143,645	320,721.8	0.14
October	6,390	3,954,085	6,390	644,629	1,764.9	15,665	15,746	601,852	620,693	122,143,428	334,410.5	0.14
November	6,724	3,947,378	6,724	525,055	1,437.5	14,060	14,089	492,195	508,931	118,088,007	323,307.3	0.14
December	7,045	4,035,199	7,045	493,811	1,352.0	11,710	11,827	460,281	465,158	121,919,441	333,797.2	0.14
2015												
January	7,465	3,977,814	7,465	604,757	1,655.7	16,310	16,524	568,776	587,089	122,856,260	336,362.1	0.14
February	7,784	3,971,081	7,784	475,502	1,301.9	13,298	13,391	442,318	450,580	110,546,414	302,659.6	0.14
March	8,155	3,958,182	8,155	550,707	1,507.8	15,405	15,588	516,227	526,484	122,339,281	334,946.7	0.14
April	8,614	3,994,408	8,614	701,624	1,920.9	17,709	17,877	659,091	685,045	119,424,477	326,966.4	0.14
May	8,946	3,991,068	8,946	589,229	1,613.2	16,187	16,206	551,775	565,237	123,359,288	337,739.3	0.14
June	9,350	3,984,059	9,350	599,067	1,640.2	15,473	15,858	559,406	572,086	119,193,678	326,334.5	0.14
July	9,613	4,010,800	9,613	528,388	1,446.6	14,122	14,355	492,979	506,262	123,891,882	339,197.5	0.14
August	9,759	4,008,896	9,759	431,231	1,180.6	11,993	12,016	404,417	414,174	123,891,294	339,195.9	0.14
September	9,922	4,003,250	9,922	461,664	1,264.0	11,352	11,380	431,202	440,555	119,789,102	327,964.7	0.14
October	10,239	4,039,478	10,239	547,331	1,498.5	12,345	12,375	512,209	521,987	124,790,972	341,659.1	0.14
November	10,539	4,031,998	10,539	537,432	1,471.4	15,289	15,349	503,546	517,561	120,629,470	330,265.5	0.14
December	10,835	4,117,723	10,835	506,179	1,385.8	14,028	14,239	473,413	483,027	124,547,867	340,993.5	0.14

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2016</i>												
January	11,130	4,062,262	11,130	534,401	1,463.1	13,772	13,804	500,602	506,697	125,490,045	343,573.0	0.14
February	11,381	4,056,572	11,381	488,153	1,336.5	11,954	11,969	454,535	466,185	117,308,826	321,174.1	0.14
March	11,733	4,055,992	11,733	527,378	1,443.9	14,948	15,194	491,816	507,483	125,357,995	343,211.5	0.14
April	12,044	4,093,102	12,044	634,081	1,736.0	16,009	16,062	595,304	616,483	122,442,996	335,230.7	0.14
May	12,419	4,089,844	12,419	587,954	1,609.7	15,075	15,226	550,568	566,217	126,424,947	346,132.6	0.14
June	12,675	4,083,023	12,675	524,000	1,434.6	12,327	12,365	491,042	498,533	122,166,862	334,474.6	0.14
July	12,795	4,111,988	12,795	440,554	1,206.2	11,147	11,508	411,542	422,623	127,083,483	347,935.6	0.14
August	12,934	4,112,457	12,934	414,298	1,134.3	11,663	11,681	387,516	392,071	127,078,360	347,921.6	0.13
September	13,159	4,107,785	13,159	499,355	1,367.2	12,309	12,325	466,882	480,896	122,921,663	336,541.2	0.13
October	13,443	4,145,779	13,443	500,151	1,369.3	13,713	13,805	465,476	486,749	128,072,234	350,642.7	0.14
November	13,680	4,140,062	13,680	466,575	1,277.4	11,230	11,271	433,819	450,355	123,854,935	339,096.3	0.13
December	13,799	4,223,583	13,799	412,060	1,128.2	10,911	10,995	384,818	395,748	127,910,903	350,201.0	0.13
<i>2017</i>												
January	14,034	4,171,811	14,034	482,758	1,321.7	12,476	12,482	449,207	460,604	128,861,537	352,803.7	0.13
February	14,253	4,166,346	14,253	469,412	1,285.2	12,291	12,477	437,979	448,551	116,333,737	318,504.4	0.13
March	14,569	4,166,395	14,569	490,871	1,343.9	14,038	14,062	457,335	470,085	128,774,973	352,566.7	0.13
April	14,826	4,202,135	14,826	502,659	1,376.2	11,317	11,343	467,253	482,711	125,658,584	344,034.5	0.13
May	15,167	4,199,855	15,167	524,615	1,436.3	13,588	13,607	489,070	506,172	129,810,535	355,401.9	0.13
June	15,414	4,192,375	15,414	490,746	1,343.6	13,867	14,047	455,546	466,586	125,417,553	343,374.5	0.13
July	15,483	4,223,214	15,483	382,937	1,048.4	10,972	11,073	355,659	375,954	130,447,938	357,147.0	0.13
August	15,640	4,221,159	15,640	394,012	1,078.7	9,681	9,715	366,478	373,605	130,447,348	357,145.4	0.13
September	15,819	4,215,600	15,819	434,003	1,188.2	11,665	11,708	405,328	412,986	126,137,671	345,346.1	0.13
October	16,062	4,255,290	16,062	443,496	1,214.2	11,316	11,358	408,658	426,765	131,472,312	359,951.6	0.13
November	16,312	4,248,890	16,312	470,819	1,289.0	12,813	12,865	438,428	456,763	127,107,293	348,000.8	0.13
December	16,459	4,331,104	16,459	357,583	979.0	9,785	9,825	330,995	342,305	131,200,902	359,208.5	0.13

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2018</i>												
January	16,657	4,283,694	16,657	458,504	1,255.3	12,598	12,674	427,887	439,836	132,312,321	362,251.4	0.13
February	16,799	4,276,832	16,799	365,488	1,000.7	9,263	9,300	337,820	350,514	119,400,020	326,899.4	0.13
March	17,068	4,276,339	17,068	416,741	1,141.0	10,624	10,676	386,514	399,429	132,158,682	361,830.8	0.13
April	17,410	4,335,267	17,410	508,168	1,391.3	12,864	12,918	472,623	490,362	129,593,413	354,807.4	0.13
May	17,794	4,316,054	17,794	502,841	1,376.7	13,385	13,479	467,173	482,550	133,402,524	365,236.2	0.13
June	17,990	4,307,951	17,990	385,590	1,055.7	9,770	9,786	356,847	365,382	128,882,112	352,860.0	0.13
July	18,390	4,524,921	18,390	485,173	1,328.3	12,955	12,975	449,436	458,226	139,358,582	381,543.0	0.13
August	18,689	4,522,472	18,689	409,715	1,121.7	10,616	10,632	377,933	385,607	139,745,700	382,602.9	0.13
September	18,901	4,509,048	18,901	379,162	1,038.1	9,995	10,018	350,443	359,837	134,911,121	369,366.5	0.13
October	19,209	4,550,816	19,209	439,981	1,204.6	11,095	11,137	406,008	420,784	140,592,626	384,921.6	0.13
November	19,527	4,544,969	19,527	426,996	1,169.1	10,722	10,780	395,865	407,302	135,947,974	372,205.3	0.13
December	19,701	4,686,840	19,701	363,026	993.9	9,937	9,997	335,643	345,206	140,438,162	384,498.7	0.13
<i>2019</i>												
January	19,998	4,578,064	19,998	389,294	1,065.8	9,886	9,907	358,300	368,677	141,400,648	387,133.9	0.13
February	20,154	4,573,799	20,154	325,040	889.9	9,512	9,536	299,482	308,695	127,698,813	349,620.3	0.13
March	20,555	4,575,557	20,555	380,875	1,042.8	9,469	9,475	347,396	357,880	141,386,404	387,094.9	0.13
April	20,940	4,471,456	20,940	439,998	1,204.6	11,204	11,262	406,756	425,780	133,649,309	365,911.9	0.13
May	21,438	4,467,437	21,438	440,643	1,206.4	12,564	12,586	404,394	420,698	138,069,018	378,012.4	0.13
June	21,634	4,458,874	21,634	351,099	961.3	9,067	9,110	319,407	329,578	133,392,174	365,207.9	0.13
July	21,962	4,471,134	21,962	330,964	906.1	8,221	8,229	298,944	310,924	138,086,832	378,061.1	0.13
August	22,131	4,468,836	22,131	297,308	814.0	7,875	7,913	270,883	281,377	138,107,214	378,116.9	0.13
September	22,337	4,463,007	22,337	302,155	827.3	8,900	8,930	274,648	285,919	133,533,748	365,595.5	0.13
October	22,612	4,495,572	22,612	313,928	859.5	8,434	8,444	284,581	295,558	138,885,668	380,248.2	0.13
November	22,752	4,488,234	22,752	263,387	721.1	6,968	6,997	237,589	244,264	134,244,281	367,540.8	0.13
December	22,875	4,604,657	22,875	253,249	693.4	6,989	7,015	228,104	233,311	138,667,704	379,651.5	0.13

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2020</i>												
January	23,203	4,493,846	23,203	296,039	810.5	8,030	8,078	267,924	270,372	138,826,148	380,085.3	0.13
February	23,641	4,487,264	23,641	297,920	815.7	8,841	8,849	267,097	267,485	129,775,896	355,307.0	0.13
March	23,908	4,486,857	23,908	258,352	707.3	7,143	7,148	230,648	235,301	138,678,094	379,679.9	0.13
April	23,706	4,528,175	23,706	153,140	419.3	4,338	4,342	136,764	142,023	135,480,505	370,925.4	0.14
May	23,502	4,526,073	23,502	149,443	409.2	4,033	4,050	134,427	138,706	139,906,223	383,042.4	0.14
June	23,139	4,520,879	23,139	141,825	388.3	3,626	3,628	127,633	132,185	135,254,130	370,305.6	0.13
July	22,976	4,560,189	22,976	121,618	333.0	3,032	3,045	108,451	112,814	140,876,944	385,700.1	0.13
August	22,848	4,563,755	22,848	93,708	256.6	2,753	2,766	84,685	87,418	141,007,873	386,058.5	0.13
September	23,102	4,561,471	23,102	85,551	234.2	2,576	2,587	77,511	81,175	136,464,652	373,619.9	0.13
October	23,458	4,595,920	23,458	73,086	200.1	2,410	2,413	67,254	72,441	142,020,010	388,829.6	0.13
November	23,512	4,587,818	23,512	37,644	103.1	1,493	1,498	35,442	37,240	137,251,792	375,774.9	0.13
December	23,494	4,700,304	23,494	16,405	44.9	1,098	1,104	16,366	16,992	141,703,001	387,961.7	0.13
Losartan												
<i>Incident Losartan episodes</i>												
<i>2014</i>												
January	642	3,897,370	642	455,127	1,246.1	14,218	14,420	422,806	440,391	120,378,135	329,577.4	0.11
February	1,230	3,891,646	1,230	446,869	1,223.5	14,252	14,358	416,453	438,256	108,658,404	297,490.5	0.11
March	1,833	3,891,232	1,833	437,937	1,199.0	12,761	12,806	408,083	420,997	120,270,640	329,283.1	0.11
April	2,453	3,912,584	2,453	495,964	1,357.9	11,943	11,981	464,540	477,185	116,967,074	320,238.4	0.11
May	3,051	3,910,095	3,051	481,511	1,318.3	11,426	11,470	444,096	461,526	120,847,157	330,861.5	0.11
June	3,538	3,903,251	3,538	477,683	1,307.8	11,811	11,881	444,504	463,147	116,767,748	319,692.7	0.11
July	3,983	3,921,603	3,983	492,631	1,348.8	12,392	12,472	458,149	476,695	121,113,484	331,590.6	0.11
August	4,329	3,920,557	4,329	361,396	989.4	7,278	7,293	332,988	344,912	121,150,545	331,692.1	0.11
September	4,664	3,915,378	4,664	404,743	1,108.1	9,547	9,553	373,673	393,300	117,143,645	320,721.8	0.11
October	5,064	3,954,085	5,064	469,134	1,284.4	11,588	11,934	434,467	461,909	122,143,428	334,410.5	0.11
November	5,346	3,947,378	5,346	391,123	1,070.8	9,815	9,853	361,696	377,622	118,088,007	323,307.3	0.11
December	5,607	4,035,199	5,607	396,774	1,086.3	11,079	11,114	365,931	381,363	121,919,441	333,797.2	0.11

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2015</i>												
January	5,904	3,977,814	5,904	443,281	1,213.6	10,936	10,962	411,658	423,930	122,856,260	336,362.1	0.11
February	6,062	3,971,081	6,062	329,924	903.3	8,418	8,692	305,919	324,207	110,546,414	302,659.6	0.11
March	6,413	3,958,182	6,413	432,470	1,184.0	11,593	11,640	399,988	423,317	122,339,281	334,946.7	0.11
April	6,732	3,994,408	6,732	477,403	1,307.1	11,404	11,443	444,621	470,563	119,424,477	326,966.4	0.11
May	7,025	3,991,068	7,025	441,073	1,207.6	9,788	9,810	408,769	429,227	123,359,288	337,739.3	0.11
June	7,287	3,984,059	7,287	441,673	1,209.2	10,770	10,879	410,803	421,910	119,193,678	326,334.5	0.11
July	7,484	4,010,800	7,484	383,719	1,050.6	8,803	8,933	354,713	372,510	123,891,882	339,197.5	0.11
August	7,592	4,008,896	7,592	336,112	920.2	7,578	7,593	310,286	322,972	123,891,294	339,195.9	0.11
September	7,863	4,003,250	7,863	381,335	1,044.0	10,875	10,902	353,956	372,602	119,789,102	327,964.7	0.11
October	8,132	4,039,478	8,132	408,436	1,118.2	10,433	10,496	376,568	395,704	124,790,972	341,659.1	0.11
November	8,396	4,031,998	8,396	392,137	1,073.6	9,776	9,839	361,899	376,970	120,629,470	330,265.5	0.11
December	8,557	4,117,723	8,557	340,087	931.1	8,156	8,297	314,960	329,216	124,547,867	340,993.5	0.11
<i>2016</i>												
January	8,779	4,062,262	8,779	384,370	1,052.3	9,174	9,210	354,234	371,707	125,490,045	343,573.0	0.11
February	8,948	4,056,572	8,948	369,141	1,010.7	10,149	10,460	342,556	364,427	117,308,826	321,174.1	0.11
March	9,253	4,055,992	9,253	405,459	1,110.1	10,974	11,095	373,166	392,813	125,357,995	343,211.5	0.11
April	9,529	4,093,102	9,529	446,896	1,223.5	11,463	11,616	413,246	436,539	122,442,996	335,230.7	0.11
May	9,854	4,089,844	9,854	423,406	1,159.2	11,607	11,723	390,432	419,643	126,424,947	346,132.6	0.11
June	10,151	4,083,023	10,151	444,265	1,216.3	10,294	10,415	408,947	428,998	122,166,862	334,474.6	0.11
July	10,317	4,111,988	10,317	366,994	1,004.8	9,988	9,993	337,308	351,732	127,083,483	347,935.6	0.11
August	10,460	4,112,457	10,460	355,743	974.0	8,687	8,735	328,230	342,185	127,078,360	347,921.6	0.11
September	10,633	4,107,785	10,633	364,451	997.8	8,289	8,338	336,079	345,703	122,921,663	336,541.2	0.11
October	10,853	4,145,779	10,853	363,367	994.8	8,177	8,189	332,610	351,488	128,072,234	350,642.7	0.11
November	11,006	4,140,062	11,006	338,977	928.1	8,610	8,706	311,635	332,514	123,854,935	339,096.3	0.11
December	11,129	4,223,583	11,129	322,084	881.8	7,532	7,563	295,615	307,752	127,910,903	350,201.0	0.11

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2017</i>												
January	11,299	4,171,811	11,299	363,990	996.6	8,060	8,076	335,641	343,664	128,861,537	352,803.7	0.11
February	11,423	4,166,346	11,423	288,499	789.9	7,089	7,097	263,524	274,611	116,333,737	318,504.4	0.11
March	11,660	4,166,395	11,660	328,465	899.3	8,966	8,984	298,998	317,332	128,774,973	352,566.7	0.11
April	11,883	4,202,135	11,883	386,159	1,057.2	9,535	9,614	355,969	379,500	125,658,584	344,034.5	0.11
May	12,231	4,199,855	12,231	394,238	1,079.4	8,959	8,978	359,492	378,933	129,810,535	355,401.9	0.11
June	12,480	4,192,375	12,480	360,557	987.2	8,518	8,565	328,049	346,082	125,417,553	343,374.5	0.11
July	12,663	4,223,214	12,663	341,739	935.6	7,715	7,743	311,444	327,148	130,447,938	357,147.0	0.11
August	12,800	4,221,159	12,800	304,210	832.9	7,799	7,870	276,380	294,370	130,447,348	357,145.4	0.11
September	12,918	4,215,600	12,918	296,358	811.4	7,384	7,400	269,315	285,487	126,137,671	345,346.1	0.11
October	13,150	4,255,290	13,150	335,911	919.7	7,463	7,631	305,159	321,423	131,472,312	359,951.6	0.11
November	13,471	4,248,890	13,471	352,810	965.9	8,779	8,820	320,555	337,301	127,107,293	348,000.8	0.11
December	13,583	4,331,104	13,583	254,836	697.7	5,928	5,961	229,311	245,462	131,200,902	359,208.5	0.11
<i>2018</i>												
January	13,750	4,283,694	13,750	288,958	791.1	7,962	7,989	260,567	272,067	132,312,321	362,251.4	0.11
February	13,870	4,276,832	13,870	255,887	700.6	5,931	5,954	229,360	243,697	119,400,020	326,899.4	0.11
March	14,091	4,276,339	14,091	296,965	813.0	6,942	6,979	267,996	279,834	132,158,682	361,830.8	0.11
April	14,316	4,335,267	14,316	341,030	933.7	8,130	8,305	307,297	321,332	129,593,413	354,807.4	0.11
May	14,736	4,316,054	14,736	360,576	987.2	9,147	9,233	323,383	338,814	133,402,524	365,236.2	0.11
June	14,923	4,307,951	14,923	277,355	759.4	6,574	6,610	246,214	256,078	128,882,112	352,860.0	0.11
July	15,340	4,524,921	15,340	344,682	943.7	7,883	7,946	307,024	316,865	139,358,582	381,543.0	0.11
August	15,672	4,522,472	15,672	273,428	748.6	7,050	7,071	242,262	251,663	139,745,700	382,602.9	0.11
September	15,895	4,509,048	15,895	255,103	698.4	5,757	5,769	226,417	237,700	134,911,121	369,366.5	0.11
October	16,100	4,550,816	16,100	275,521	754.3	6,896	6,993	243,501	254,188	140,592,626	384,921.6	0.11
November	16,382	4,544,969	16,382	256,885	703.3	6,306	6,339	225,501	237,637	135,947,974	372,205.3	0.11
December	16,548	4,686,840	16,548	214,221	586.5	5,865	5,890	186,358	194,453	140,438,162	384,498.7	0.11

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2019</i>												
January	16,757	4,578,064	16,757	220,816	604.6	5,499	5,508	191,679	202,363	141,400,648	387,133.9	0.11
February	16,812	4,573,799	16,812	154,829	423.9	3,724	3,728	132,607	140,424	127,698,813	349,620.3	0.11
March	16,756	4,575,557	16,756	138,868	380.2	3,529	3,600	119,447	124,227	141,386,404	387,094.9	0.11
April	16,388	4,471,456	16,388	157,814	432.1	3,811	3,824	138,395	148,702	133,649,309	365,911.9	0.10
May	15,481	4,467,437	15,481	180,083	493.0	4,444	4,452	154,807	160,666	138,069,018	378,012.4	0.09
June	14,765	4,458,874	14,765	150,237	411.3	4,644	4,686	129,135	134,960	133,392,174	365,207.9	0.09
July	14,312	4,471,134	14,312	125,355	343.2	3,125	3,136	107,253	114,281	138,086,832	378,061.1	0.08
August	13,791	4,468,836	13,791	86,668	237.3	2,132	2,139	73,359	78,631	138,107,214	378,116.9	0.08
September	13,006	4,463,007	13,006	77,339	211.7	1,882	1,885	66,084	71,735	133,533,748	365,595.5	0.08
October	12,150	4,495,572	12,150	63,173	173.0	1,374	1,376	53,976	58,749	138,885,668	380,248.2	0.07
November	10,943	4,488,234	10,943	68,323	187.1	1,706	1,708	59,448	63,721	134,244,281	367,540.8	0.06
December	9,357	4,604,657	9,357	62,041	169.9	1,771	1,789	54,193	55,807	138,667,704	379,651.5	0.05
<i>2020</i>												
January	8,450	4,493,846	8,450	67,247	184.1	2,012	2,020	59,313	63,566	138,826,148	380,085.3	0.05
February	7,939	4,487,264	7,939	64,862	177.6	1,614	1,614	57,071	63,052	129,775,896	355,307.0	0.04
March	7,587	4,486,857	7,587	84,614	231.7	2,153	2,160	74,528	79,212	138,678,094	379,679.9	0.04
April	7,331	4,528,175	7,331	76,366	209.1	2,039	2,053	67,854	73,766	135,480,505	370,925.4	0.04
May	7,283	4,526,073	7,283	62,175	170.2	1,660	1,663	54,676	59,316	139,906,223	383,042.4	0.04
June	7,313	4,520,879	7,313	64,034	175.3	1,590	1,591	57,291	59,196	135,254,130	370,305.6	0.04
July	7,398	4,560,189	7,398	66,337	181.6	1,676	1,702	59,133	62,529	140,876,944	385,700.1	0.04
August	7,532	4,563,755	7,532	53,978	147.8	1,424	1,428	47,588	50,904	141,007,873	386,058.5	0.04
September	7,868	4,561,471	7,868	55,486	151.9	1,570	1,573	51,073	54,818	136,464,652	373,619.9	0.04
October	8,225	4,595,920	8,225	42,873	117.4	1,285	1,299	39,457	41,854	142,020,010	388,829.6	0.05
November	8,446	4,587,818	8,446	23,819	65.2	907	909	22,153	23,613	137,251,792	375,774.9	0.05
December	8,640	4,700,304	8,640	8,617	23.6	540	542	8,590	9,081	141,703,001	387,961.7	0.05

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Incident Olmesartan episodes</i>												
2014												
January	1,058	3,897,370	1,058	778,759	2,132.1	20,495	20,565	727,156	730,914	120,378,135	329,577.4	0.18
February	2,091	3,891,646	2,091	838,377	2,295.4	23,039	23,041	787,694	793,918	108,658,404	297,490.5	0.19
March	3,216	3,891,232	3,216	836,170	2,289.3	21,084	21,090	783,264	786,648	120,270,640	329,283.1	0.19
April	4,221	3,912,584	4,221	884,878	2,422.7	23,977	23,984	828,377	832,087	116,967,074	320,238.4	0.19
May	5,233	3,910,095	5,233	929,493	2,544.8	23,283	23,286	868,707	872,996	120,847,157	330,861.5	0.19
June	6,004	3,903,251	6,004	856,807	2,345.8	20,304	20,313	799,365	803,743	116,767,748	319,692.7	0.19
July	6,644	3,921,603	6,644	721,524	1,975.4	17,111	17,117	672,802	674,503	121,113,484	331,590.6	0.18
August	7,046	3,920,557	7,046	632,078	1,730.5	18,630	18,633	590,247	596,368	121,150,545	331,692.1	0.18
September	7,606	3,915,378	7,606	757,502	2,073.9	21,058	21,065	708,114	710,438	117,143,645	320,721.8	0.18
October	8,260	3,954,085	8,260	804,278	2,202.0	20,507	20,520	749,561	752,167	122,143,428	334,410.5	0.18
November	8,801	3,947,378	8,801	695,854	1,905.1	16,755	16,761	646,763	655,979	118,088,007	323,307.3	0.18
December	9,259	4,035,199	9,259	625,326	1,712.0	16,963	16,965	579,124	578,727	121,919,441	333,797.2	0.18
2015												
January	9,752	3,977,814	9,752	681,327	1,865.4	16,528	16,542	635,323	642,605	122,856,260	336,362.1	0.18
February	10,111	3,971,081	10,111	629,144	1,722.5	15,185	15,195	586,863	595,743	110,546,414	302,659.6	0.18
March	10,683	3,958,182	10,683	677,452	1,854.8	17,072	17,077	630,282	636,737	122,339,281	334,946.7	0.19
April	11,233	3,994,408	11,233	820,409	2,246.2	21,231	21,239	764,030	773,521	119,424,477	326,966.4	0.18
May	11,689	3,991,068	11,689	703,122	1,925.0	18,574	18,583	656,966	659,262	123,359,288	337,739.3	0.18
June	12,125	3,984,059	12,125	688,889	1,886.1	18,158	18,163	639,596	648,190	119,193,678	326,334.5	0.18
July	12,485	4,010,800	12,485	643,195	1,761.0	16,659	16,665	597,264	599,611	123,891,882	339,197.5	0.18
August	12,713	4,008,896	12,713	537,222	1,470.8	12,946	12,946	500,434	499,688	123,891,294	339,195.9	0.18
September	13,115	4,003,250	13,115	613,200	1,678.9	15,322	15,326	567,728	571,133	119,789,102	327,964.7	0.18
October	13,535	4,039,478	13,535	723,428	1,980.6	18,481	18,485	672,736	676,349	124,790,972	341,659.1	0.18
November	13,927	4,031,998	13,927	640,930	1,754.8	15,640	15,646	594,714	599,315	120,629,470	330,265.5	0.18
December	14,339	4,117,723	14,339	653,800	1,790.0	17,537	17,544	609,572	614,519	124,547,867	340,993.5	0.18

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2016</i>												
January	14,788	4,062,262	14,788	633,979	1,735.7	16,309	16,317	589,090	594,507	125,490,045	343,573.0	0.18
February	15,149	4,056,572	15,149	633,790	1,735.2	16,117	16,120	591,331	595,265	117,308,826	321,174.1	0.18
March	15,678	4,055,992	15,678	675,131	1,848.4	18,916	18,924	625,340	637,091	125,357,995	343,211.5	0.18
April	16,168	4,093,102	16,168	703,512	1,926.1	15,842	15,887	649,588	658,194	122,442,996	335,230.7	0.18
May	16,774	4,089,844	16,774	772,081	2,113.8	19,736	19,822	715,727	719,727	126,424,947	346,132.6	0.18
June	17,197	4,083,023	17,197	698,037	1,911.1	17,876	17,908	646,609	653,864	122,166,862	334,474.6	0.18
July	17,443	4,111,988	17,443	591,741	1,620.1	15,494	15,497	548,073	551,482	127,083,483	347,935.6	0.18
August	17,687	4,112,457	17,687	532,817	1,458.8	13,413	13,482	492,230	495,216	127,078,360	347,921.6	0.18
September	17,938	4,107,785	17,938	529,111	1,448.6	12,562	12,582	487,660	488,527	122,921,663	336,541.2	0.18
October	18,177	4,145,779	18,177	616,378	1,687.6	15,330	15,331	566,886	570,870	128,072,234	350,642.7	0.18
November	18,545	4,140,062	18,545	591,066	1,618.3	14,166	14,170	544,337	548,376	123,854,935	339,096.3	0.18
December	18,803	4,223,583	18,803	525,811	1,439.6	13,720	13,735	485,692	485,983	127,910,903	350,201.0	0.18
<i>2017</i>												
January	19,019	4,171,811	19,019	513,158	1,405.0	12,227	12,232	473,465	476,458	128,861,537	352,803.7	0.18
February	19,257	4,166,346	19,257	498,928	1,366.0	12,393	12,394	460,012	470,259	116,333,737	318,504.4	0.18
March	19,749	4,166,395	19,749	551,012	1,508.6	12,522	12,535	504,257	510,694	128,774,973	352,566.7	0.18
April	19,927	4,202,135	19,927	508,301	1,391.7	12,260	12,266	467,046	467,569	125,658,584	344,034.5	0.18
May	20,200	4,199,855	20,200	508,987	1,393.5	12,646	12,654	466,428	470,027	129,810,535	355,401.9	0.18
June	20,350	4,192,375	20,350	474,611	1,299.4	11,581	11,582	434,551	437,788	125,417,553	343,374.5	0.17
July	20,402	4,223,214	20,402	403,516	1,104.8	10,571	10,577	366,413	371,673	130,447,938	357,147.0	0.17
August	20,415	4,221,159	20,415	362,089	991.3	8,874	8,957	329,552	332,254	130,447,348	357,145.4	0.17
September	20,362	4,215,600	20,362	353,156	966.9	9,318	9,323	322,456	323,912	126,137,671	345,346.1	0.17
October	20,393	4,255,290	20,393	406,273	1,112.3	9,932	9,937	370,204	374,222	131,472,312	359,951.6	0.16
November	20,511	4,248,890	20,511	397,085	1,087.2	9,407	9,413	359,668	363,233	127,107,293	348,000.8	0.16
December	20,503	4,331,104	20,503	321,668	880.7	8,105	8,108	289,821	296,076	131,200,902	359,208.5	0.16

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2018</i>												
January	20,716	4,283,694	20,716	409,265	1,120.5	10,520	10,526	371,468	373,469	132,312,321	362,251.4	0.16
February	20,811	4,276,832	20,811	338,502	926.8	8,786	8,790	305,393	313,536	119,400,020	326,899.4	0.16
March	21,036	4,276,339	21,036	331,576	907.8	9,455	9,461	298,473	301,713	132,158,682	361,830.8	0.16
April	21,280	4,335,267	21,280	401,982	1,100.6	9,463	9,480	362,412	369,079	129,593,413	354,807.4	0.16
May	21,691	4,316,054	21,691	412,655	1,129.8	10,642	10,651	371,774	372,679	133,402,524	365,236.2	0.16
June	21,826	4,307,951	21,826	342,141	936.7	8,599	8,603	306,518	309,688	128,882,112	352,860.0	0.15
July	21,915	4,524,921	21,915	312,733	856.2	7,244	7,278	278,116	279,456	139,358,582	381,543.0	0.15
August	21,961	4,522,472	21,961	292,644	801.2	7,150	7,157	261,286	260,680	139,745,700	382,602.9	0.15
September	22,030	4,509,048	22,030	268,877	736.1	6,549	6,551	237,916	242,044	134,911,121	369,366.5	0.15
October	22,239	4,550,816	22,239	326,262	893.3	7,591	7,602	289,968	293,746	140,592,626	384,921.6	0.15
November	22,581	4,544,969	22,581	327,535	896.7	7,664	7,665	288,534	294,586	135,947,974	372,205.3	0.15
December	22,626	4,686,840	22,626	223,277	611.3	5,253	5,254	194,719	199,481	140,438,162	384,498.7	0.15
<i>2019</i>												
January	22,819	4,578,064	22,819	255,851	700.5	6,021	6,028	222,815	227,292	141,400,648	387,133.9	0.15
February	22,948	4,573,799	22,948	227,898	624.0	5,859	5,864	197,083	199,724	127,698,813	349,620.3	0.15
March	23,330	4,575,557	23,330	243,955	667.9	6,263	6,268	207,628	213,244	141,386,404	387,094.9	0.15
April	23,453	4,471,456	23,453	217,467	595.4	5,034	5,037	185,104	192,525	133,649,309	365,911.9	0.14
May	23,330	4,467,437	23,330	158,467	433.9	3,667	3,669	133,531	140,021	138,069,018	378,012.4	0.14
June	22,403	4,458,874	22,403	99,882	273.5	2,383	2,383	83,704	86,280	133,392,174	365,207.9	0.13
July	21,043	4,471,134	21,043	66,602	182.3	1,796	1,797	55,701	57,442	138,086,832	378,061.1	0.12
August	19,087	4,468,836	19,087	75,265	206.1	2,024	2,026	64,266	64,421	138,107,214	378,116.9	0.11
September	16,814	4,463,007	16,814	61,699	168.9	1,319	1,319	51,524	52,614	133,533,748	365,595.5	0.10
October	15,519	4,495,572	15,519	88,139	241.3	2,366	2,368	73,560	76,216	138,885,668	380,248.2	0.09
November	14,416	4,488,234	14,416	60,732	166.3	1,481	1,483	50,532	51,737	134,244,281	367,540.8	0.08
December	13,560	4,604,657	13,560	34,009	93.1	885	885	28,004	27,535	138,667,704	379,651.5	0.08

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2020</i>												
January	12,391	4,493,846	12,391	48,232	132.1	1,068	1,070	40,149	39,530	138,826,148	380,085.3	0.07
February	10,357	4,487,264	10,357	34,202	93.6	866	867	29,234	28,640	129,775,896	355,307.0	0.06
March	8,956	4,486,857	8,956	35,930	98.4	797	798	29,873	29,211	138,678,094	379,679.9	0.05
April	7,828	4,528,175	7,828	45,805	125.4	1,106	1,106	39,563	39,727	135,480,505	370,925.4	0.04
May	7,159	4,526,073	7,159	47,917	131.2	1,111	1,111	41,794	43,278	139,906,223	383,042.4	0.04
June	6,826	4,520,879	6,826	53,294	145.9	1,171	1,172	46,677	46,543	135,254,130	370,305.6	0.04
July	6,743	4,560,189	6,743	50,383	137.9	1,197	1,197	44,102	43,675	140,876,944	385,700.1	0.04
August	6,834	4,563,755	6,834	50,015	136.9	1,206	1,206	43,981	44,883	141,007,873	386,058.5	0.04
September	7,119	4,561,471	7,119	49,754	136.2	1,428	1,428	44,872	44,842	136,464,652	373,619.9	0.04
October	7,395	4,595,920	7,395	35,819	98.1	1,016	1,017	32,160	32,322	142,020,010	388,829.6	0.04
November	7,616	4,587,818	7,616	22,801	62.4	851	853	20,994	21,121	137,251,792	375,774.9	0.04
December	7,749	4,700,304	7,749	8,445	23.1	536	536	8,384	8,422	141,703,001	387,961.7	0.04
Telmisartan												
<i>Incident Telmisartan episodes</i>												
<i>2014</i>												
January	1,092	3,897,370	1,092	908,913	2,488.5	23,305	23,324	855,298	863,225	120,378,135	329,577.4	0.19
February	2,080	3,891,646	2,080	778,466	2,131.3	19,977	19,988	730,823	729,785	108,658,404	297,490.5	0.19
March	3,238	3,891,232	3,238	838,201	2,294.9	21,350	21,356	784,805	793,969	120,270,640	329,283.1	0.19
April	4,305	3,912,584	4,305	935,273	2,560.6	20,487	20,492	879,546	879,221	116,967,074	320,238.4	0.19
May	5,280	3,910,095	5,280	932,748	2,553.7	23,686	23,700	879,215	882,166	120,847,157	330,861.5	0.19
June	6,095	3,903,251	6,095	842,347	2,306.2	21,932	21,936	789,382	788,859	116,767,748	319,692.7	0.19
July	6,732	3,921,603	6,732	815,436	2,232.5	20,804	20,853	765,344	769,146	121,113,484	331,590.6	0.19
August	7,133	3,920,557	7,133	610,301	1,670.9	16,523	16,545	571,931	574,238	121,150,545	331,692.1	0.19
September	7,648	3,915,378	7,648	705,778	1,932.3	19,554	19,558	664,980	671,040	117,143,645	320,721.8	0.18
October	8,251	3,954,085	8,251	897,048	2,456.0	24,406	24,413	845,632	846,527	122,143,428	334,410.5	0.18
November	8,769	3,947,378	8,769	703,615	1,926.4	17,760	17,824	658,882	652,842	118,088,007	323,307.3	0.18
December	9,157	4,035,199	9,157	657,780	1,800.9	15,601	15,603	618,487	612,931	121,919,441	333,797.2	0.18

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2015</i>												
January	9,634	3,977,814	9,634	768,927	2,105.2	17,902	17,915	720,955	719,596	122,856,260	336,362.1	0.18
February	9,920	3,971,081	9,920	642,523	1,759.1	17,769	17,805	604,632	604,905	110,546,414	302,659.6	0.18
March	10,518	3,958,182	10,518	740,610	2,027.7	19,095	19,102	693,795	691,381	122,339,281	334,946.7	0.18
April	11,227	3,994,408	11,227	912,592	2,498.5	21,746	21,757	855,562	854,855	119,424,477	326,966.4	0.18
May	11,790	3,991,068	11,790	774,390	2,120.2	18,879	18,881	723,284	719,269	123,359,288	337,739.3	0.18
June	12,212	3,984,059	12,212	735,643	2,014.1	16,902	16,905	692,025	691,124	119,193,678	326,334.5	0.18
July	12,485	4,010,800	12,485	644,107	1,763.5	16,228	16,235	603,917	613,281	123,891,882	339,197.5	0.18
August	12,636	4,008,896	12,636	536,923	1,470.0	12,917	12,922	500,885	496,003	123,891,294	339,195.9	0.18
September	12,982	4,003,250	12,982	651,970	1,785.0	18,063	18,070	611,075	599,207	119,789,102	327,964.7	0.18
October	13,407	4,039,478	13,407	708,624	1,940.1	17,894	17,897	664,308	659,013	124,790,972	341,659.1	0.18
November	13,846	4,031,998	13,846	655,873	1,795.7	16,638	16,646	610,737	604,734	120,629,470	330,265.5	0.18
December	14,208	4,117,723	14,208	629,288	1,722.9	15,974	15,985	588,773	582,677	124,547,867	340,993.5	0.18
<i>2016</i>												
January	14,646	4,062,262	14,646	729,139	1,996.3	16,683	16,691	685,884	684,553	125,490,045	343,573.0	0.18
February	14,984	4,056,572	14,984	611,999	1,675.6	18,369	18,374	571,444	570,149	117,308,826	321,174.1	0.18
March	15,492	4,055,992	15,492	700,882	1,918.9	18,189	18,228	652,018	641,195	125,357,995	343,211.5	0.18
April	15,963	4,093,102	15,963	858,775	2,351.2	19,306	19,318	804,412	795,913	122,442,996	335,230.7	0.18
May	16,415	4,089,844	16,415	747,925	2,047.7	16,944	16,952	698,740	686,865	126,424,947	346,132.6	0.18
June	16,814	4,083,023	16,814	741,416	2,029.9	18,662	18,675	694,228	692,271	122,166,862	334,474.6	0.18
July	17,000	4,111,988	17,000	620,994	1,700.2	16,812	16,817	580,299	568,678	127,083,483	347,935.6	0.18
August	17,399	4,112,457	17,399	666,580	1,825.0	18,791	18,794	623,685	617,559	127,078,360	347,921.6	0.18
September	17,662	4,107,785	17,662	616,346	1,687.5	16,621	16,719	577,264	577,373	122,921,663	336,541.2	0.18
October	17,964	4,145,779	17,964	704,473	1,928.7	19,291	19,300	659,302	657,348	128,072,234	350,642.7	0.18
November	18,328	4,140,062	18,328	692,876	1,897.0	18,077	18,081	646,517	638,094	123,854,935	339,096.3	0.18
December	18,645	4,223,583	18,645	589,216	1,613.2	14,976	14,980	547,787	544,266	127,910,903	350,201.0	0.18

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2017</i>												
January	19,012	4,171,811	19,012	706,030	1,933.0	18,065	18,069	660,880	656,294	128,861,537	352,803.7	0.18
February	19,308	4,166,346	19,308	579,769	1,587.3	14,744	14,750	539,196	537,680	116,333,737	318,504.4	0.18
March	19,835	4,166,395	19,835	690,194	1,889.6	17,585	17,599	641,505	633,245	128,774,973	352,566.7	0.18
April	20,304	4,202,135	20,304	742,946	2,034.1	18,112	18,116	693,088	687,216	125,658,584	344,034.5	0.18
May	20,988	4,199,855	20,988	847,528	2,320.4	20,894	20,897	789,666	782,194	129,810,535	355,401.9	0.18
June	21,389	4,192,375	21,389	709,113	1,941.4	17,714	17,719	662,978	650,888	125,417,553	343,374.5	0.18
July	21,595	4,223,214	21,595	612,931	1,678.1	15,257	15,267	571,133	563,132	130,447,938	357,147.0	0.18
August	21,825	4,221,159	21,825	611,800	1,675.0	14,935	14,940	570,677	565,626	130,447,348	357,145.4	0.18
September	22,085	4,215,600	22,085	583,110	1,596.5	15,318	15,371	542,485	542,833	126,137,671	345,346.1	0.18
October	22,299	4,255,290	22,299	602,205	1,648.7	16,233	16,239	559,159	557,438	131,472,312	359,951.6	0.18
November	22,706	4,248,890	22,706	668,811	1,831.1	16,374	16,391	622,136	617,794	127,107,293	348,000.8	0.18
December	22,911	4,331,104	22,911	520,810	1,425.9	13,762	13,767	481,667	479,577	131,200,902	359,208.5	0.18
<i>2018</i>												
January	23,327	4,283,694	23,327	632,382	1,731.4	15,965	15,968	588,250	580,792	132,312,321	362,251.4	0.18
February	23,580	4,276,832	23,580	529,498	1,449.7	13,244	13,249	488,883	479,002	119,400,020	326,899.4	0.18
March	24,232	4,276,339	24,232	654,608	1,792.2	17,932	17,944	606,735	596,322	132,158,682	361,830.8	0.18
April	24,860	4,335,267	24,860	743,477	2,035.5	17,021	17,033	688,687	683,423	129,593,413	354,807.4	0.18
May	25,587	4,316,054	25,587	729,512	1,997.3	18,655	18,668	672,558	663,152	133,402,524	365,236.2	0.18
June	25,999	4,307,951	25,999	658,484	1,802.8	17,229	17,237	609,704	600,955	128,882,112	352,860.0	0.18
July	26,864	4,524,921	26,864	822,239	2,251.2	20,597	20,605	756,775	722,489	139,358,582	381,543.0	0.19
August	27,529	4,522,472	27,529	679,325	1,859.9	16,781	16,791	624,517	605,850	139,745,700	382,602.9	0.19
September	28,084	4,509,048	28,084	635,053	1,738.7	15,895	15,898	582,972	566,838	134,911,121	369,366.5	0.19
October	28,685	4,550,816	28,685	754,032	2,064.4	18,869	18,879	691,475	679,514	140,592,626	384,921.6	0.19
November	29,446	4,544,969	29,446	728,746	1,995.2	18,190	18,197	670,353	650,929	135,947,974	372,205.3	0.19
December	29,927	4,686,840	29,927	589,027	1,612.7	14,997	15,006	539,233	530,765	140,438,162	384,498.7	0.20

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2019</i>												
January	30,409	4,578,064	30,409	606,810	1,661.4	15,871	15,881	557,364	543,382	141,400,648	387,133.9	0.20
February	30,627	4,573,799	30,627	525,710	1,439.3	14,012	14,019	482,736	469,217	127,698,813	349,620.3	0.20
March	31,310	4,575,557	31,310	624,245	1,709.1	15,768	15,772	567,118	548,203	141,386,404	387,094.9	0.20
April	32,120	4,471,456	32,120	736,657	2,016.9	19,325	19,340	670,406	653,667	133,649,309	365,911.9	0.20
May	33,113	4,467,437	33,113	705,484	1,931.5	17,383	17,392	640,562	627,243	138,069,018	378,012.4	0.20
June	33,768	4,458,874	33,768	588,180	1,610.3	16,134	16,138	532,635	518,533	133,392,174	365,207.9	0.20
July	34,362	4,471,134	34,362	548,108	1,500.6	14,470	14,478	492,504	482,031	138,086,832	378,061.1	0.20
August	34,796	4,468,836	34,796	464,221	1,271.0	11,904	11,915	415,901	406,129	138,107,214	378,116.9	0.21
September	35,467	4,463,007	35,467	515,740	1,412.0	14,158	14,166	462,607	446,707	133,533,748	365,595.5	0.21
October	36,459	4,495,572	36,459	564,770	1,546.3	14,287	14,302	499,942	491,079	138,885,668	380,248.2	0.21
November	37,314	4,488,234	37,314	477,878	1,308.4	12,522	12,533	421,088	411,801	134,244,281	367,540.8	0.21
December	37,471	4,604,657	37,471	317,497	869.3	8,456	8,459	281,020	273,528	138,667,704	379,651.5	0.21
<i>2020</i>												
January	37,169	4,493,846	37,169	269,844	738.8	7,164	7,168	238,662	228,690	138,826,148	380,085.3	0.21
February	35,650	4,487,264	35,650	178,514	488.7	5,005	5,014	160,264	155,322	129,775,896	355,307.0	0.20
March	33,201	4,486,857	33,201	201,434	551.5	5,335	5,336	179,264	169,797	138,678,094	379,679.9	0.19
April	29,569	4,528,175	29,569	178,126	487.7	4,606	4,607	157,424	152,118	135,480,505	370,925.4	0.17
May	28,117	4,526,073	28,117	173,417	474.8	4,497	4,501	156,163	150,755	139,906,223	383,042.4	0.16
June	27,725	4,520,879	27,725	179,509	491.5	4,302	4,306	161,610	154,843	135,254,130	370,305.6	0.16
July	27,622	4,560,189	27,622	176,075	482.1	4,355	4,357	157,758	153,653	140,876,944	385,700.1	0.16
August	27,647	4,563,755	27,647	148,026	405.3	3,908	3,910	132,069	129,028	141,007,873	386,058.5	0.16
September	28,527	4,561,471	28,527	157,327	430.7	4,511	4,512	143,587	140,986	136,464,652	373,619.9	0.16
October	29,533	4,595,920	29,533	125,074	342.4	3,866	3,867	114,790	112,255	142,020,010	388,829.6	0.17
November	30,321	4,587,818	30,321	80,734	221.0	3,167	3,171	75,606	73,398	137,251,792	375,774.9	0.17
December	30,767	4,700,304	30,767	25,779	70.6	1,645	1,647	25,727	24,914	141,703,001	387,961.7	0.17

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Incident Valsartan episodes</i>												
2014												
January	1,039	3,897,370	1,039	717,163	1,963.5	16,793	16,967	669,506	680,559	120,378,135	329,577.4	0.18
February	1,929	3,891,646	1,929	585,589	1,603.3	16,917	16,937	542,474	553,933	108,658,404	297,490.5	0.17
March	2,912	3,891,232	2,912	667,971	1,828.8	17,273	17,381	620,081	640,859	120,270,640	329,283.1	0.17
April	3,900	3,912,584	3,900	821,727	2,249.8	21,220	21,316	768,845	795,102	116,967,074	320,238.4	0.17
May	4,803	3,910,095	4,803	721,950	1,976.6	18,737	19,037	673,747	691,174	120,847,157	330,861.5	0.17
June	5,514	3,903,251	5,514	680,332	1,862.6	18,334	18,344	630,819	652,174	116,767,748	319,692.7	0.17
July	6,110	3,921,603	6,110	667,339	1,827.1	18,303	18,328	621,064	629,055	121,113,484	331,590.6	0.17
August	6,518	3,920,557	6,518	505,003	1,382.6	12,192	12,209	469,321	472,344	121,150,545	331,692.1	0.17
September	7,000	3,915,378	7,000	589,959	1,615.2	15,396	15,607	545,114	560,978	117,143,645	320,721.8	0.17
October	7,627	3,954,085	7,627	701,472	1,920.5	17,506	17,537	649,924	661,264	122,143,428	334,410.5	0.17
November	8,105	3,947,378	8,105	591,974	1,620.7	14,642	14,953	548,139	573,478	118,088,007	323,307.3	0.17
December	8,571	4,035,199	8,571	587,895	1,609.6	14,946	15,028	544,273	555,728	121,919,441	333,797.2	0.17
2015												
January	9,009	3,977,814	9,009	552,690	1,513.2	14,222	14,260	509,949	517,591	122,856,260	336,362.1	0.17
February	9,318	3,971,081	9,318	495,541	1,356.7	13,061	13,078	458,731	471,856	110,546,414	302,659.6	0.17
March	9,777	3,958,182	9,777	564,920	1,546.7	14,910	15,174	521,573	540,504	122,339,281	334,946.7	0.17
April	10,270	3,994,408	10,270	714,521	1,956.3	19,382	19,461	663,580	683,869	119,424,477	326,966.4	0.17
May	10,782	3,991,068	10,782	613,636	1,680.0	14,727	14,780	566,490	577,598	123,359,288	337,739.3	0.17
June	11,147	3,984,059	11,147	571,670	1,565.1	14,727	14,797	528,031	529,194	119,193,678	326,334.5	0.17
July	11,529	4,010,800	11,529	563,467	1,542.7	13,872	13,905	519,632	528,779	123,891,882	339,197.5	0.17
August	11,746	4,008,896	11,746	466,096	1,276.1	11,478	11,584	430,249	444,153	123,891,294	339,195.9	0.17
September	12,074	4,003,250	12,074	521,287	1,427.2	13,626	13,661	478,772	488,493	119,789,102	327,964.7	0.17
October	12,553	4,039,478	12,553	614,506	1,682.4	15,323	15,343	566,333	582,384	124,790,972	341,659.1	0.17
November	12,917	4,031,998	12,917	548,405	1,501.5	13,635	13,732	504,454	546,481	120,629,470	330,265.5	0.17
December	13,291	4,117,723	13,291	517,414	1,416.6	13,565	13,626	477,552	483,795	124,547,867	340,993.5	0.17

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
January	13,744	4,062,262	13,744	574,740	1,573.6	14,992	15,161	527,078	530,518	125,490,045	343,573.0	0.17
February	14,012	4,056,572	14,012	468,939	1,283.9	11,166	11,219	429,568	433,044	117,308,826	321,174.1	0.17
March	14,481	4,055,992	14,481	543,550	1,488.2	13,294	13,351	499,115	515,489	125,357,995	343,211.5	0.17
April	14,966	4,093,102	14,966	640,178	1,752.7	15,009	15,059	588,882	603,968	122,442,996	335,230.7	0.17
May	15,482	4,089,844	15,482	628,440	1,720.6	16,797	16,869	580,473	599,382	126,424,947	346,132.6	0.17
June	15,828	4,083,023	15,828	524,491	1,436.0	11,579	11,620	479,731	495,508	122,166,862	334,474.6	0.17
July	16,113	4,111,988	16,113	478,350	1,309.7	10,985	11,080	437,183	456,136	127,083,483	347,935.6	0.17
August	16,348	4,112,457	16,348	450,378	1,233.1	10,516	10,530	409,808	422,306	127,078,360	347,921.6	0.17
September	16,588	4,107,785	16,588	436,075	1,193.9	10,129	10,212	397,337	415,778	122,921,663	336,541.2	0.17
October	16,945	4,145,779	16,945	482,487	1,321.0	11,979	12,054	437,803	449,223	128,072,234	350,642.7	0.17
November	17,364	4,140,062	17,364	517,574	1,417.0	12,473	12,511	471,454	493,722	123,854,935	339,096.3	0.17
December	17,696	4,223,583	17,696	411,184	1,125.8	9,830	9,851	371,123	400,002	127,910,903	350,201.0	0.17
2017												
January	18,029	4,171,811	18,029	464,666	1,272.2	10,632	10,648	422,760	436,216	128,861,537	352,803.7	0.17
February	18,347	4,166,346	18,347	411,578	1,126.8	9,989	10,008	371,758	395,809	116,333,737	318,504.4	0.17
March	18,812	4,166,395	18,812	469,305	1,284.9	12,495	12,552	424,672	436,847	128,774,973	352,566.7	0.17
April	19,304	4,202,135	19,304	547,708	1,499.5	14,279	14,313	497,166	566,213	125,658,584	344,034.5	0.17
May	20,513	4,199,855	20,513	1,025,884	2,808.7	37,496	37,728	951,615	1,489,491	129,810,535	355,401.9	0.18
June	21,824	4,192,375	21,824	1,211,990	3,318.2	47,667	47,856	1,134,920	1,907,631	125,417,553	343,374.5	0.19
July	22,705	4,223,214	22,705	830,661	2,274.2	21,615	21,702	768,918	1,180,788	130,447,938	357,147.0	0.19
August	23,329	4,221,159	23,329	673,540	1,844.1	17,440	17,498	620,075	941,102	130,447,348	357,145.4	0.19
September	23,754	4,215,600	23,754	526,263	1,440.8	15,852	15,907	477,670	675,388	126,137,671	345,346.1	0.19
October	24,245	4,255,290	24,245	523,954	1,434.5	16,048	16,223	474,265	652,550	131,472,312	359,951.6	0.20
November	24,825	4,248,890	24,825	546,292	1,495.7	16,191	16,246	492,755	665,753	127,107,293	348,000.8	0.20
December	25,241	4,331,104	25,241	454,377	1,244.0	13,313	13,360	408,692	547,451	131,200,902	359,208.5	0.20

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2018</i>												
January	25,819	4,283,694	25,819	495,937	1,357.8	14,144	14,211	444,586	584,616	132,312,321	362,251.4	0.20
February	26,153	4,276,832	26,153	379,889	1,040.1	11,280	11,307	338,068	454,954	119,400,020	326,899.4	0.20
March	26,761	4,276,339	26,761	444,333	1,216.5	13,516	13,552	395,792	552,848	132,158,682	361,830.8	0.20
April	27,407	4,335,267	27,407	465,564	1,274.6	13,382	13,412	413,898	571,763	129,593,413	354,807.4	0.20
May	28,152	4,316,054	28,152	440,472	1,205.9	12,331	12,477	386,926	546,657	133,402,524	365,236.2	0.20
June	28,615	4,307,951	28,615	381,598	1,044.8	11,662	11,690	334,064	491,203	128,882,112	352,860.0	0.20
July	28,314	4,524,921	28,314	218,695	598.8	7,177	7,204	195,405	317,794	139,358,582	381,543.0	0.20
August	27,456	4,522,472	27,456	155,932	426.9	6,124	6,134	143,093	253,820	139,745,700	382,602.9	0.19
September	20,693	4,509,048	20,693	156,988	429.8	5,208	5,278	146,389	241,388	134,911,121	369,366.5	0.14
October	16,220	4,550,816	16,220	217,520	595.5	7,550	7,570	199,616	334,529	140,592,626	384,921.6	0.11
November	12,934	4,544,969	12,934	247,094	676.5	8,936	8,974	229,764	386,673	135,947,974	372,205.3	0.08
December	11,554	4,686,840	11,554	208,996	572.2	7,419	7,527	192,787	319,103	140,438,162	384,498.7	0.08
<i>2019</i>												
January	11,549	4,578,064	11,549	236,407	647.2	8,147	8,231	218,679	351,174	141,400,648	387,133.9	0.07
February	11,591	4,573,799	11,591	215,357	589.6	7,318	7,336	197,999	316,721	127,698,813	349,620.3	0.07
March	11,853	4,575,557	11,853	261,461	715.8	9,129	9,151	242,039	388,301	141,386,404	387,094.9	0.07
April	12,197	4,471,456	12,197	313,967	859.6	10,931	11,062	290,003	459,367	133,649,309	365,911.9	0.08
May	12,608	4,467,437	12,608	302,322	827.7	10,298	10,381	279,414	450,341	138,069,018	378,012.4	0.08
June	12,929	4,458,874	12,929	268,031	733.8	9,401	9,428	246,093	379,188	133,392,174	365,207.9	0.08
July	13,286	4,471,134	13,286	261,079	714.8	9,237	9,338	239,109	381,281	138,086,832	378,061.1	0.08
August	13,568	4,468,836	13,568	235,033	643.5	8,449	8,467	214,120	335,258	138,107,214	378,116.9	0.08
September	13,862	4,463,007	13,862	242,482	663.9	8,374	8,408	222,935	366,513	133,533,748	365,595.5	0.08
October	14,205	4,495,572	14,205	258,113	706.7	9,757	9,792	237,607	385,353	138,885,668	380,248.2	0.08
November	14,557	4,488,234	14,557	224,374	614.3	8,092	8,127	205,124	332,819	134,244,281	367,540.8	0.08
December	14,756	4,604,657	14,756	180,077	493.0	6,726	6,751	163,198	270,510	138,667,704	379,651.5	0.08

Table 2c. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Month

Month	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2020</i>												
January	14,997	4,493,846	14,997	189,413	518.6	7,800	7,829	173,226	289,224	138,826,148	380,085.3	0.08
February	15,055	4,487,264	15,055	156,347	428.1	6,142	6,193	142,879	240,376	129,775,896	355,307.0	0.08
March	14,961	4,486,857	14,961	142,959	391.4	5,458	5,475	131,088	210,016	138,678,094	379,679.9	0.08
April	14,615	4,528,175	14,615	93,703	256.5	3,273	3,290	85,248	125,896	135,480,505	370,925.4	0.08
May	14,351	4,526,073	14,351	90,046	246.5	3,223	3,240	82,086	124,226	139,906,223	383,042.4	0.08
June	14,328	4,520,879	14,328	95,737	262.1	3,228	3,247	87,251	138,356	135,254,130	370,305.6	0.08
July	14,464	4,560,189	14,464	91,765	251.2	3,201	3,223	83,186	128,610	140,876,944	385,700.1	0.08
August	14,603	4,563,755	14,603	84,656	231.8	3,157	3,180	77,781	119,548	141,007,873	386,058.5	0.08
September	14,988	4,561,471	14,988	75,528	206.8	2,825	2,830	68,989	104,055	136,464,652	373,619.9	0.09
October	15,493	4,595,920	15,493	64,643	177.0	2,811	2,818	59,680	90,646	142,020,010	388,829.6	0.09
November	15,909	4,587,818	15,909	41,992	115.0	2,046	2,051	38,617	58,691	137,251,792	375,774.9	0.09
December	16,262	4,700,304	16,262	15,146	41.5	1,159	1,163	15,035	22,847	141,703,001	387,961.7	0.09

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year month divided by all ARB episodes in the same year month

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
<i>Incident ARB episodes</i>												
2014												
Q1: January - March	16,982	3,921,482	16,982	13,836,365	37,881.9	385,840	388,123	13,060,225	13,384,831	349,307,179	956,350.9	1.00
Q2: April - June	35,142	3,938,431	35,142	15,265,602	41,794.9	402,233	404,087	14,416,641	14,769,617	354,581,979	970,792.6	1.00
Q3: July - September	46,174	3,945,952	46,174	12,426,094	34,020.8	339,251	341,730	11,718,887	12,045,456	359,407,674	984,004.6	1.00
Q4: October - December	55,375	4,070,867	55,375	12,665,374	34,675.9	339,245	341,879	11,929,694	12,241,645	362,150,876	991,515.1	1.00
2015												
Q1: January - March	63,221	4,001,976	63,221	11,845,346	32,430.8	322,772	325,039	11,156,704	11,435,594	355,741,955	973,968.4	1.00
Q2: April - June	72,993	4,019,644	72,993	13,822,938	37,845.1	362,899	364,966	13,035,598	13,353,928	361,977,443	991,040.2	1.00
Q3: July - September	78,559	4,033,972	78,559	10,793,270	29,550.4	290,958	292,825	10,157,756	10,407,523	367,572,278	1,006,358.1	1.00
Q4: October - December	85,007	4,153,561	85,007	11,842,729	32,423.6	312,447	313,869	11,156,792	11,469,321	369,968,309	1,012,918.0	1.00
2016												
Q1: January - March	92,177	4,087,087	92,177	11,867,141	32,490.5	327,484	329,700	11,176,600	11,466,313	368,156,866	1,007,958.6	1.00
Q2: April - June	101,130	4,118,442	101,130	13,339,130	36,520.5	344,565	346,762	12,569,384	12,934,324	371,034,805	1,015,837.9	1.00
Q3: July - September	105,623	4,137,151	105,623	10,559,077	28,909.2	284,351	286,321	9,933,096	10,163,840	377,083,506	1,032,398.4	1.00
Q4: October - December	111,113	4,258,424	111,113	11,034,428	30,210.6	295,518	296,838	10,363,440	10,676,224	379,838,072	1,039,940.0	1.00
2017												
Q1: January - March	116,946	4,197,321	116,946	10,783,664	29,524.1	290,118	292,044	10,136,816	10,409,222	373,970,247	1,023,874.7	1.00
Q2: April - June	126,472	4,227,625	126,472	13,145,944	35,991.6	378,796	380,822	12,379,997	14,039,876	380,886,672	1,042,810.9	1.00
Q3: July - September	131,372	4,247,686	131,372	10,445,821	28,599.1	290,398	291,969	9,817,236	10,990,261	387,032,957	1,059,638.5	1.00
Q4: October - December	136,608	4,368,668	136,608	10,303,933	28,210.6	288,505	290,430	9,660,509	10,434,688	389,780,507	1,067,160.9	1.00
2018												
Q1: January - March	142,403	4,310,535	142,403	10,053,322	27,524.5	287,740	289,051	9,439,200	10,058,963	383,871,023	1,050,981.6	1.00
Q2: April - June	151,699	4,360,702	151,699	11,585,361	31,719.0	315,888	317,676	10,883,962	11,606,191	391,878,049	1,072,903.6	1.00
Q3: July - September	158,155	4,552,517	158,155	9,888,184	27,072.4	277,699	279,036	9,229,675	9,694,386	414,015,403	1,133,512.4	1.00
Q4: October - December	163,899	4,725,780	163,899	9,459,714	25,899.3	263,847	265,198	8,809,595	9,409,027	416,978,762	1,141,625.6	1.00
2019												
Q1: January - March	169,499	4,608,997	169,499	8,477,198	23,209.3	242,196	243,300	7,863,968	8,440,084	410,485,865	1,123,849.0	1.00
Q2: April - June	178,605	4,498,391	178,605	9,185,050	25,147.3	259,906	261,129	8,511,934	9,186,774	405,110,501	1,109,132.1	1.00
Q3: July - September	182,461	4,496,523	182,461	6,783,162	18,571.3	198,774	199,826	6,240,024	6,814,893	409,727,794	1,121,773.6	1.00
Q4: October - December	187,397	4,643,653	187,397	6,474,101	17,725.1	191,840	192,649	5,932,897	6,465,405	411,797,653	1,127,440.5	1.00

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2020</i>												
Q1: January - March	190,377	4,520,543	190,377	4,762,696	13,039.6	145,457	146,168	4,331,255	4,734,497	407,280,138	1,115,072.2	1.00
Q2: April - June	185,876	4,556,197	185,876	2,823,851	7,731.3	80,022	80,271	2,562,015	2,741,411	410,640,858	1,124,273.4	1.00
Q3: July - September	185,020	4,591,948	185,020	2,255,864	6,176.2	67,721	67,991	2,051,768	2,213,223	418,349,469	1,145,378.4	1.00
Q4: October - December	193,104	4,738,974	193,104	1,040,680	2,849.2	42,405	42,565	974,181	1,046,806	420,974,803	1,152,566.2	1.00
Candesartan												
<i>Incident Candesartan episodes</i>												
<i>2014</i>												
Q1: January - March	3,229	3,921,482	3,229	2,586,814	7,082.3	72,754	73,864	2,433,605	2,546,633	349,307,179	956,350.9	0.19
Q2: April - June	6,777	3,938,431	6,777	2,901,820	7,944.8	79,535	80,486	2,725,169	2,824,884	354,581,979	970,792.6	0.19
Q3: July - September	9,123	3,945,952	9,123	2,570,105	7,036.6	75,647	77,106	2,419,315	2,545,049	359,407,674	984,004.6	0.20
Q4: October - December	10,981	4,070,867	10,981	2,532,349	6,933.2	72,055	73,030	2,378,504	2,486,461	362,150,876	991,515.1	0.20
<i>2015</i>												
Q1: January - March	12,564	4,001,976	12,564	2,346,895	6,425.4	69,693	70,618	2,202,308	2,285,808	355,741,955	973,968.4	0.20
Q2: April - June	14,705	4,019,644	14,705	2,928,567	8,018.0	78,325	79,241	2,752,592	2,847,799	361,977,443	991,040.2	0.20
Q3: July - September	15,851	4,033,972	15,851	2,170,099	5,941.4	60,992	62,027	2,035,444	2,136,405	367,572,278	1,006,358.1	0.20
Q4: October - December	17,170	4,153,561	17,170	2,411,840	6,603.3	61,971	62,526	2,267,531	2,379,183	369,968,309	1,012,918.0	0.20
<i>2016</i>												
Q1: January - March	18,650	4,087,087	18,650	2,427,754	6,646.8	70,972	71,898	2,276,620	2,377,100	368,156,866	1,007,958.6	0.20
Q2: April - June	20,546	4,118,442	20,546	2,739,784	7,501.1	74,269	75,256	2,576,447	2,714,379	371,034,805	1,015,837.9	0.20
Q3: July - September	21,401	4,137,151	21,401	2,117,865	5,798.4	58,652	59,346	1,980,576	2,047,398	377,083,506	1,032,398.4	0.20
Q4: October - December	22,566	4,258,424	22,566	2,311,073	6,327.4	64,942	65,567	2,159,397	2,253,032	379,838,072	1,039,940.0	0.20
<i>2017</i>												
Q1: January - March	23,849	4,197,321	23,849	2,208,946	6,047.8	60,997	62,087	2,065,416	2,146,944	373,970,247	1,023,874.7	0.20
Q2: April - June	25,415	4,227,625	25,415	2,475,405	6,777.3	68,738	69,738	2,317,410	2,424,126	380,886,672	1,042,810.9	0.20
Q3: July - September	26,256	4,247,686	26,256	2,048,161	5,607.6	58,547	59,279	1,907,903	1,995,255	387,032,957	1,059,638.5	0.20
Q4: October - December	27,581	4,368,668	27,581	2,233,357	6,114.6	64,114	64,961	2,080,823	2,164,468	389,780,507	1,067,160.9	0.20
<i>2018</i>												
Q1: January - March	28,959	4,310,535	28,959	2,133,757	5,841.9	63,444	64,014	1,986,472	2,061,371	383,871,023	1,050,981.6	0.20
Q2: April - June	31,026	4,360,702	31,026	2,499,681	6,843.8	67,827	68,436	2,327,814	2,417,858	391,878,049	1,072,903.6	0.20
Q3: July - September	34,562	4,552,517	34,562	3,132,478	8,576.3	92,667	93,554	2,916,187	2,996,055	414,015,403	1,133,512.4	0.22
Q4: October - December	37,580	4,725,780	37,580	2,868,447	7,853.4	79,614	80,328	2,665,236	2,748,187	416,978,762	1,141,625.6	0.23

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2019</i>												
Q1: January - March	40,538	4,608,997	40,538	2,740,828	7,504.0	78,479	79,173	2,538,334	2,641,863	410,485,865	1,123,849.0	0.24
Q2: April - June	45,080	4,498,391	45,080	3,225,851	8,831.9	88,455	89,125	2,984,103	3,089,546	405,110,501	1,109,132.1	0.25
Q3: July - September	48,501	4,496,523	48,501	2,531,283	6,930.3	72,664	73,213	2,319,584	2,420,922	409,727,794	1,121,773.6	0.27
Q4: October - December	53,308	4,643,653	53,308	2,742,763	7,509.3	80,601	81,111	2,504,936	2,607,906	411,797,653	1,127,440.5	0.28
<i>2020</i>												
Q1: January - March	58,040	4,520,543	58,040	2,271,652	6,219.4	68,853	69,327	2,059,411	2,158,924	407,280,138	1,115,072.2	0.30
Q2: April - June	57,726	4,556,197	57,726	1,189,522	3,256.7	34,933	35,076	1,083,729	1,113,855	410,640,858	1,124,273.4	0.31
Q3: July - September	57,910	4,591,948	57,910	883,981	2,420.2	28,023	28,167	804,041	830,133	418,349,469	1,145,378.4	0.31
Q4: October - December	61,750	4,738,974	61,750	416,324	1,139.8	17,283	17,385	387,851	394,288	420,974,803	1,152,566.2	0.32
Irbesartan												
<i>Incident Irbesartan episodes</i>												
<i>2014</i>												
Q1: January - March	2,513	3,921,482	2,513	2,020,118	5,530.8	54,953	55,171	1,896,212	1,936,925	349,307,179	956,350.9	0.15
Q2: April - June	5,143	3,938,431	5,143	2,228,676	6,101.8	57,162	57,350	2,095,556	2,162,497	354,581,979	970,792.6	0.15
Q3: July - September	6,649	3,945,952	6,649	1,664,401	4,556.9	41,782	42,038	1,560,118	1,608,437	359,407,674	984,004.6	0.14
Q4: October - December	7,823	4,070,867	7,823	1,663,495	4,554.4	41,435	41,662	1,554,328	1,594,783	362,150,876	991,515.1	0.14
<i>2015</i>												
Q1: January - March	8,939	4,001,976	8,939	1,630,966	4,465.3	45,013	45,503	1,527,321	1,564,154	355,741,955	973,968.4	0.14
Q2: April - June	10,281	4,019,644	10,281	1,889,920	5,174.3	49,369	49,941	1,770,272	1,822,368	361,977,443	991,040.2	0.14
Q3: July - September	10,971	4,033,972	10,971	1,421,283	3,891.3	37,467	37,751	1,328,598	1,360,990	367,572,278	1,006,358.1	0.14
Q4: October - December	11,806	4,153,561	11,806	1,590,942	4,355.8	41,662	41,963	1,489,168	1,522,575	369,968,309	1,012,918.0	0.14
<i>2016</i>												
Q1: January - March	12,677	4,087,087	12,677	1,549,932	4,243.5	40,674	40,967	1,446,953	1,480,365	368,156,866	1,007,958.6	0.14
Q2: April - June	13,736	4,118,442	13,736	1,746,035	4,780.4	43,411	43,653	1,636,914	1,681,234	371,034,805	1,015,837.9	0.14
Q3: July - September	14,262	4,137,151	14,262	1,354,207	3,707.6	35,119	35,514	1,265,940	1,295,591	377,083,506	1,032,398.4	0.14
Q4: October - December	14,903	4,258,424	14,903	1,378,786	3,774.9	35,854	36,071	1,284,113	1,332,851	379,838,072	1,039,940.0	0.13
<i>2017</i>												
Q1: January - March	15,646	4,197,321	15,646	1,443,041	3,950.8	38,805	39,021	1,344,521	1,379,239	373,970,247	1,023,874.7	0.13
Q2: April - June	16,594	4,227,625	16,594	1,518,020	4,156.1	38,772	38,997	1,411,869	1,455,469	380,886,672	1,042,810.9	0.13
Q3: July - September	17,014	4,247,686	17,014	1,210,952	3,315.4	32,318	32,496	1,127,465	1,162,544	387,032,957	1,059,638.5	0.13
Q4: October - December	17,622	4,368,668	17,622	1,271,898	3,482.3	33,914	34,048	1,178,081	1,225,834	389,780,507	1,067,160.9	0.13

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2018</i>												
Q1: January - March	18,230	4,310,535	18,230	1,240,733	3,396.9	32,485	32,650	1,152,221	1,189,779	383,871,023	1,050,981.6	0.13
Q2: April - June	19,261	4,360,702	19,261	1,396,599	3,823.7	36,019	36,183	1,296,643	1,338,294	391,878,049	1,072,903.6	0.13
Q3: July - September	20,179	4,552,517	20,179	1,274,050	3,488.2	33,566	33,625	1,177,812	1,203,670	414,015,403	1,133,512.4	0.13
Q4: October - December	21,068	4,725,780	21,068	1,230,003	3,367.6	31,754	31,914	1,137,516	1,173,292	416,978,762	1,141,625.6	0.13
<i>2019</i>												
Q1: January - March	21,842	4,608,997	21,842	1,095,209	2,998.5	28,867	28,918	1,005,178	1,035,252	410,485,865	1,123,849.0	0.13
Q2: April - June	23,229	4,498,391	23,229	1,231,740	3,372.3	32,835	32,958	1,130,557	1,176,056	405,110,501	1,109,132.1	0.13
Q3: July - September	23,953	4,496,523	23,953	930,427	2,547.4	24,996	25,072	844,475	878,220	409,727,794	1,121,773.6	0.13
Q4: October - December	24,586	4,643,653	24,586	830,564	2,274.0	22,391	22,456	750,274	773,133	411,797,653	1,127,440.5	0.13
<i>2020</i>												
Q1: January - March	25,757	4,520,543	25,757	852,311	2,333.5	24,014	24,075	765,669	773,158	407,280,138	1,115,072.2	0.14
Q2: April - June	25,384	4,556,197	25,384	444,408	1,216.7	11,997	12,020	398,824	412,914	410,640,858	1,124,273.4	0.14
Q3: July - September	24,581	4,591,948	24,581	300,877	823.8	8,361	8,398	270,647	281,407	418,349,469	1,145,378.4	0.13
Q4: October - December	25,208	4,738,974	25,208	127,135	348.1	5,001	5,015	119,062	126,672	420,974,803	1,152,566.2	0.13
Losartan												
<i>Incident Losartan episodes</i>												
<i>2014</i>												
Q1: January - March	1,839	3,921,482	1,839	1,339,933	3,668.5	41,231	41,584	1,247,342	1,299,644	349,307,179	956,350.9	0.11
Q2: April - June	3,875	3,938,431	3,875	1,455,158	3,984.0	35,180	35,332	1,353,140	1,401,859	354,581,979	970,792.6	0.11
Q3: July - September	5,186	3,945,952	5,186	1,258,770	3,446.3	29,217	29,318	1,164,810	1,214,907	359,407,674	984,004.6	0.11
Q4: October - December	6,274	4,070,867	6,274	1,257,031	3,441.6	32,482	32,901	1,162,094	1,220,894	362,150,876	991,515.1	0.11
<i>2015</i>												
Q1: January - March	7,080	4,001,976	7,080	1,205,675	3,301.0	30,947	31,294	1,117,565	1,171,453	355,741,955	973,968.4	0.11
Q2: April - June	8,084	4,019,644	8,084	1,360,149	3,723.9	31,962	32,132	1,264,193	1,321,700	361,977,443	991,040.2	0.11
Q3: July - September	8,667	4,033,972	8,667	1,101,166	3,014.8	27,256	27,428	1,018,955	1,068,084	367,572,278	1,006,358.1	0.11
Q4: October - December	9,319	4,153,561	9,319	1,140,660	3,123.0	28,365	28,632	1,053,427	1,101,890	369,968,309	1,012,918.0	0.11
<i>2016</i>												
Q1: January - March	10,046	4,087,087	10,046	1,158,970	3,173.1	30,297	30,765	1,069,956	1,128,947	368,156,866	1,007,958.6	0.11
Q2: April - June	11,032	4,118,442	11,032	1,314,567	3,599.1	33,364	33,754	1,212,625	1,285,180	371,034,805	1,015,837.9	0.11
Q3: July - September	11,580	4,137,151	11,580	1,087,188	2,976.6	26,964	27,066	1,001,617	1,039,621	377,083,506	1,032,398.4	0.11
Q4: October - December	12,093	4,258,424	12,093	1,024,428	2,804.7	24,319	24,458	939,860	991,753	379,838,072	1,039,940.0	0.11

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Losartan												
<i>2017</i>												
Q1: January - March	12,575	4,197,321	12,575	980,954	2,685.7	24,115	24,157	898,163	935,606	373,970,247	1,023,874.7	0.11
Q2: April - June	13,486	4,227,625	13,486	1,140,954	3,123.8	27,012	27,157	1,043,510	1,104,515	380,886,672	1,042,810.9	0.11
Q3: July - September	14,003	4,247,686	14,003	942,307	2,579.9	22,898	23,013	857,139	907,004	387,032,957	1,059,638.5	0.11
Q4: October - December	14,578	4,368,668	14,578	943,557	2,583.3	22,170	22,412	855,025	904,186	389,780,507	1,067,160.9	0.11
<i>2018</i>												
Q1: January - March	15,142	4,310,535	15,142	841,810	2,304.8	20,835	20,922	757,923	795,598	383,871,023	1,050,981.6	0.11
Q2: April - June	16,068	4,360,702	16,068	978,961	2,680.2	23,851	24,148	876,894	916,223	391,878,049	1,072,903.6	0.11
Q3: July - September	17,023	4,552,517	17,023	873,213	2,390.7	20,690	20,786	775,703	806,228	414,015,403	1,133,512.4	0.11
Q4: October - December	17,759	4,725,780	17,759	746,627	2,044.2	19,067	19,222	655,360	686,278	416,978,762	1,141,625.6	0.11
<i>2019</i>												
Q1: January - March	17,997	4,608,997	17,997	514,513	1,408.7	12,752	12,836	443,733	467,014	410,485,865	1,123,849.0	0.11
Q2: April - June	17,809	4,498,391	17,809	488,134	1,336.4	12,899	12,962	422,337	444,329	405,110,501	1,109,132.1	0.10
Q3: July - September	15,146	4,496,523	15,146	289,362	792.2	7,139	7,160	246,696	264,647	409,727,794	1,121,773.6	0.08
Q4: October - December	12,749	4,643,653	12,749	193,537	529.9	4,851	4,873	167,617	178,277	411,797,653	1,127,440.5	0.07
<i>2020</i>												
Q1: January - March	9,182	4,520,543	9,182	216,723	593.4	5,779	5,794	190,912	205,830	407,280,138	1,115,072.2	0.05
Q2: April - June	8,082	4,556,197	8,082	202,575	554.6	5,289	5,307	179,821	192,278	410,640,858	1,124,273.4	0.04
Q3: July - September	8,389	4,591,948	8,389	175,801	481.3	4,670	4,703	157,794	168,250	418,349,469	1,145,378.4	0.05
Q4: October - December	9,228	4,738,974	9,228	75,309	206.2	2,732	2,750	70,200	74,547	420,974,803	1,152,566.2	0.05
Olmesartan												
<i>Incident Olmesartan episodes</i>												
<i>2014</i>												
Q1: January - March	3,222	3,921,482	3,222	2,453,306	6,716.8	64,618	64,696	2,298,114	2,311,481	349,307,179	956,350.9	0.19
Q2: April - June	6,597	3,938,431	6,597	2,671,178	7,313.3	67,564	67,583	2,496,449	2,508,826	354,581,979	970,792.6	0.19
Q3: July - September	8,548	3,945,952	8,548	2,111,104	5,779.9	56,799	56,815	1,971,163	1,981,309	359,407,674	984,004.6	0.19
Q4: October - December	10,236	4,070,867	10,236	2,125,458	5,819.2	54,225	54,246	1,975,448	1,986,872	362,150,876	991,515.1	0.18
<i>2015</i>												
Q1: January - March	11,689	4,001,976	11,689	1,987,923	5,442.6	48,785	48,814	1,852,468	1,875,085	355,741,955	973,968.4	0.18
Q2: April - June	13,403	4,019,644	13,403	2,212,420	6,057.3	57,963	57,985	2,060,592	2,080,973	361,977,443	991,040.2	0.18
Q3: July - September	14,380	4,033,972	14,380	1,793,617	4,910.7	44,927	44,937	1,665,426	1,670,432	367,572,278	1,006,358.1	0.18
Q4: October - December	15,575	4,153,561	15,575	2,018,158	5,525.4	51,658	51,675	1,877,022	1,890,183	369,968,309	1,012,918.0	0.18

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2016</i>												
Q1: January - March	16,958	4,087,087	16,958	1,942,900	5,319.4	51,342	51,361	1,805,761	1,826,864	368,156,866	1,007,958.6	0.18
Q2: April - June	18,685	4,118,442	18,685	2,173,630	5,951.1	53,454	53,617	2,011,924	2,031,785	371,034,805	1,015,837.9	0.18
Q3: July - September	19,425	4,137,151	19,425	1,653,669	4,527.5	41,469	41,561	1,527,963	1,535,225	377,083,506	1,032,398.4	0.18
Q4: October - December	20,263	4,258,424	20,263	1,733,255	4,745.4	43,216	43,236	1,596,915	1,605,228	379,838,072	1,039,940.0	0.18
<i>2017</i>												
Q1: January - March	21,167	4,197,321	21,167	1,563,098	4,279.5	37,142	37,161	1,437,734	1,457,411	373,970,247	1,023,874.7	0.18
Q2: April - June	22,021	4,227,625	22,021	1,491,899	4,084.6	36,487	36,502	1,368,025	1,375,384	380,886,672	1,042,810.9	0.17
Q3: July - September	22,027	4,247,686	22,027	1,118,761	3,063.0	28,763	28,857	1,018,421	1,027,839	387,032,957	1,059,638.5	0.17
Q4: October - December	22,152	4,368,668	22,152	1,125,026	3,080.2	27,444	27,458	1,019,693	1,033,531	389,780,507	1,067,160.9	0.16
<i>2018</i>												
Q1: January - March	22,474	4,310,535	22,474	1,079,343	2,955.1	28,761	28,777	975,334	988,718	383,871,023	1,050,981.6	0.16
Q2: April - June	23,402	4,360,702	23,402	1,156,778	3,167.1	28,704	28,734	1,040,704	1,051,445	391,878,049	1,072,903.6	0.15
Q3: July - September	23,692	4,552,517	23,692	874,254	2,393.6	20,943	20,986	777,318	782,180	414,015,403	1,133,512.4	0.15
Q4: October - December	24,190	4,725,780	24,190	877,074	2,401.3	20,508	20,521	773,221	787,813	416,978,762	1,141,625.6	0.15
<i>2019</i>												
Q1: January - March	24,834	4,608,997	24,834	727,704	1,992.3	18,143	18,160	627,526	640,261	410,485,865	1,123,849.0	0.15
Q2: April - June	24,721	4,498,391	24,721	475,816	1,302.7	11,084	11,089	402,339	418,827	405,110,501	1,109,132.1	0.14
Q3: July - September	21,734	4,496,523	21,734	203,566	557.3	5,139	5,142	171,491	174,477	409,727,794	1,121,773.6	0.12
Q4: October - December	16,075	4,643,653	16,075	182,880	500.7	4,732	4,736	152,096	155,488	411,797,653	1,127,440.5	0.09
<i>2020</i>												
Q1: January - March	12,788	4,520,543	12,788	118,364	324.1	2,731	2,735	99,256	97,381	407,280,138	1,115,072.2	0.07
Q2: April - June	8,468	4,556,197	8,468	147,016	402.5	3,388	3,389	128,034	129,548	410,640,858	1,124,273.4	0.05
Q3: July - September	7,663	4,591,948	7,663	150,152	411.1	3,831	3,831	132,955	133,401	418,349,469	1,145,378.4	0.04
Q4: October - December	8,342	4,738,974	8,342	67,065	183.6	2,403	2,406	61,538	61,865	420,974,803	1,152,566.2	0.04
Telmisartan												
<i>Incident Telmisartan episodes</i>												
<i>2014</i>												
Q1: January - March	3,246	3,921,482	3,246	2,525,580	6,914.7	64,632	64,668	2,370,926	2,386,979	349,307,179	956,350.9	0.19
Q2: April - June	6,656	3,938,431	6,656	2,710,368	7,420.6	66,105	66,128	2,548,143	2,550,247	354,581,979	970,792.6	0.19
Q3: July - September	8,577	3,945,952	8,577	2,131,515	5,835.8	56,881	56,956	2,002,255	2,014,423	359,407,674	984,004.6	0.19
Q4: October - December	10,154	4,070,867	10,154	2,258,443	6,183.3	57,767	57,840	2,123,001	2,112,300	362,150,876	991,515.1	0.18

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2015</i>												
Q1: January - March	11,560	4,001,976	11,560	2,152,060	5,892.0	54,766	54,822	2,019,382	2,015,882	355,741,955	973,968.4	0.18
Q2: April - June	13,424	4,019,644	13,424	2,422,625	6,632.8	57,527	57,543	2,270,871	2,265,248	361,977,443	991,040.2	0.18
Q3: July - September	14,334	4,033,972	14,334	1,833,000	5,018.5	47,208	47,227	1,715,877	1,708,492	367,572,278	1,006,358.1	0.18
Q4: October - December	15,446	4,153,561	15,446	1,993,785	5,458.7	50,506	50,528	1,863,818	1,846,424	369,968,309	1,012,918.0	0.18
<i>2016</i>												
Q1: January - March	16,754	4,087,087	16,754	2,042,020	5,590.7	53,241	53,293	1,909,346	1,895,897	368,156,866	1,007,958.6	0.18
Q2: April - June	18,327	4,118,442	18,327	2,348,116	6,428.8	54,912	54,945	2,197,380	2,175,049	371,034,805	1,015,837.9	0.18
Q3: July - September	19,086	4,137,151	19,086	1,903,920	5,212.6	52,224	52,330	1,781,248	1,763,611	377,083,506	1,032,398.4	0.18
Q4: October - December	20,187	4,258,424	20,187	1,986,565	5,438.9	52,344	52,361	1,853,606	1,839,709	379,838,072	1,039,940.0	0.18
<i>2017</i>												
Q1: January - March	21,244	4,197,321	21,244	1,975,993	5,410.0	50,394	50,418	1,841,581	1,827,219	373,970,247	1,023,874.7	0.18
Q2: April - June	23,089	4,227,625	23,089	2,299,587	6,295.9	56,720	56,732	2,145,732	2,120,299	380,886,672	1,042,810.9	0.18
Q3: July - September	23,819	4,247,686	23,819	1,807,841	4,949.6	45,510	45,578	1,684,295	1,671,591	387,032,957	1,059,638.5	0.18
Q4: October - December	24,662	4,368,668	24,662	1,791,826	4,905.8	46,369	46,397	1,662,962	1,654,809	389,780,507	1,067,160.9	0.18
<i>2018</i>												
Q1: January - March	25,838	4,310,535	25,838	1,816,488	4,973.3	47,141	47,161	1,683,868	1,656,117	383,871,023	1,050,981.6	0.18
Q2: April - June	27,932	4,360,702	27,932	2,131,473	5,835.7	52,905	52,938	1,970,949	1,947,530	391,878,049	1,072,903.6	0.18
Q3: July - September	30,059	4,552,517	30,059	2,136,617	5,849.7	53,273	53,294	1,964,264	1,895,177	414,015,403	1,133,512.4	0.19
Q4: October - December	32,052	4,725,780	32,052	2,071,805	5,672.3	52,056	52,082	1,901,061	1,861,208	416,978,762	1,141,625.6	0.20
<i>2019</i>												
Q1: January - March	33,683	4,608,997	33,683	1,756,765	4,809.8	45,651	45,672	1,607,218	1,560,802	410,485,865	1,123,849.0	0.20
Q2: April - June	36,162	4,498,391	36,162	2,030,321	5,558.7	52,842	52,870	1,843,603	1,799,442	405,110,501	1,109,132.1	0.20
Q3: July - September	37,994	4,496,523	37,994	1,528,069	4,183.6	40,532	40,559	1,371,012	1,334,867	409,727,794	1,121,773.6	0.21
Q4: October - December	40,013	4,643,653	40,013	1,360,145	3,723.9	35,265	35,294	1,202,050	1,176,407	411,797,653	1,127,440.5	0.21
<i>2020</i>												
Q1: January - March	38,967	4,520,543	38,967	649,792	1,779.0	17,504	17,518	578,190	553,809	407,280,138	1,115,072.2	0.20
Q2: April - June	31,656	4,556,197	31,656	531,052	1,453.9	13,405	13,414	475,197	457,716	410,640,858	1,124,273.4	0.17
Q3: July - September	30,416	4,591,948	30,416	481,428	1,318.1	12,774	12,779	433,414	423,668	418,349,469	1,145,378.4	0.16
Q4: October - December	32,698	4,738,974	32,698	231,587	634.1	8,678	8,685	216,123	210,567	420,974,803	1,152,566.2	0.17

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Incident Valsartan episodes</i>												
<i>2014</i>												
Q1: January - March	2,920	3,921,482	2,920	1,970,723	5,395.5	50,983	51,285	1,832,061	1,875,351	349,307,179	956,350.9	0.17
Q2: April - June	6,017	3,938,431	6,017	2,224,009	6,089.0	58,291	58,697	2,073,411	2,138,450	354,581,979	970,792.6	0.17
Q3: July - September	7,848	3,945,952	7,848	1,762,301	4,824.9	45,891	46,144	1,635,499	1,662,377	359,407,674	984,004.6	0.17
Q4: October - December	9,476	4,070,867	9,476	1,881,341	5,150.8	47,094	47,518	1,742,336	1,790,470	362,150,876	991,515.1	0.17
<i>2015</i>												
Q1: January - March	10,750	4,001,976	10,750	1,613,151	4,416.6	42,193	42,512	1,490,253	1,529,952	355,741,955	973,968.4	0.17
Q2: April - June	12,271	4,019,644	12,271	1,899,827	5,201.4	48,836	49,038	1,758,101	1,790,661	361,977,443	991,040.2	0.17
Q3: July - September	13,293	4,033,972	13,293	1,550,850	4,246.0	38,976	39,150	1,428,653	1,461,425	367,572,278	1,006,358.1	0.17
Q4: October - December	14,452	4,153,561	14,452	1,680,325	4,600.5	42,523	42,701	1,548,339	1,612,660	369,968,309	1,012,918.0	0.17
<i>2016</i>												
Q1: January - March	15,659	4,087,087	15,659	1,587,229	4,345.6	39,452	39,731	1,455,761	1,479,051	368,156,866	1,007,958.6	0.17
Q2: April - June	17,171	4,118,442	17,171	1,793,109	4,909.3	43,385	43,548	1,649,086	1,698,858	371,034,805	1,015,837.9	0.17
Q3: July - September	17,979	4,137,151	17,979	1,364,803	3,736.6	31,630	31,822	1,244,328	1,294,220	377,083,506	1,032,398.4	0.17
Q4: October - December	19,011	4,258,424	19,011	1,411,245	3,863.8	34,282	34,416	1,280,380	1,342,946	379,838,072	1,039,940.0	0.17
<i>2017</i>												
Q1: January - March	20,143	4,197,321	20,143	1,345,549	3,683.9	33,116	33,208	1,219,190	1,268,871	373,970,247	1,023,874.7	0.17
Q2: April - June	23,380	4,227,625	23,380	2,785,582	7,626.5	99,442	99,897	2,583,701	3,963,336	380,886,672	1,042,810.9	0.18
Q3: July - September	25,524	4,247,686	25,524	2,030,464	5,559.1	54,907	55,107	1,866,663	2,797,278	387,032,957	1,059,638.5	0.19
Q4: October - December	27,039	4,368,668	27,039	1,524,623	4,174.2	45,552	45,829	1,375,712	1,865,754	389,780,507	1,067,160.9	0.20
<i>2018</i>												
Q1: January - March	28,562	4,310,535	28,562	1,320,159	3,614.4	38,940	39,070	1,178,446	1,592,418	383,871,023	1,050,981.6	0.20
Q2: April - June	30,637	4,360,702	30,637	1,287,634	3,525.3	37,375	37,579	1,134,888	1,609,622	391,878,049	1,072,903.6	0.20
Q3: July - September	29,053	4,552,517	29,053	531,615	1,455.5	18,509	18,616	484,887	813,003	414,015,403	1,133,512.4	0.18
Q4: October - December	17,295	4,725,780	17,295	673,610	1,844.2	23,905	24,071	622,167	1,040,306	416,978,762	1,141,625.6	0.11
<i>2019</i>												
Q1: January - March	12,787	4,608,997	12,787	713,225	1,952.7	24,594	24,718	658,717	1,056,195	410,485,865	1,123,849.0	0.08
Q2: April - June	13,826	4,498,391	13,826	884,320	2,421.1	30,630	30,871	815,510	1,288,895	405,110,501	1,109,132.1	0.08
Q3: July - September	14,820	4,496,523	14,820	738,594	2,022.2	26,060	26,213	676,164	1,083,052	409,727,794	1,121,773.6	0.08
Q4: October - December	15,733	4,643,653	15,733	662,564	1,814.0	24,575	24,670	605,929	988,682	411,797,653	1,127,440.5	0.08

Table 2d. Summary of Incident Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020, by Year and Quarter

Quarter	New Users ¹	Eligible Members ²	New Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2020</i>												
Q1: January - March	16,313	4,520,543	16,313	488,719	1,338.0	19,400	19,497	447,193	739,616	407,280,138	1,115,072.2	0.09
Q2: April - June	15,687	4,556,197	15,687	279,486	765.2	9,724	9,777	254,585	388,478	410,640,858	1,124,273.4	0.08
Q3: July - September	15,905	4,591,948	15,905	251,949	689.8	9,183	9,233	229,956	352,213	418,349,469	1,145,378.4	0.09
Q4: October - December	17,241	4,738,974	17,241	121,781	333.4	6,016	6,032	113,332	172,184	420,974,803	1,152,566.2	0.09

¹Total number of users by year quarter may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year quarter divided by all ARB episodes in the same year quarter

Table 2e. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 Overall

	Prevalent Users	Eligible Members ¹	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member Years ¹	Proportion of All ARB Use ²
ARB												
<i>Prevalent ARB episodes</i>												
	798,231	7,274,399	1,775,080	818,145,389	2,239,960.0	19,136,296	19,230,735	755,297,333	792,510,007	12,612,619,771	34,531,471.0	1.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
	274,514	7,274,399	487,844	200,487,640	548,905.2	5,118,943	5,165,617	184,426,825	195,987,733	12,612,619,771	34,531,471.0	0.27
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
	158,462	7,274,399	324,855	143,808,548	393,726.3	3,289,195	3,303,439	131,592,029	136,722,387	12,612,619,771	34,531,471.0	0.18
Losartan												
<i>Prevalent Losartan episodes</i>												
	97,927	7,274,399	201,565	86,367,551	236,461.5	1,895,087	1,905,683	78,137,891	82,673,103	12,612,619,771	34,531,471.0	0.11
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
	106,348	7,274,399	217,392	88,223,338	241,542.3	1,989,258	1,990,596	79,630,167	80,620,171	12,612,619,771	34,531,471.0	0.12
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
	188,840	7,274,399	374,239	154,058,256	421,788.5	3,453,824	3,456,630	140,704,233	140,766,723	12,612,619,771	34,531,471.0	0.21
Valsartan												
<i>Prevalent Valsartan episodes</i>												
	148,284	7,274,399	290,191	120,145,110	328,939.4	2,745,768	2,759,270	108,770,831	121,794,583	12,612,619,771	34,531,471.0	0.16

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

²Proportion of ARB use estimated as number of episodes for each individual ARB divided by all ARB episodes

Table 2f. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Age Group

Age Group	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
18-44 years	28,521	2,197,514	61,559	20,599,152	56,397.4	549,389	551,916	17,852,520	18,506,567	2,800,479,398	7,667,294.7	1.00
45-64 years	139,615	1,615,496	312,170	131,366,473	359,661.8	3,325,267	3,339,275	117,934,298	122,011,021	2,370,306,948	6,489,546.7	1.00
More than 65 years	648,200	4,117,806	1,401,351	666,179,764	1,823,900.8	15,261,640	15,339,544	619,510,515	651,992,420	7,441,833,425	20,374,629.5	1.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
18-44 years	8,688	2,197,514	15,168	4,556,826	12,475.9	127,656	128,974	3,951,790	4,195,809	2,800,479,398	7,667,294.7	0.25
45-64 years	41,875	1,615,496	75,556	28,629,822	78,384.2	780,143	786,870	25,655,614	26,960,533	2,370,306,948	6,489,546.7	0.24
More than 65 years	227,341	4,117,806	397,120	167,300,992	458,045.2	4,211,144	4,249,773	154,819,421	164,831,391	7,441,833,425	20,374,629.5	0.28
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
18-44 years	5,582	2,197,514	11,787	3,972,222	10,875.4	100,572	100,934	3,432,355	3,527,545	2,800,479,398	7,667,294.7	0.19
45-64 years	30,356	1,615,496	64,001	26,351,995	72,147.8	618,511	620,550	23,556,511	24,088,108	2,370,306,948	6,489,546.7	0.21
More than 65 years	125,867	4,117,806	249,067	113,484,331	310,703.2	2,570,112	2,581,955	104,603,163	109,106,734	7,441,833,425	20,374,629.5	0.18
Losartan												
<i>Prevalent Losartan episodes</i>												
18-44 years	3,874	2,197,514	7,817	2,507,799	6,866.0	62,537	62,842	2,138,863	2,208,246	2,800,479,398	7,667,294.7	0.13
45-64 years	18,924	1,615,496	39,377	15,627,294	42,785.2	364,551	366,072	13,766,854	14,187,165	2,370,306,948	6,489,546.7	0.13
More than 65 years	77,190	4,117,806	154,371	68,232,458	186,810.3	1,467,999	1,476,769	62,232,174	66,277,692	7,441,833,425	20,374,629.5	0.11
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
18-44 years	4,150	2,197,514	8,873	2,681,563	7,341.7	73,481	73,525	2,251,330	2,263,526	2,800,479,398	7,667,294.7	0.14
45-64 years	19,289	1,615,496	40,723	15,091,244	41,317.6	409,920	410,247	13,226,224	13,299,746	2,370,306,948	6,489,546.7	0.13
More than 65 years	84,875	4,117,806	167,796	70,450,531	192,883.0	1,505,857	1,506,824	64,152,613	65,056,899	7,441,833,425	20,374,629.5	0.12
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
18-44 years	5,943	2,197,514	12,137	3,651,334	9,996.8	95,207	95,272	3,138,522	3,106,200	2,800,479,398	7,667,294.7	0.20
45-64 years	29,511	1,615,496	60,237	22,385,294	61,287.6	550,908	551,148	19,896,196	19,802,728	2,370,306,948	6,489,546.7	0.19
More than 65 years	156,391	4,117,806	301,865	128,021,628	350,504.1	2,807,709	2,810,210	117,669,515	117,857,796	7,441,833,425	20,374,629.5	0.22

Table 2f. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Age Group

Age Group	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Prevalent Valsartan episodes</i>												
18-44 years	4,039	2,197,514	7,973	2,502,585	6,851.7	64,561	64,915	2,120,850	2,364,408	2,800,479,398	7,667,294.7	0.13
45-64 years	24,331	1,615,496	49,346	19,097,503	52,286.1	472,433	474,849	16,797,193	18,415,273	2,370,306,948	6,489,546.7	0.16
More than 65 years	122,278	4,117,806	232,872	98,545,022	269,801.6	2,208,774	2,219,506	89,852,788	101,014,901	7,441,833,425	20,374,629.5	0.17

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year month divided by all ARB episodes in the same year month

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
<i>2014</i>												
January	19,169	4,531,255	19,169	12,961,502	35,486.7	322,354	323,642	12,049,282	12,495,940	140,156,968	383,728.9	1.00
February	36,013	4,525,425	36,015	11,339,808	31,046.7	283,798	285,192	10,522,223	10,922,877	126,514,507	346,377.8	1.00
March	54,793	4,524,556	55,234	12,954,782	35,468.3	316,885	318,666	12,031,266	12,492,950	140,036,195	383,398.2	1.00
April	74,691	4,551,212	75,266	15,407,626	42,183.8	355,035	357,170	14,356,349	14,879,338	136,259,621	373,058.5	1.00
May	94,446	4,549,461	95,739	15,739,326	43,091.9	360,829	362,855	14,658,812	15,255,189	140,812,634	385,524.0	1.00
June	109,307	4,543,585	110,664	14,336,279	39,250.6	329,057	330,095	13,342,416	13,829,148	136,112,338	372,655.3	1.00
July	122,270	4,567,206	123,959	13,932,281	38,144.5	321,056	322,363	12,957,270	13,508,716	141,244,393	386,706.1	1.00
August	131,885	4,566,372	133,638	11,427,766	31,287.5	282,901	284,893	10,604,690	10,944,792	141,287,064	386,822.9	1.00
September	142,123	4,560,192	144,250	12,798,630	35,040.7	307,287	309,350	11,893,371	12,350,654	136,611,694	374,022.4	1.00
October	152,730	4,603,390	155,090	13,733,951	37,601.5	329,422	331,140	12,761,655	13,271,446	142,414,439	389,909.5	1.00
November	161,594	4,596,452	163,674	11,942,165	32,695.9	283,572	285,823	11,087,858	11,538,115	137,689,334	376,972.9	1.00
December	169,854	4,690,727	171,844	11,474,012	31,414.1	279,091	280,534	10,635,643	10,974,824	142,159,405	389,211.2	1.00
<i>2015</i>												
January	177,481	4,630,053	179,971	11,878,810	32,522.4	290,310	291,998	11,014,964	11,405,623	143,195,395	392,047.6	1.00
February	182,955	4,622,633	184,974	10,275,927	28,134.0	247,908	249,478	9,531,374	9,899,789	128,891,444	352,885.5	1.00
March	190,756	4,608,204	193,381	12,585,423	34,457.0	302,485	304,280	11,692,362	12,145,054	142,621,979	390,477.7	1.00
April	199,863	4,649,181	202,969	15,308,908	41,913.5	348,851	350,300	14,260,179	14,719,890	139,200,373	381,109.9	1.00
May	209,824	4,646,557	212,746	14,430,296	39,508.0	318,076	319,505	13,425,186	13,898,074	143,820,934	393,760.3	1.00
June	218,712	4,639,786	221,568	14,020,922	38,387.2	312,956	315,218	13,044,204	13,525,905	139,000,288	380,562.0	1.00
July	225,619	4,670,939	228,545	12,481,936	34,173.7	293,266	294,659	11,579,009	11,984,179	144,470,455	395,538.5	1.00
August	230,857	4,668,567	233,715	10,710,723	29,324.4	243,156	244,356	9,928,795	10,309,003	144,458,311	395,505.3	1.00
September	237,023	4,661,777	240,095	11,825,339	32,376.0	277,961	279,399	10,957,282	11,415,064	139,666,252	382,385.4	1.00
October	243,675	4,702,725	246,828	12,622,693	34,559.0	288,680	289,837	11,713,927	12,140,901	145,490,180	398,330.4	1.00
November	250,070	4,694,981	252,928	11,481,398	31,434.4	261,129	261,948	10,639,220	11,034,561	140,653,325	385,087.8	1.00
December	256,023	4,787,323	258,682	11,005,949	30,132.6	256,432	257,691	10,207,949	10,580,021	145,235,622	397,633.5	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2016</i>												
January	261,306	4,728,935	264,076	11,009,605	30,142.7	260,323	261,479	10,210,911	10,551,775	146,290,949	400,522.8	1.00
February	265,962	4,722,828	268,516	10,090,693	27,626.8	244,036	245,369	9,353,430	9,706,575	136,754,625	374,413.8	1.00
March	271,316	4,721,494	274,392	11,665,160	31,937.5	280,279	281,848	10,836,146	11,228,176	146,130,012	400,082.2	1.00
April	277,731	4,763,745	281,161	13,884,700	38,014.2	305,029	306,618	12,911,766	13,390,389	142,710,057	390,718.8	1.00
May	285,918	4,761,475	289,497	14,053,202	38,475.6	308,824	310,246	13,077,053	13,556,418	147,398,347	403,554.7	1.00
June	292,769	4,755,765	296,069	12,830,269	35,127.4	286,531	288,442	11,923,913	12,353,834	142,485,590	390,104.3	1.00
July	297,322	4,789,659	300,469	11,019,925	30,170.9	254,436	256,176	10,210,527	10,611,880	148,216,944	405,795.9	1.00
August	302,112	4,789,879	305,394	10,613,137	29,057.2	249,118	250,178	9,817,637	10,204,073	148,205,722	405,765.2	1.00
September	306,485	4,784,732	309,857	10,777,992	29,508.5	250,924	252,696	9,972,686	10,317,865	143,351,972	392,476.3	1.00
October	311,281	4,827,419	314,691	11,364,391	31,114.0	262,287	263,468	10,511,630	10,931,042	149,343,093	408,879.1	1.00
November	316,896	4,821,453	320,125	11,213,515	30,700.9	257,877	259,208	10,377,390	10,837,516	144,440,669	395,457.0	1.00
December	321,445	4,912,146	324,467	9,799,466	26,829.5	226,612	227,750	9,044,959	9,381,168	149,183,800	408,443.0	1.00
<i>2017</i>												
January	325,406	4,857,234	328,640	10,015,317	27,420.4	230,729	231,775	9,257,671	9,590,149	150,243,342	411,343.9	1.00
February	328,589	4,851,354	331,310	9,087,000	24,878.9	217,049	218,493	8,397,126	8,706,765	135,630,146	371,335.1	1.00
March	333,298	4,850,455	336,671	10,700,728	29,297.0	256,370	257,397	9,903,658	10,278,869	150,130,789	411,035.7	1.00
April	337,500	4,891,602	341,041	11,966,516	32,762.5	265,575	266,872	11,104,269	11,594,069	146,479,408	401,038.8	1.00
May	346,191	4,889,743	350,219	13,697,177	37,500.8	311,071	312,391	12,711,747	13,743,333	151,368,663	414,424.8	1.00
June	352,780	4,884,152	356,371	12,550,670	34,361.9	302,490	303,940	11,656,795	12,909,294	146,327,826	400,623.8	1.00
July	357,381	4,921,394	360,801	10,551,746	28,889.1	243,361	244,722	9,757,183	10,565,315	152,222,136	416,761.5	1.00
August	361,903	4,919,729	365,450	10,015,353	27,420.5	236,131	237,348	9,251,616	9,978,440	152,243,200	416,819.2	1.00
September	365,341	4,914,078	368,946	9,657,238	26,440.1	230,325	231,315	8,905,979	9,425,647	147,221,835	403,071.4	1.00
October	369,685	4,958,836	373,501	10,575,905	28,955.2	246,921	248,428	9,761,193	10,332,511	153,436,270	420,085.6	1.00
November	374,968	4,952,572	378,531	10,314,601	28,239.8	242,053	243,363	9,529,716	10,046,916	148,367,001	406,206.7	1.00
December	378,561	5,042,972	381,462	8,611,386	23,576.7	200,307	201,309	7,928,621	8,439,884	153,189,380	419,409.7	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2018</i>												
January	382,643	4,992,613	386,238	9,745,061	26,680.5	235,039	236,149	8,997,168	9,516,632	154,431,922	422,811.6	1.00
February	385,352	4,985,838	388,383	8,384,656	22,955.9	200,569	201,516	7,724,663	8,138,562	139,376,482	381,592.0	1.00
March	389,416	4,984,546	393,050	9,509,717	26,036.2	231,470	232,722	8,798,655	9,275,813	154,273,374	422,377.5	1.00
April	394,505	5,049,616	398,609	11,634,633	31,853.9	259,310	260,805	10,789,019	11,424,143	151,180,465	413,909.6	1.00
May	402,697	5,031,719	406,991	11,901,817	32,585.4	269,196	270,527	11,033,706	11,659,859	155,771,715	426,479.7	1.00
June	408,027	5,025,754	411,899	10,374,308	28,403.3	236,637	237,643	9,631,648	10,186,971	150,569,752	412,237.5	1.00
July	414,088	5,248,659	418,009	10,466,535	28,655.8	242,197	243,422	9,652,636	10,129,236	161,952,925	443,402.9	1.00
August	418,489	5,248,206	422,138	8,522,287	23,332.8	203,532	204,567	7,804,714	8,219,815	162,396,364	444,617.0	1.00
September	421,158	5,235,591	424,926	8,207,069	22,469.7	194,383	195,239	7,512,502	7,899,961	156,845,789	429,420.4	1.00
October	424,998	5,283,080	429,247	9,534,974	26,105.3	219,683	220,518	8,720,437	9,220,483	163,464,170	447,540.5	1.00
November	430,214	5,278,165	434,044	8,854,471	24,242.2	207,558	208,376	8,096,814	8,599,760	158,110,407	432,882.7	1.00
December	433,253	5,429,046	436,427	7,483,421	20,488.5	177,982	178,733	6,830,279	7,234,316	163,374,287	447,294.4	1.00
<i>2019</i>												
January	437,099	5,316,623	441,018	8,067,094	22,086.5	190,208	191,176	7,361,076	7,813,009	164,467,330	450,287.0	1.00
February	439,367	5,311,853	442,633	6,894,257	18,875.4	167,079	167,680	6,283,370	6,692,524	148,509,460	406,596.7	1.00
March	443,701	5,312,441	447,600	7,898,995	21,626.3	186,989	187,660	7,191,235	7,636,044	164,414,315	450,141.9	1.00
April	448,611	5,214,111	453,055	9,566,930	26,192.8	216,893	217,737	8,759,027	9,342,179	156,117,169	427,425.5	1.00
May	456,434	5,211,993	461,132	9,615,605	26,326.1	212,857	213,932	8,793,159	9,376,850	161,342,233	441,731.0	1.00
June	460,962	5,205,734	464,912	7,992,589	21,882.5	183,882	184,672	7,281,704	7,753,915	155,963,416	427,004.6	1.00
July	465,115	5,223,637	469,417	7,616,875	20,853.9	175,971	176,979	6,909,232	7,399,502	161,568,268	442,349.8	1.00
August	467,997	5,221,894	472,279	6,617,526	18,117.8	153,239	153,736	5,976,225	6,469,508	161,610,996	442,466.8	1.00
September	471,223	5,215,944	475,444	6,650,402	18,207.8	157,949	158,494	6,021,401	6,490,670	156,283,032	427,879.6	1.00
October	476,119	5,254,354	480,688	7,254,844	19,862.7	171,251	171,954	6,554,926	7,037,071	162,602,021	445,180.1	1.00
November	480,980	5,247,911	485,078	6,408,309	17,545.0	151,603	152,166	5,777,663	6,242,442	157,212,007	430,423.0	1.00
December	484,271	5,373,061	487,920	5,478,199	14,998.5	131,398	131,840	4,916,518	5,266,827	162,419,938	444,681.6	1.00

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
ARB												
<i>2020</i>												
January	487,734	5,259,449	492,130	5,764,209	15,781.5	142,610	143,131	5,170,081	5,568,089	162,724,489	445,515.4	1.00
February	488,592	5,252,961	492,737	4,820,894	13,198.9	119,438	119,831	4,316,922	4,660,175	152,125,581	416,497.1	1.00
March	491,607	5,251,492	496,885	5,565,775	15,238.3	132,484	132,966	4,948,138	5,279,312	162,553,946	445,048.4	1.00
April	489,649	5,298,169	493,625	4,309,029	11,797.5	105,769	105,998	3,823,507	4,083,486	158,709,018	434,521.6	1.00
May	490,651	5,293,064	495,411	4,074,398	11,155.1	92,469	92,723	3,635,479	3,884,677	163,826,174	448,531.6	1.00
June	492,542	5,285,120	498,521	4,426,339	12,118.7	92,509	92,727	3,971,876	4,266,090	158,335,539	433,499.1	1.00
July	495,074	5,326,175	501,321	3,999,031	10,948.8	80,606	80,905	3,594,913	3,874,332	164,801,989	451,203.3	1.00
August	497,314	5,325,535	500,995	2,809,395	7,691.7	63,226	63,407	2,508,535	2,690,695	164,812,478	451,232.0	1.00
September	504,782	5,320,247	507,649	2,028,744	5,554.4	51,374	51,529	1,833,500	1,975,637	159,403,146	436,422.0	1.00
October	510,855	5,358,904	515,002	1,557,412	4,264.0	41,623	41,752	1,449,630	1,575,862	165,861,675	454,104.5	1.00
November	513,207	5,350,616	517,643	1,019,990	2,792.6	33,549	33,638	971,529	1,047,055	160,308,637	438,901.1	1.00
December	515,945	5,470,746	519,017	347,455	951.3	22,609	22,662	346,538	374,547	165,524,336	453,180.9	1.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
<i>2014</i>												
January	3,773	4,531,255	3,773	2,513,023	6,880.3	64,607	64,887	2,341,207	2,473,420	140,156,968	383,728.9	0.20
February	7,152	4,525,425	7,153	2,314,201	6,335.9	57,566	58,264	2,145,809	2,272,090	126,514,507	346,377.8	0.20
March	10,817	4,524,556	10,899	2,472,382	6,769.0	61,692	62,408	2,287,782	2,416,495	140,036,195	383,398.2	0.20
April	14,714	4,551,212	14,811	2,975,865	8,147.5	72,361	73,528	2,764,557	2,910,553	136,259,621	373,058.5	0.20
May	18,614	4,549,461	18,854	3,021,598	8,272.7	74,612	75,290	2,801,906	3,004,813	140,812,634	385,524.0	0.20
June	21,403	4,543,585	21,662	2,664,167	7,294.1	62,537	62,904	2,472,772	2,640,511	136,112,338	372,655.3	0.20
July	23,979	4,567,206	24,339	2,812,586	7,700.4	67,405	67,879	2,612,014	2,798,546	141,244,393	386,706.1	0.20
August	25,868	4,566,372	26,206	2,319,436	6,350.3	64,097	65,420	2,157,069	2,290,963	141,287,064	386,822.9	0.20
September	28,006	4,560,192	28,410	2,579,176	7,061.4	63,585	64,542	2,395,244	2,541,674	136,611,694	374,022.4	0.20
October	30,153	4,603,390	30,608	2,769,209	7,581.7	68,373	68,965	2,566,210	2,736,070	142,414,439	389,909.5	0.20
November	31,990	4,596,452	32,393	2,451,960	6,713.1	61,083	61,816	2,272,725	2,419,057	137,689,334	376,972.9	0.20
December	33,710	4,690,727	34,074	2,338,569	6,402.7	57,749	58,308	2,160,845	2,281,364	142,159,405	389,211.2	0.20

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2015</i>												
January	35,148	4,630,053	35,588	2,268,194	6,210.0	59,312	60,248	2,097,172	2,229,252	143,195,395	392,047.6	0.20
February	36,185	4,622,633	36,576	1,982,661	5,428.2	53,663	54,379	1,834,460	1,949,749	128,891,444	352,885.5	0.20
March	37,863	4,608,204	38,350	2,545,698	6,969.7	63,611	63,977	2,364,443	2,515,986	142,621,979	390,477.7	0.20
April	39,616	4,649,181	40,193	3,035,381	8,310.4	73,984	74,504	2,824,429	2,968,774	139,200,373	381,109.9	0.20
May	41,716	4,646,557	42,255	2,880,748	7,887.1	64,674	65,323	2,680,448	2,841,991	143,820,934	393,760.3	0.20
June	43,598	4,639,786	44,193	2,833,859	7,758.7	66,193	67,475	2,631,428	2,795,857	139,000,288	380,562.0	0.20
July	44,921	4,670,939	45,452	2,376,437	6,506.3	57,722	58,393	2,195,173	2,317,877	144,470,455	395,538.5	0.20
August	45,924	4,668,567	46,484	2,139,810	5,858.5	53,258	54,039	1,978,395	2,112,672	144,458,311	395,505.3	0.20
September	47,128	4,661,777	47,701	2,334,590	6,391.8	56,193	56,963	2,154,118	2,321,949	139,666,252	382,385.4	0.20
October	48,438	4,702,725	49,046	2,510,930	6,874.6	56,783	57,305	2,328,727	2,474,210	145,490,180	398,330.4	0.20
November	49,690	4,694,981	50,272	2,352,116	6,439.7	53,551	53,793	2,174,988	2,293,590	140,653,325	385,087.8	0.20
December	50,929	4,787,323	51,444	2,257,224	6,179.9	53,632	53,954	2,088,053	2,226,355	145,235,622	397,633.5	0.20
<i>2016</i>												
January	52,093	4,728,935	52,644	2,297,339	6,289.8	57,164	57,762	2,128,408	2,228,173	146,290,949	400,522.8	0.20
February	53,045	4,722,828	53,549	2,022,439	5,537.1	53,216	53,754	1,870,995	1,996,261	136,754,625	374,413.8	0.20
March	54,165	4,721,494	54,718	2,301,991	6,302.5	57,613	58,327	2,136,413	2,271,564	146,130,012	400,082.2	0.20
April	55,513	4,763,745	56,144	2,840,828	7,777.8	63,663	64,342	2,636,495	2,798,755	142,710,057	390,718.8	0.20
May	57,121	4,761,475	57,793	2,776,546	7,601.8	63,511	63,786	2,576,795	2,730,805	147,398,347	403,554.7	0.20
June	58,399	4,755,765	59,005	2,493,395	6,826.5	60,669	61,491	2,311,466	2,462,528	142,485,590	390,104.3	0.20
July	59,223	4,789,659	59,822	2,183,392	5,977.8	51,233	51,824	2,017,973	2,139,236	148,216,944	405,795.9	0.20
August	60,063	4,789,879	60,656	1,984,066	5,432.1	45,760	46,045	1,826,517	1,931,088	148,205,722	405,765.2	0.20
September	60,930	4,784,732	61,572	2,221,667	6,082.6	53,445	54,487	2,058,939	2,189,194	143,351,972	392,476.3	0.20
October	61,865	4,827,419	62,527	2,273,491	6,224.5	55,503	56,081	2,099,655	2,243,866	149,343,093	408,879.1	0.20
November	63,178	4,821,453	63,787	2,375,209	6,503.0	56,983	57,636	2,193,904	2,360,819	144,440,669	395,457.0	0.20
December	64,128	4,912,146	64,742	1,977,614	5,414.4	49,281	49,756	1,816,595	1,926,950	149,183,800	408,443.0	0.20

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2017</i>												
January	64,988	4,857,234	65,588	2,013,221	5,511.9	45,233	46,005	1,854,738	1,984,992	150,243,342	411,343.9	0.20
February	65,610	4,851,354	66,096	1,803,642	4,938.1	44,522	45,098	1,663,408	1,754,476	135,630,146	371,335.1	0.20
March	66,613	4,850,455	67,246	2,193,123	6,004.4	54,298	54,847	2,022,372	2,168,047	150,130,789	411,035.7	0.20
April	67,337	4,891,602	68,042	2,384,255	6,527.7	54,085	54,704	2,206,120	2,325,025	146,479,408	401,038.8	0.20
May	68,898	4,889,743	69,699	2,631,015	7,203.3	57,864	58,297	2,427,463	2,571,676	151,368,663	414,424.8	0.20
June	70,073	4,884,152	70,757	2,395,056	6,557.3	55,257	55,781	2,210,190	2,335,197	146,327,826	400,623.8	0.20
July	70,847	4,921,394	71,479	1,977,513	5,414.1	46,644	47,168	1,818,020	1,940,852	152,222,136	416,761.5	0.20
August	71,802	4,919,729	72,474	2,009,080	5,500.6	49,190	49,805	1,844,301	1,959,885	152,243,200	416,819.2	0.20
September	72,517	4,914,078	73,200	1,901,261	5,205.4	46,658	47,187	1,742,735	1,840,825	147,221,835	403,071.4	0.20
October	73,488	4,958,836	74,248	2,242,071	6,138.5	52,671	53,255	2,061,923	2,188,013	153,436,270	420,085.6	0.20
November	74,611	4,952,572	75,247	2,113,538	5,786.6	51,856	52,349	1,944,620	2,058,081	148,367,001	406,206.7	0.20
December	75,442	5,042,972	75,974	1,766,093	4,835.3	41,163	41,640	1,619,518	1,715,951	153,189,380	419,409.7	0.20
<i>2018</i>												
January	76,295	4,992,613	77,020	2,008,211	5,498.2	49,046	49,310	1,840,753	1,954,052	154,431,922	422,811.6	0.20
February	76,849	4,985,838	77,406	1,751,411	4,795.1	45,354	45,820	1,608,842	1,684,533	139,376,482	381,592.0	0.20
March	77,700	4,984,546	78,418	1,922,910	5,264.6	48,316	49,039	1,765,085	1,852,443	154,273,374	422,377.5	0.20
April	78,744	5,049,616	79,529	2,361,831	6,466.3	53,570	54,201	2,172,003	2,314,351	151,180,465	413,909.6	0.20
May	80,460	5,031,719	81,331	2,464,993	6,748.8	55,072	55,567	2,266,842	2,414,713	155,771,715	426,479.7	0.20
June	81,652	5,025,754	82,379	2,073,966	5,678.2	48,048	48,438	1,900,774	2,018,466	150,569,752	412,237.5	0.20
July	89,561	5,248,659	90,289	6,033,549	16,519.0	254,873	257,132	5,621,696	5,954,914	161,952,925	443,402.9	0.22
August	93,230	5,248,206	94,018	3,273,626	8,962.7	91,759	92,900	3,022,616	3,186,353	162,396,364	444,617.0	0.22
September	95,470	5,235,591	96,257	2,602,699	7,125.8	68,274	68,746	2,391,937	2,510,526	156,845,789	429,420.4	0.23
October	97,745	5,283,080	98,680	2,826,853	7,739.5	66,170	66,771	2,591,665	2,719,169	163,464,170	447,540.5	0.23
November	99,977	5,278,165	100,802	2,461,173	6,738.3	60,558	60,939	2,250,142	2,373,119	158,110,407	432,882.7	0.23
December	101,561	5,429,046	102,286	2,218,806	6,074.8	55,694	56,076	2,027,485	2,143,293	163,374,287	447,294.4	0.23

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2019</i>												
January	103,349	5,316,623	104,248	2,382,534	6,523.0	59,126	59,677	2,180,788	2,303,065	164,467,330	450,287.0	0.24
February	104,559	5,311,853	105,311	2,018,147	5,525.4	50,871	51,312	1,839,238	1,951,865	148,509,460	406,596.7	0.24
March	107,680	5,312,441	108,521	2,816,050	7,709.9	78,221	78,639	2,581,209	2,716,641	164,414,315	450,141.9	0.24
April	110,874	5,214,111	111,891	3,135,282	8,583.9	76,649	77,033	2,870,983	3,043,314	156,117,169	427,425.5	0.25
May	114,736	5,211,993	115,767	3,085,466	8,447.5	77,332	77,899	2,820,859	2,954,473	161,342,233	441,731.0	0.25
June	118,202	5,205,734	119,145	2,869,732	7,856.9	70,064	70,527	2,621,257	2,756,013	155,963,416	427,004.6	0.26
July	122,686	5,223,637	123,682	3,180,156	8,706.8	82,156	82,731	2,892,909	3,048,482	161,568,268	442,349.8	0.26
August	125,931	5,221,894	126,923	2,573,466	7,045.8	65,448	65,797	2,332,489	2,522,115	161,610,996	442,466.8	0.27
September	129,964	5,215,944	131,040	2,849,840	7,802.4	76,082	76,462	2,593,261	2,742,837	156,283,032	427,879.6	0.28
October	135,592	5,254,354	136,747	3,359,885	9,198.9	93,040	93,606	3,056,738	3,227,928	162,602,021	445,180.1	0.28
November	140,431	5,247,911	141,499	2,853,890	7,813.5	76,431	76,878	2,588,586	2,761,678	157,212,007	430,423.0	0.29
December	147,961	5,373,061	148,847	3,393,232	9,290.2	98,403	98,830	3,078,565	3,303,741	162,419,938	444,681.6	0.31
<i>2020</i>												
January	159,232	5,259,449	160,460	4,344,816	11,895.5	137,149	137,857	3,943,100	4,277,435	162,724,489	445,515.4	0.33
February	167,381	5,252,961	168,517	3,416,151	9,352.9	104,102	104,574	3,101,319	3,398,475	152,125,581	416,497.1	0.34
March	173,404	5,251,492	174,846	2,933,166	8,030.6	82,659	83,054	2,623,399	2,849,877	162,553,946	445,048.4	0.35
April	172,804	5,298,169	174,016	1,763,747	4,828.9	49,558	49,779	1,570,811	1,682,375	158,709,018	434,521.6	0.35
May	172,406	5,293,064	173,958	1,525,795	4,177.4	36,492	36,613	1,362,377	1,452,774	163,826,174	448,531.6	0.35
June	172,289	5,285,120	174,255	1,665,484	4,559.8	36,809	36,933	1,492,062	1,610,367	158,335,539	433,499.1	0.35
July	172,941	5,326,175	174,951	1,476,082	4,041.3	31,153	31,349	1,329,279	1,444,567	164,801,989	451,203.3	0.35
August	173,241	5,325,535	174,490	1,037,502	2,840.5	25,393	25,515	927,781	992,387	164,812,478	451,232.0	0.35
September	175,796	5,320,247	176,739	747,478	2,046.5	19,650	19,759	674,403	722,923	159,403,146	436,422.0	0.35
October	178,707	5,358,904	180,078	620,829	1,699.7	18,165	18,250	574,842	618,599	165,861,675	454,104.5	0.35
November	179,750	5,350,616	181,187	382,056	1,046.0	13,095	13,146	362,517	386,257	160,308,637	438,901.1	0.35
December	180,867	5,470,746	181,870	129,161	353.6	8,436	8,467	128,676	137,536	165,524,336	453,180.9	0.35

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
2014												
January	3,567	4,531,255	3,567	2,335,517	6,394.3	54,346	54,499	2,151,023	2,232,773	140,156,968	383,728.9	0.19
February	6,563	4,525,425	6,563	1,958,074	5,360.9	46,962	47,145	1,803,625	1,876,919	126,514,507	346,377.8	0.18
March	9,999	4,524,556	10,077	2,385,325	6,530.7	56,651	56,926	2,198,484	2,269,981	140,036,195	383,398.2	0.18
April	13,694	4,551,212	13,806	2,832,020	7,753.6	63,082	63,412	2,626,197	2,736,918	136,259,621	373,058.5	0.18
May	17,401	4,549,461	17,652	2,893,882	7,923.0	65,378	65,533	2,680,713	2,777,520	140,812,634	385,524.0	0.18
June	20,101	4,543,585	20,341	2,512,686	6,879.4	55,521	55,678	2,322,560	2,390,633	136,112,338	372,655.3	0.18
July	22,404	4,567,206	22,717	2,394,290	6,555.2	51,307	51,476	2,209,688	2,289,252	141,244,393	386,706.1	0.18
August	24,102	4,566,372	24,419	1,967,993	5,388.1	45,194	45,523	1,808,826	1,863,208	141,287,064	386,822.9	0.18
September	25,773	4,560,192	26,210	2,216,798	6,069.3	50,790	51,126	2,042,980	2,130,125	136,611,694	374,022.4	0.18
October	27,630	4,603,390	28,047	2,317,572	6,345.2	52,623	52,804	2,130,945	2,204,024	142,414,439	389,909.5	0.18
November	29,100	4,596,452	29,490	2,074,066	5,678.5	48,760	48,887	1,912,285	1,980,794	137,689,334	376,972.9	0.18
December	30,516	4,690,727	30,877	1,981,359	5,424.7	46,964	47,424	1,819,896	1,876,312	142,159,405	389,211.2	0.18
2015												
January	31,946	4,630,053	32,390	2,083,003	5,703.0	49,827	50,086	1,923,442	1,982,495	143,195,395	392,047.6	0.18
February	32,876	4,622,633	33,238	1,740,580	4,765.4	40,139	40,315	1,599,441	1,649,549	128,891,444	352,885.5	0.18
March	34,038	4,608,204	34,516	2,125,818	5,820.2	49,575	49,968	1,961,807	2,031,844	142,621,979	390,477.7	0.18
April	35,533	4,649,181	36,103	2,639,763	7,227.3	58,888	59,172	2,443,760	2,531,800	139,200,373	381,109.9	0.18
May	37,134	4,646,557	37,678	2,485,347	6,804.5	54,393	54,560	2,297,137	2,356,332	143,820,934	393,760.3	0.18
June	38,756	4,639,786	39,268	2,480,887	6,792.3	52,084	52,514	2,290,311	2,376,960	139,000,288	380,562.0	0.18
July	40,002	4,670,939	40,505	2,230,606	6,107.1	50,525	50,842	2,057,502	2,127,675	144,470,455	395,538.5	0.18
August	40,863	4,668,567	41,388	1,830,377	5,011.3	41,005	41,054	1,685,801	1,727,362	144,458,311	395,505.3	0.18
September	41,800	4,661,777	42,369	1,988,852	5,445.2	45,282	45,421	1,830,408	1,904,420	139,666,252	382,385.4	0.18
October	42,882	4,702,725	43,455	2,070,803	5,669.5	43,895	44,087	1,901,485	1,965,612	145,490,180	398,330.4	0.18
November	43,853	4,694,981	44,327	1,892,150	5,180.4	42,117	42,241	1,741,098	1,794,713	140,653,325	385,087.8	0.18
December	44,771	4,787,323	45,258	1,815,795	4,971.4	42,493	42,766	1,668,450	1,730,141	145,235,622	397,633.5	0.17

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2016</i>												
January	45,540	4,728,935	46,033	1,803,668	4,938.2	43,897	43,958	1,656,109	1,702,728	146,290,949	400,522.8	0.17
February	46,240	4,722,828	46,694	1,667,107	4,564.3	35,948	36,084	1,531,501	1,589,891	136,754,625	374,413.8	0.17
March	46,973	4,721,494	47,544	1,888,567	5,170.6	43,041	43,495	1,741,282	1,809,371	146,130,012	400,082.2	0.17
April	47,952	4,763,745	48,560	2,333,875	6,389.8	50,522	50,700	2,152,365	2,227,360	142,710,057	390,718.8	0.17
May	49,276	4,761,475	49,923	2,435,820	6,668.9	51,152	51,564	2,250,652	2,339,266	147,398,347	403,554.7	0.17
June	50,403	4,755,765	51,025	2,218,260	6,073.3	45,896	46,148	2,047,748	2,105,405	142,485,590	390,104.3	0.17
July	51,187	4,789,659	51,726	1,858,937	5,089.5	40,305	40,851	1,710,089	1,763,810	148,216,944	405,795.9	0.17
August	51,855	4,789,879	52,422	1,730,046	4,736.6	39,757	39,848	1,584,299	1,639,175	148,205,722	405,765.2	0.17
September	52,556	4,784,732	53,144	1,753,390	4,800.5	40,107	40,193	1,606,106	1,675,006	143,351,972	392,476.3	0.17
October	53,302	4,827,419	53,927	1,851,026	5,067.8	41,340	41,658	1,693,794	1,765,752	149,343,093	408,879.1	0.17
November	54,042	4,821,453	54,603	1,806,984	4,947.3	37,507	37,617	1,655,505	1,735,298	144,440,669	395,457.0	0.17
December	54,620	4,912,146	55,162	1,564,923	4,284.5	33,599	33,938	1,428,864	1,475,260	149,183,800	408,443.0	0.17
<i>2017</i>												
January	55,189	4,857,234	55,789	1,593,059	4,361.6	36,093	36,106	1,454,689	1,493,479	150,243,342	411,343.9	0.17
February	55,626	4,851,354	56,108	1,530,440	4,190.1	34,521	34,751	1,397,177	1,461,911	135,630,146	371,335.1	0.17
March	56,242	4,850,455	56,836	1,774,084	4,857.2	41,150	41,193	1,626,485	1,682,412	150,130,789	411,035.7	0.17
April	56,792	4,891,602	57,402	1,933,598	5,293.9	39,535	39,728	1,776,435	1,849,245	146,479,408	401,038.8	0.17
May	58,010	4,889,743	58,689	2,124,271	5,815.9	43,113	43,222	1,951,838	2,034,236	151,368,663	414,424.8	0.17
June	58,785	4,884,152	59,410	1,910,122	5,229.6	39,950	40,169	1,752,962	1,823,039	146,327,826	400,623.8	0.17
July	59,416	4,921,394	60,021	1,699,614	4,653.3	38,016	38,440	1,556,803	1,632,081	152,222,136	416,761.5	0.17
August	60,005	4,919,729	60,586	1,512,147	4,140.0	33,598	33,676	1,380,014	1,435,825	152,243,200	416,819.2	0.17
September	60,418	4,914,078	61,042	1,527,137	4,181.1	33,200	33,310	1,396,880	1,439,087	147,221,835	403,071.4	0.17
October	61,057	4,958,836	61,705	1,675,486	4,587.2	36,663	36,804	1,528,978	1,594,666	153,436,270	420,085.6	0.17
November	61,774	4,952,572	62,357	1,604,487	4,392.8	36,909	37,137	1,462,743	1,522,642	148,367,001	406,206.7	0.16
December	62,204	5,042,972	62,716	1,380,695	3,780.1	31,350	31,504	1,259,550	1,306,610	153,189,380	419,409.7	0.16

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2018</i>												
January	62,742	4,992,613	63,341	1,517,210	4,153.9	33,988	34,111	1,383,278	1,441,056	154,431,922	422,811.6	0.16
February	63,022	4,985,838	63,535	1,323,233	3,622.8	29,382	29,530	1,202,489	1,252,504	139,376,482	381,592.0	0.16
March	63,462	4,984,546	64,098	1,485,229	4,066.3	35,544	35,624	1,357,155	1,409,062	154,273,374	422,377.5	0.16
April	64,085	5,049,616	64,758	1,783,334	4,882.5	39,234	39,361	1,635,590	1,701,563	151,180,465	413,909.6	0.16
May	65,231	5,031,719	65,926	1,859,750	5,091.7	38,379	38,526	1,702,815	1,781,658	155,771,715	426,479.7	0.16
June	65,890	5,025,754	66,502	1,553,480	4,253.2	31,865	32,023	1,418,054	1,470,007	150,569,752	412,237.5	0.16
July	68,818	5,248,659	69,424	2,794,845	7,651.9	89,211	89,439	2,576,640	2,668,449	161,952,925	443,402.9	0.17
August	70,139	5,248,206	70,783	1,748,494	4,787.1	42,210	42,271	1,595,441	1,653,557	162,396,364	444,617.0	0.17
September	70,977	5,235,591	71,590	1,499,568	4,105.6	33,499	33,725	1,369,051	1,424,088	156,845,789	429,420.4	0.17
October	71,804	5,283,080	72,522	1,640,849	4,492.4	35,108	35,201	1,490,044	1,551,153	163,464,170	447,540.5	0.17
November	72,732	5,278,165	73,408	1,497,217	4,099.2	32,426	32,543	1,356,235	1,414,553	158,110,407	432,882.7	0.17
December	73,354	5,429,046	73,881	1,292,036	3,537.4	29,806	29,960	1,171,228	1,215,759	163,374,287	447,294.4	0.17
<i>2019</i>												
January	74,017	5,316,623	74,671	1,347,406	3,689.0	30,981	31,064	1,218,306	1,268,679	164,467,330	450,287.0	0.17
February	74,395	5,311,853	74,952	1,168,768	3,199.9	28,250	28,307	1,054,465	1,104,501	148,509,460	406,596.7	0.17
March	75,393	5,312,441	76,050	1,422,309	3,894.1	35,529	35,598	1,286,786	1,345,348	164,414,315	450,141.9	0.17
April	76,507	5,214,111	77,254	1,753,249	4,800.1	38,272	38,452	1,593,106	1,665,476	156,117,169	427,425.5	0.17
May	78,194	5,211,993	78,989	1,786,222	4,890.4	38,957	39,117	1,626,341	1,708,305	161,342,233	441,731.0	0.17
June	79,365	5,205,734	80,028	1,537,229	4,208.7	33,398	33,513	1,387,534	1,457,250	155,963,416	427,004.6	0.17
July	81,272	5,223,637	82,055	1,709,372	4,680.0	37,928	38,053	1,539,833	1,613,582	161,568,268	442,349.8	0.17
August	82,213	5,221,894	82,925	1,257,205	3,442.0	27,441	27,534	1,128,472	1,199,548	161,610,996	442,466.8	0.18
September	83,398	5,215,944	84,089	1,316,790	3,605.2	32,669	32,720	1,181,898	1,268,811	156,283,032	427,879.6	0.18
October	84,874	5,254,354	85,638	1,418,085	3,882.5	33,569	33,827	1,269,665	1,338,857	162,602,021	445,180.1	0.18
November	85,922	5,247,911	86,649	1,223,073	3,348.6	27,346	27,401	1,091,550	1,139,392	157,212,007	430,423.0	0.18
December	87,528	5,373,061	88,226	1,347,237	3,688.5	34,222	34,314	1,204,171	1,252,393	162,419,938	444,681.6	0.18

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2020</i>												
January	90,426	5,259,449	91,141	1,661,307	4,548.4	45,248	45,420	1,490,541	1,545,320	162,724,489	445,515.4	0.19
February	95,778	5,252,961	96,502	2,135,735	5,847.3	67,891	68,072	1,925,089	1,972,090	152,125,581	416,497.1	0.20
March	98,501	5,251,492	99,323	1,540,294	4,217.1	42,533	42,623	1,370,296	1,421,335	162,553,946	445,048.4	0.20
April	98,254	5,298,169	98,967	876,243	2,399.0	22,703	22,741	771,992	813,020	158,709,018	434,521.6	0.20
May	97,520	5,293,064	98,414	817,958	2,239.4	17,978	18,027	725,918	767,167	163,826,174	448,531.6	0.20
June	96,801	5,285,120	97,941	885,023	2,423.1	17,713	17,734	788,343	841,510	158,335,539	433,499.1	0.20
July	96,654	5,326,175	97,881	780,315	2,136.4	14,743	14,771	694,045	741,470	164,801,989	451,203.3	0.20
August	96,499	5,325,535	97,196	514,426	1,408.4	11,064	11,083	456,247	480,085	164,812,478	451,232.0	0.19
September	97,242	5,320,247	97,818	355,932	974.5	8,433	8,464	318,550	340,465	159,403,146	436,422.0	0.19
October	97,755	5,358,904	98,571	285,210	780.9	7,058	7,064	265,836	292,848	165,861,675	454,104.5	0.19
November	97,421	5,350,616	98,324	179,891	492.5	5,585	5,601	171,736	183,368	160,308,637	438,901.1	0.19
December	96,744	5,470,746	97,369	62,718	171.7	4,062	4,072	62,557	67,243	165,524,336	453,180.9	0.19
Losartan												
<i>Prevalent Losartan episodes</i>												
<i>2014</i>												
January	2,416	4,531,255	2,416	1,593,129	4,361.7	41,148	41,488	1,464,966	1,533,260	140,156,968	383,728.9	0.13
February	4,486	4,525,425	4,486	1,342,575	3,675.8	34,808	35,018	1,232,017	1,303,071	126,514,507	346,377.8	0.12
March	6,774	4,524,556	6,832	1,461,919	4,002.5	35,893	36,006	1,342,308	1,418,182	140,036,195	383,398.2	0.12
April	9,288	4,551,212	9,358	1,769,434	4,844.4	36,959	37,237	1,629,482	1,703,716	136,259,621	373,058.5	0.12
May	11,812	4,549,461	11,981	1,860,193	5,092.9	39,147	39,318	1,706,876	1,783,599	140,812,634	385,524.0	0.13
June	13,796	4,543,585	13,953	1,746,614	4,782.0	37,370	37,550	1,605,722	1,675,752	136,112,338	372,655.3	0.13
July	15,547	4,567,206	15,762	1,708,670	4,678.1	38,832	39,040	1,569,679	1,656,469	141,244,393	386,706.1	0.13
August	16,899	4,566,372	17,114	1,426,584	3,905.8	31,212	31,292	1,304,062	1,361,181	141,287,064	386,822.9	0.13
September	18,217	4,560,192	18,472	1,510,239	4,134.8	33,893	34,060	1,384,497	1,454,925	136,611,694	374,022.4	0.13
October	19,547	4,603,390	19,849	1,610,685	4,409.8	34,599	35,119	1,478,325	1,566,931	142,414,439	389,909.5	0.13
November	20,623	4,596,452	20,892	1,414,280	3,872.1	31,931	32,064	1,295,812	1,367,036	137,689,334	376,972.9	0.13
December	21,563	4,690,727	21,839	1,367,933	3,745.2	31,158	31,216	1,253,576	1,300,942	142,159,405	389,211.2	0.13

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2015</i>												
January	22,489	4,630,053	22,817	1,415,922	3,876.6	33,431	33,681	1,296,750	1,372,679	143,195,395	392,047.6	0.13
February	23,122	4,622,633	23,349	1,156,209	3,165.5	25,247	25,624	1,061,557	1,122,206	128,891,444	352,885.5	0.13
March	24,086	4,608,204	24,417	1,505,473	4,121.8	36,273	36,446	1,379,808	1,461,076	142,621,979	390,477.7	0.13
April	25,147	4,649,181	25,552	1,702,992	4,662.5	35,230	35,389	1,564,586	1,646,447	139,200,373	381,109.9	0.13
May	26,365	4,646,557	26,719	1,748,508	4,787.2	35,014	35,106	1,605,907	1,683,093	143,820,934	393,760.3	0.13
June	27,383	4,639,786	27,710	1,598,046	4,375.2	33,069	33,283	1,464,802	1,533,574	139,000,288	380,562.0	0.13
July	28,229	4,670,939	28,613	1,450,417	3,971.0	31,323	31,487	1,328,928	1,394,136	144,470,455	395,538.5	0.13
August	28,957	4,668,567	29,313	1,304,158	3,570.6	27,391	27,454	1,191,289	1,254,468	144,458,311	395,505.3	0.13
September	29,719	4,661,777	30,113	1,377,085	3,770.3	31,600	31,757	1,259,713	1,340,235	139,666,252	382,385.4	0.13
October	30,512	4,702,725	30,920	1,403,110	3,841.5	31,370	31,452	1,276,958	1,357,148	145,490,180	398,330.4	0.13
November	31,272	4,694,981	31,591	1,269,238	3,475.0	27,349	27,472	1,159,233	1,217,725	140,653,325	385,087.8	0.12
December	31,845	4,787,323	32,171	1,170,661	3,205.1	25,381	25,566	1,070,895	1,127,715	145,235,622	397,633.5	0.12
<i>2016</i>												
January	32,372	4,728,935	32,707	1,198,051	3,280.1	25,747	25,844	1,091,115	1,149,466	146,290,949	400,522.8	0.12
February	32,806	4,722,828	33,125	1,120,422	3,067.5	25,177	25,602	1,023,312	1,074,250	136,754,625	374,413.8	0.12
March	33,412	4,721,494	33,781	1,305,941	3,575.5	30,351	30,529	1,191,657	1,254,721	146,130,012	400,082.2	0.12
April	34,152	4,763,745	34,577	1,519,545	4,160.3	31,934	32,191	1,390,296	1,466,199	142,710,057	390,718.8	0.12
May	35,122	4,761,475	35,554	1,575,037	4,312.2	33,076	33,306	1,447,439	1,543,181	147,398,347	403,554.7	0.12
June	35,936	4,755,765	36,328	1,482,751	4,059.6	30,064	30,378	1,356,050	1,431,931	142,485,590	390,104.3	0.12
July	36,507	4,789,659	36,882	1,281,527	3,508.6	28,309	28,440	1,167,731	1,242,766	148,216,944	405,795.9	0.12
August	37,034	4,789,879	37,429	1,219,639	3,339.2	26,324	26,470	1,110,110	1,184,461	148,205,722	405,765.2	0.12
September	37,571	4,784,732	38,000	1,225,412	3,355.0	25,922	26,050	1,113,549	1,151,931	143,351,972	392,476.3	0.12
October	38,141	4,827,419	38,559	1,200,641	3,287.2	24,999	25,101	1,090,134	1,159,645	149,343,093	408,879.1	0.12
November	38,651	4,821,453	39,045	1,132,417	3,100.4	24,796	25,021	1,027,698	1,100,605	144,440,669	395,457.0	0.12
December	39,055	4,912,146	39,404	1,045,476	2,862.4	20,882	20,978	946,552	999,247	149,183,800	408,443.0	0.12

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2017</i>												
January	39,406	4,857,234	39,767	1,033,804	2,830.4	22,213	22,234	938,212	979,918	150,243,342	411,343.9	0.12
February	39,633	4,851,354	39,969	920,167	2,519.3	21,061	21,103	830,803	869,127	135,630,146	371,335.1	0.12
March	40,075	4,850,455	40,480	1,129,630	3,092.8	25,752	25,832	1,023,477	1,073,486	150,130,789	411,035.7	0.12
April	40,539	4,891,602	40,938	1,247,871	3,416.5	26,333	26,463	1,131,373	1,205,072	146,479,408	401,038.8	0.12
May	41,492	4,889,743	41,997	1,416,792	3,879.0	27,916	28,120	1,282,565	1,365,806	151,368,663	414,424.8	0.12
June	42,214	4,884,152	42,647	1,272,722	3,484.5	26,121	26,216	1,151,176	1,219,327	146,327,826	400,623.8	0.12
July	42,755	4,921,394	43,201	1,094,100	2,995.5	22,471	22,515	986,272	1,048,131	152,222,136	416,761.5	0.12
August	43,221	4,919,729	43,660	1,014,396	2,777.3	21,822	21,978	913,497	977,952	152,243,200	416,819.2	0.12
September	43,592	4,914,078	43,998	963,141	2,636.9	20,474	20,519	864,398	908,657	147,221,835	403,071.4	0.12
October	44,051	4,958,836	44,478	1,003,614	2,747.7	21,179	21,521	898,902	948,685	153,436,270	420,085.6	0.12
November	44,671	4,952,572	45,099	1,032,024	2,825.5	21,448	21,533	923,451	972,941	148,367,001	406,206.7	0.12
December	45,026	5,042,972	45,374	832,116	2,278.2	16,465	16,610	740,991	790,018	153,189,380	419,409.7	0.12
<i>2018</i>												
January	45,363	4,992,613	45,780	913,122	2,500.0	20,565	20,676	815,564	861,304	154,431,922	422,811.6	0.12
February	45,565	4,985,838	45,919	794,182	2,174.4	16,300	16,372	706,489	745,094	139,376,482	381,592.0	0.12
March	45,876	4,984,546	46,291	926,691	2,537.1	18,537	18,625	829,962	869,169	154,273,374	422,377.5	0.12
April	46,399	5,049,616	46,875	1,125,051	3,080.2	22,320	22,600	1,009,140	1,073,594	151,180,465	413,909.6	0.12
May	47,447	5,031,719	47,980	1,205,740	3,301.1	24,855	24,972	1,075,617	1,139,298	155,771,715	426,479.7	0.12
June	48,009	5,025,754	48,460	952,575	2,608.0	18,795	18,901	847,042	900,033	150,569,752	412,237.5	0.12
July	50,135	5,248,659	50,588	1,522,298	4,167.8	46,560	46,819	1,352,559	1,433,045	161,952,925	443,402.9	0.12
August	51,119	5,248,206	51,590	987,689	2,704.1	21,846	21,969	870,480	924,186	162,396,364	444,617.0	0.12
September	51,737	5,235,591	52,196	848,729	2,323.7	17,953	18,007	743,428	782,734	156,845,789	429,420.4	0.12
October	52,341	5,283,080	52,857	920,740	2,520.8	19,797	19,959	806,700	859,337	163,464,170	447,540.5	0.12
November	53,000	5,278,165	53,515	808,507	2,213.6	17,024	17,078	702,844	744,281	158,110,407	432,882.7	0.12
December	53,437	5,429,046	53,829	660,066	1,807.2	15,030	15,087	572,659	608,102	163,374,287	447,294.4	0.12

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Losartan												
<i>2019</i>												
January	53,882	5,316,623	54,353	740,409	2,027.1	15,584	15,695	641,037	688,142	164,467,330	450,287.0	0.12
February	53,962	5,311,853	54,349	558,233	1,528.4	11,532	11,553	478,739	511,229	148,509,460	406,596.7	0.12
March	53,781	5,312,441	54,202	558,975	1,530.4	12,103	12,193	480,454	513,290	164,414,315	450,141.9	0.12
April	53,149	5,214,111	53,668	754,504	2,065.7	15,312	15,349	660,473	705,382	156,117,169	427,425.5	0.12
May	51,165	5,211,993	51,728	853,626	2,337.1	15,719	15,761	743,166	787,188	161,342,233	441,731.0	0.11
June	49,482	5,205,734	49,932	689,544	1,887.9	14,673	14,739	597,142	641,706	155,963,416	427,004.6	0.11
July	48,651	5,223,637	49,085	632,375	1,731.3	12,993	13,020	547,580	585,751	161,568,268	442,349.8	0.10
August	47,557	5,221,894	47,975	469,390	1,285.1	9,492	9,519	402,620	435,609	161,610,996	442,466.8	0.10
September	45,738	5,215,944	46,114	404,987	1,108.8	9,009	9,107	348,264	376,175	156,283,032	427,879.6	0.10
October	43,435	5,254,354	43,766	373,997	1,023.9	7,659	7,676	323,480	354,029	162,602,021	445,180.1	0.09
November	40,209	5,247,911	40,606	474,295	1,298.5	10,030	10,065	418,509	459,275	157,212,007	430,423.0	0.08
December	35,923	5,373,061	36,201	436,523	1,195.1	9,900	9,948	386,465	427,226	162,419,938	444,681.6	0.07
<i>2020</i>												
January	33,712	5,259,449	34,010	507,633	1,389.8	14,452	14,493	454,004	496,770	162,724,489	445,515.4	0.07
February	32,714	5,252,961	32,964	492,885	1,349.4	12,951	12,962	444,120	488,848	152,125,581	416,497.1	0.07
March	32,348	5,251,492	32,703	597,636	1,636.2	15,972	16,018	534,780	576,691	162,553,946	445,048.4	0.07
April	31,626	5,298,169	31,876	409,662	1,121.6	11,450	11,505	366,304	399,370	158,709,018	434,521.6	0.06
May	31,465	5,293,064	31,775	332,055	909.1	7,528	7,543	294,747	323,412	163,826,174	448,531.6	0.06
June	31,525	5,285,120	31,910	331,413	907.4	6,945	6,950	297,593	321,251	158,335,539	433,499.1	0.06
July	31,709	5,326,175	32,143	303,499	830.9	6,129	6,174	271,117	294,315	164,801,989	451,203.3	0.06
August	31,963	5,325,535	32,199	213,873	585.6	4,504	4,521	189,816	207,735	164,812,478	451,232.0	0.06
September	32,623	5,320,247	32,842	161,325	441.7	3,972	3,980	145,866	158,736	159,403,146	436,422.0	0.06
October	33,282	5,358,904	33,556	125,761	344.3	3,259	3,286	116,525	126,408	165,861,675	454,104.5	0.07
November	33,525	5,350,616	33,827	73,971	202.5	2,337	2,344	69,879	75,304	160,308,637	438,901.1	0.07
December	33,733	5,470,746	33,938	24,280	66.5	1,536	1,538	24,219	25,991	165,524,336	453,180.9	0.07

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
<i>2014</i>												
January	2,265	4,531,255	2,265	1,410,017	3,860.4	36,708	36,780	1,297,683	1,306,446	140,156,968	383,728.9	0.12
February	4,424	4,525,425	4,424	1,428,900	3,912.1	38,001	38,012	1,324,222	1,336,085	126,514,507	346,377.8	0.12
March	6,742	4,524,556	6,799	1,529,060	4,186.3	36,939	36,953	1,411,970	1,421,947	140,036,195	383,398.2	0.12
April	8,992	4,551,212	9,064	1,729,224	4,734.4	43,268	43,278	1,600,672	1,604,883	136,259,621	373,058.5	0.12
May	11,270	4,549,461	11,430	1,794,436	4,912.9	43,451	43,458	1,657,280	1,672,233	140,812,634	385,524.0	0.12
June	12,903	4,543,585	13,062	1,564,355	4,283.0	34,864	34,876	1,445,742	1,452,238	136,112,338	372,655.3	0.12
July	14,361	4,567,206	14,541	1,469,444	4,023.1	32,819	32,830	1,354,437	1,362,854	141,244,393	386,706.1	0.12
August	15,454	4,566,372	15,644	1,296,739	3,550.3	34,550	34,553	1,190,804	1,194,721	141,287,064	386,822.9	0.12
September	16,716	4,560,192	16,933	1,526,399	4,179.1	38,842	38,861	1,409,997	1,410,822	136,611,694	374,022.4	0.12
October	18,038	4,603,390	18,288	1,611,807	4,412.9	39,373	39,388	1,485,022	1,497,627	142,414,439	389,909.5	0.12
November	19,242	4,596,452	19,466	1,390,139	3,806.0	33,088	33,096	1,276,871	1,293,646	137,689,334	376,972.9	0.12
December	20,340	4,690,727	20,535	1,287,139	3,524.0	31,378	31,382	1,180,930	1,180,051	142,159,405	389,211.2	0.12
<i>2015</i>												
January	21,341	4,630,053	21,612	1,404,447	3,845.2	31,792	31,810	1,290,188	1,311,095	143,195,395	392,047.6	0.12
February	22,185	4,622,633	22,408	1,296,662	3,550.1	29,486	29,501	1,191,326	1,207,270	128,891,444	352,885.5	0.12
March	23,254	4,608,204	23,551	1,391,550	3,809.9	32,904	32,911	1,275,333	1,284,044	142,621,979	390,477.7	0.12
April	24,386	4,649,181	24,709	1,727,056	4,728.4	39,393	39,404	1,586,133	1,608,549	139,200,373	381,109.9	0.12
May	25,585	4,646,557	25,915	1,572,872	4,306.3	37,679	37,693	1,447,038	1,456,500	143,820,934	393,760.3	0.12
June	26,700	4,639,786	27,018	1,547,218	4,236.1	35,182	35,192	1,420,776	1,438,303	139,000,288	380,562.0	0.12
July	27,542	4,670,939	27,890	1,408,423	3,856.1	33,341	33,350	1,288,274	1,296,876	144,470,455	395,538.5	0.12
August	28,249	4,668,567	28,550	1,206,455	3,303.1	25,806	25,809	1,105,945	1,115,086	144,458,311	395,505.3	0.12
September	29,167	4,661,777	29,546	1,399,867	3,832.6	30,785	30,792	1,279,168	1,292,254	139,666,252	382,385.4	0.12
October	30,100	4,702,725	30,458	1,581,325	4,329.4	36,903	36,912	1,451,102	1,465,067	145,490,180	398,330.4	0.12
November	31,054	4,694,981	31,390	1,363,380	3,732.7	29,888	29,900	1,244,586	1,254,574	140,653,325	385,087.8	0.12
December	31,966	4,787,323	32,290	1,380,782	3,780.4	31,924	31,940	1,265,228	1,275,994	145,235,622	397,633.5	0.12

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2016</i>												
January	32,746	4,728,935	33,080	1,331,585	3,645.7	29,531	29,544	1,216,780	1,233,662	146,290,949	400,522.8	0.13
February	33,563	4,722,828	33,879	1,312,749	3,594.1	30,581	30,590	1,202,707	1,206,172	136,754,625	374,413.8	0.13
March	34,515	4,721,494	34,924	1,452,963	3,978.0	35,112	35,128	1,327,641	1,337,182	146,130,012	400,082.2	0.13
April	35,401	4,763,745	35,817	1,592,914	4,361.2	35,571	35,626	1,457,059	1,480,217	142,710,057	390,718.8	0.13
May	36,695	4,761,475	37,093	1,665,544	4,560.0	36,938	37,035	1,525,117	1,534,166	147,398,347	403,554.7	0.13
June	37,721	4,755,765	38,119	1,558,862	4,267.9	34,797	34,836	1,427,487	1,437,338	142,485,590	390,104.3	0.13
July	38,273	4,789,659	38,656	1,323,949	3,624.8	29,327	29,335	1,205,502	1,215,985	148,216,944	405,795.9	0.13
August	39,006	4,789,879	39,452	1,298,172	3,554.2	30,166	30,247	1,180,699	1,191,968	148,205,722	405,765.2	0.13
September	39,692	4,784,732	40,143	1,297,017	3,551.0	28,319	28,348	1,175,622	1,182,601	143,351,972	392,476.3	0.13
October	40,327	4,827,419	40,770	1,401,044	3,835.8	31,409	31,416	1,271,604	1,281,079	149,343,093	408,879.1	0.13
November	41,196	4,821,453	41,606	1,382,533	3,785.2	29,177	29,190	1,254,409	1,259,884	144,440,669	395,457.0	0.13
December	41,841	4,912,146	42,223	1,173,675	3,213.3	26,231	26,248	1,063,055	1,066,836	149,183,800	408,443.0	0.13
<i>2017</i>												
January	42,341	4,857,234	42,789	1,176,224	3,220.3	25,305	25,315	1,062,355	1,071,392	150,243,342	411,343.9	0.13
February	42,931	4,851,354	43,302	1,091,342	2,987.9	23,985	23,991	985,461	1,001,249	135,630,146	371,335.1	0.13
March	43,796	4,850,455	44,270	1,279,383	3,502.8	27,772	27,793	1,153,587	1,162,151	150,130,789	411,035.7	0.13
April	44,276	4,891,602	44,727	1,298,778	3,555.9	26,627	26,642	1,174,129	1,187,342	146,479,408	401,038.8	0.13
May	45,212	4,889,743	45,705	1,374,945	3,764.4	28,311	28,326	1,242,195	1,255,145	151,368,663	414,424.8	0.13
June	45,724	4,884,152	46,188	1,219,116	3,337.8	25,928	25,935	1,098,345	1,109,967	146,327,826	400,623.8	0.13
July	46,093	4,921,394	46,533	1,095,513	2,999.4	23,344	23,360	981,790	989,180	152,222,136	416,761.5	0.13
August	46,482	4,919,729	46,949	1,055,310	2,889.3	21,598	21,689	942,960	956,024	152,243,200	416,819.2	0.13
September	46,770	4,914,078	47,259	1,043,900	2,858.0	22,635	22,643	932,901	938,577	147,221,835	403,071.4	0.13
October	47,117	4,958,836	47,648	1,184,357	3,242.6	25,330	25,345	1,059,084	1,073,581	153,436,270	420,085.6	0.13
November	47,710	4,952,572	48,190	1,135,393	3,108.5	23,373	23,383	1,016,361	1,023,488	148,367,001	406,206.7	0.13
December	48,034	5,042,972	48,418	907,837	2,485.5	18,930	18,970	804,711	818,409	153,189,380	419,409.7	0.13

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2018</i>												
January	48,505	4,992,613	48,979	1,080,848	2,959.2	23,742	23,758	963,134	975,201	154,431,922	422,811.6	0.13
February	48,856	4,985,838	49,283	925,254	2,533.2	19,766	19,779	820,679	834,152	139,376,482	381,592.0	0.13
March	49,450	4,984,546	49,927	969,444	2,654.2	21,584	21,599	859,035	871,029	154,273,374	422,377.5	0.13
April	49,887	5,049,616	50,389	1,136,569	3,111.8	22,706	22,741	1,015,006	1,037,251	151,180,465	413,909.6	0.13
May	50,813	5,031,719	51,356	1,136,335	3,111.1	23,289	23,309	1,009,043	1,025,136	155,771,715	426,479.7	0.13
June	51,459	5,025,754	51,971	995,953	2,726.8	20,068	20,084	877,273	893,206	150,569,752	412,237.5	0.13
July	53,189	5,248,659	53,676	1,441,478	3,946.6	42,997	43,048	1,276,018	1,297,985	161,952,925	443,402.9	0.13
August	54,064	5,248,206	54,559	1,029,437	2,818.4	24,122	24,138	904,644	918,304	162,396,364	444,617.0	0.13
September	54,705	5,235,591	55,198	899,996	2,464.1	19,067	19,080	784,882	800,342	156,845,789	429,420.4	0.13
October	55,414	5,283,080	56,008	1,016,705	2,783.6	20,457	20,478	887,303	906,118	163,464,170	447,540.5	0.13
November	56,221	5,278,165	56,700	907,878	2,485.6	18,476	18,482	788,741	812,415	158,110,407	432,882.7	0.13
December	56,583	5,429,046	57,027	711,172	1,947.1	14,395	14,400	610,266	631,435	163,374,287	447,294.4	0.13
<i>2019</i>												
January	57,070	5,316,623	57,601	746,749	2,044.5	15,105	15,118	637,967	653,689	164,467,330	450,287.0	0.13
February	57,418	5,311,853	57,854	660,288	1,807.8	13,884	13,895	562,566	581,024	148,509,460	406,596.7	0.13
March	58,448	5,312,441	58,980	788,069	2,157.6	16,832	16,847	666,938	692,655	164,414,315	450,141.9	0.13
April	58,961	5,214,111	59,493	785,944	2,151.8	15,832	15,846	669,376	693,468	156,117,169	427,425.5	0.13
May	59,232	5,211,993	59,858	692,638	1,896.3	13,097	13,114	587,006	621,742	161,342,233	441,731.0	0.13
June	57,667	5,205,734	58,098	528,300	1,446.4	10,630	10,645	446,083	465,832	155,963,416	427,004.6	0.12
July	55,039	5,223,637	55,537	456,968	1,251.1	8,854	8,863	385,814	408,649	161,568,268	442,349.8	0.12
August	51,087	5,221,894	51,657	544,835	1,491.7	10,847	10,855	462,181	479,939	161,610,996	442,466.8	0.11
September	46,564	5,215,944	46,975	474,392	1,298.8	9,150	9,158	400,294	417,867	156,283,032	427,879.6	0.10
October	44,281	5,254,354	44,752	599,233	1,640.6	12,280	12,291	512,744	538,069	162,602,021	445,180.1	0.09
November	42,146	5,247,911	42,454	442,785	1,212.3	8,631	8,636	377,355	391,217	157,212,007	430,423.0	0.09
December	40,252	5,373,061	40,468	268,912	736.2	5,670	5,676	227,803	230,503	162,419,938	444,681.6	0.08

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2020</i>												
January	37,544	5,259,449	37,895	402,871	1,103.0	8,980	8,986	346,019	347,337	162,724,489	445,515.4	0.08
February	32,923	5,252,961	33,194	321,478	880.2	7,693	7,698	279,068	280,966	152,125,581	416,497.1	0.07
March	29,559	5,251,492	29,889	349,200	956.1	7,609	7,613	301,829	301,700	162,553,946	445,048.4	0.06
April	26,807	5,298,169	27,073	376,630	1,031.2	9,927	9,928	333,297	337,768	158,709,018	434,521.6	0.05
May	25,571	5,293,064	25,850	346,798	949.5	7,662	7,663	307,621	316,254	163,826,174	448,531.6	0.05
June	25,076	5,285,120	25,402	338,617	927.1	6,242	6,244	300,660	305,477	158,335,539	433,499.1	0.05
July	25,220	5,326,175	25,582	296,243	811.1	5,592	5,592	263,575	268,177	164,801,989	451,203.3	0.05
August	25,556	5,325,535	25,777	206,803	566.2	5,050	5,050	181,430	184,814	164,812,478	451,232.0	0.05
September	26,277	5,320,247	26,478	157,934	432.4	3,656	3,656	140,518	142,542	159,403,146	436,422.0	0.05
October	26,911	5,358,904	27,163	116,924	320.1	2,791	2,793	107,333	108,576	165,861,675	454,104.5	0.05
November	27,163	5,350,616	27,455	73,134	200.2	2,279	2,282	68,797	70,547	160,308,637	438,901.1	0.05
December	27,355	5,470,746	27,578	25,723	70.4	1,635	1,635	25,581	26,028	165,524,336	453,180.9	0.05
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
<i>2014</i>												
January	3,510	4,531,255	3,510	2,270,359	6,215.9	52,910	52,932	2,101,710	2,133,233	140,156,968	383,728.9	0.18
February	6,603	4,525,425	6,604	1,921,457	5,260.7	43,639	43,653	1,773,091	1,790,283	126,514,507	346,377.8	0.18
March	10,071	4,524,556	10,155	2,233,820	6,115.9	49,916	49,928	2,067,231	2,096,051	140,036,195	383,398.2	0.18
April	13,645	4,551,212	13,750	2,666,511	7,300.5	55,395	55,464	2,474,526	2,487,581	136,259,621	373,058.5	0.18
May	17,101	4,549,461	17,311	2,676,536	7,328.0	58,336	58,571	2,486,121	2,523,640	140,812,634	385,524.0	0.18
June	19,686	4,543,585	19,941	2,459,814	6,734.6	53,553	53,566	2,278,186	2,292,875	136,112,338	372,655.3	0.18
July	21,938	4,567,206	22,219	2,346,056	6,423.2	50,635	50,694	2,164,748	2,200,756	141,244,393	386,706.1	0.18
August	23,582	4,566,372	23,901	1,932,459	5,290.8	44,841	44,875	1,785,959	1,802,342	141,287,064	386,822.9	0.18
September	25,350	4,560,192	25,712	2,094,768	5,735.2	49,449	49,461	1,937,226	1,954,829	136,611,694	374,022.4	0.18
October	27,068	4,603,390	27,493	2,294,363	6,281.6	53,612	53,638	2,124,390	2,132,871	142,414,439	389,909.5	0.18
November	28,579	4,596,452	28,930	1,942,871	5,319.3	43,180	43,301	1,792,910	1,795,377	137,689,334	376,972.9	0.18
December	29,905	4,690,727	30,255	1,903,149	5,210.5	43,877	43,882	1,755,157	1,751,058	142,159,405	389,211.2	0.18

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2015</i>												
January	31,164	4,630,053	31,646	2,042,735	5,592.7	44,645	44,774	1,879,245	1,885,229	143,195,395	392,047.6	0.18
February	32,038	4,622,633	32,380	1,776,627	4,864.1	39,237	39,275	1,642,014	1,663,802	128,891,444	352,885.5	0.18
March	33,503	4,608,204	33,962	2,153,948	5,897.2	48,342	48,365	1,987,531	1,995,132	142,621,979	390,477.7	0.18
April	35,324	4,649,181	35,917	2,713,411	7,428.9	55,987	56,009	2,516,474	2,518,080	139,200,373	381,109.9	0.18
May	37,063	4,646,557	37,581	2,419,056	6,623.0	49,179	49,329	2,232,427	2,255,905	143,820,934	393,760.3	0.18
June	38,544	4,639,786	39,041	2,402,493	6,577.7	49,463	49,490	2,224,206	2,244,618	139,000,288	380,562.0	0.18
July	39,666	4,670,939	40,171	2,113,428	5,786.3	45,961	45,974	1,948,657	1,964,401	144,470,455	395,538.5	0.18
August	40,460	4,668,567	40,953	1,766,785	4,837.2	38,653	38,674	1,621,944	1,622,521	144,458,311	395,505.3	0.18
September	41,564	4,661,777	42,073	1,979,246	5,418.9	43,690	43,700	1,823,719	1,822,772	139,666,252	382,385.4	0.18
October	42,672	4,702,725	43,191	2,097,642	5,743.0	44,985	44,999	1,931,386	1,919,254	145,490,180	398,330.4	0.17
November	43,869	4,694,981	44,393	2,014,120	5,514.4	44,341	44,379	1,855,289	1,856,049	140,653,325	385,087.8	0.18
December	44,846	4,787,323	45,324	1,833,417	5,019.6	39,414	39,432	1,685,936	1,679,611	145,235,622	397,633.5	0.18
<i>2016</i>												
January	45,736	4,728,935	46,209	1,856,764	5,083.5	40,763	40,777	1,713,307	1,724,393	146,290,949	400,522.8	0.17
February	46,548	4,722,828	46,962	1,711,551	4,686.0	42,544	42,554	1,573,307	1,587,136	136,754,625	374,413.8	0.17
March	47,562	4,721,494	48,067	2,006,922	5,494.7	43,607	43,656	1,849,189	1,842,829	146,130,012	400,082.2	0.18
April	48,692	4,763,745	49,308	2,384,697	6,528.9	47,735	47,858	2,205,751	2,205,622	142,710,057	390,718.8	0.18
May	50,032	4,761,475	50,682	2,381,649	6,520.6	47,492	47,514	2,197,645	2,196,310	147,398,347	403,554.7	0.18
June	51,233	4,755,765	51,785	2,192,577	6,002.9	47,898	47,914	2,019,616	2,038,101	142,485,590	390,104.3	0.17
July	51,955	4,789,659	52,519	1,853,758	5,075.3	42,397	42,409	1,702,180	1,705,907	148,216,944	405,795.9	0.17
August	52,897	4,789,879	53,446	1,890,928	5,177.1	42,517	42,530	1,739,583	1,746,006	148,205,722	405,765.2	0.18
September	53,556	4,784,732	54,134	1,870,717	5,121.7	45,382	45,484	1,718,567	1,724,583	143,351,972	392,476.3	0.17
October	54,407	4,827,419	54,975	1,999,421	5,474.1	45,114	45,126	1,837,308	1,833,975	149,343,093	408,879.1	0.17
November	55,410	4,821,453	55,988	1,991,476	5,452.4	46,765	46,780	1,830,259	1,829,580	144,440,669	395,457.0	0.17
December	56,321	4,912,146	56,828	1,700,322	4,655.2	37,553	37,576	1,555,013	1,556,021	149,183,800	408,443.0	0.18

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2017</i>												
January	57,037	4,857,234	57,578	1,816,927	4,974.5	42,173	42,185	1,668,704	1,667,338	150,243,342	411,343.9	0.18
February	57,657	4,851,354	58,125	1,603,349	4,389.7	36,150	36,171	1,471,081	1,460,624	135,630,146	371,335.1	0.18
March	58,572	4,850,455	59,137	1,849,833	5,064.6	41,020	41,051	1,700,044	1,689,140	150,130,789	411,035.7	0.18
April	59,438	4,891,602	60,074	2,137,252	5,851.5	44,892	44,961	1,965,627	1,966,093	146,479,408	401,038.8	0.18
May	61,082	4,889,743	61,796	2,459,611	6,734.0	50,946	50,956	2,261,389	2,260,454	151,368,663	414,424.8	0.18
June	62,219	4,884,152	62,819	2,096,560	5,740.1	44,132	44,198	1,928,403	1,928,250	146,327,826	400,623.8	0.18
July	62,876	4,921,394	63,479	1,782,315	4,879.7	37,539	37,570	1,632,291	1,633,943	152,222,136	416,761.5	0.18
August	63,554	4,919,729	64,158	1,701,038	4,657.2	37,419	37,429	1,554,496	1,550,833	152,243,200	416,819.2	0.18
September	64,165	4,914,078	64,791	1,728,790	4,733.2	38,620	38,677	1,581,434	1,586,432	147,221,835	403,071.4	0.18
October	64,888	4,958,836	65,563	1,792,629	4,908.0	39,849	39,878	1,637,113	1,640,361	153,436,270	420,085.6	0.18
November	65,854	4,952,572	66,504	1,811,584	4,959.8	38,688	38,717	1,655,288	1,655,859	148,367,001	406,206.7	0.18
December	66,448	5,042,972	66,936	1,453,795	3,980.3	31,813	31,824	1,320,278	1,332,468	153,189,380	419,409.7	0.18
<i>2018</i>												
January	67,211	4,992,613	67,802	1,669,816	4,571.7	36,778	36,794	1,522,039	1,520,826	154,431,922	422,811.6	0.18
February	67,653	4,985,838	68,177	1,376,448	3,768.5	28,563	28,573	1,243,070	1,236,003	139,376,482	381,592.0	0.18
March	68,586	4,984,546	69,185	1,652,642	4,524.7	37,151	37,194	1,508,853	1,505,906	154,273,374	422,377.5	0.18
April	69,711	5,049,616	70,466	2,092,946	5,730.2	41,655	41,699	1,911,765	1,915,239	151,180,465	413,909.6	0.18
May	71,281	5,031,719	72,020	2,037,392	5,578.1	43,311	43,338	1,858,620	1,855,603	155,771,715	426,479.7	0.18
June	72,281	5,025,754	72,983	1,881,851	5,152.2	40,811	40,871	1,716,140	1,714,752	150,569,752	412,237.5	0.18
July	77,329	5,248,659	77,996	3,789,589	10,375.3	133,834	133,890	3,477,186	3,453,180	161,952,925	443,402.9	0.19
August	79,703	5,248,206	80,367	2,253,826	6,170.6	52,196	52,223	2,048,043	2,033,809	162,396,364	444,617.0	0.19
September	81,297	5,235,591	82,021	1,986,044	5,437.5	42,472	42,504	1,801,623	1,788,813	156,845,789	429,420.4	0.19
October	82,845	5,283,080	83,671	2,131,692	5,836.3	45,202	45,226	1,923,364	1,921,055	163,464,170	447,540.5	0.19
November	84,651	5,278,165	85,332	1,916,506	5,247.1	42,492	42,508	1,730,266	1,724,402	158,110,407	432,882.7	0.20
December	85,650	5,429,046	86,243	1,542,820	4,224.0	34,270	34,291	1,387,857	1,377,032	163,374,287	447,294.4	0.20

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2019</i>												
January	86,690	5,316,623	87,482	1,663,254	4,553.7	36,563	36,593	1,492,956	1,471,346	164,467,330	450,287.0	0.20
February	87,128	5,311,853	87,785	1,480,395	4,053.1	33,752	33,783	1,333,874	1,316,082	148,509,460	406,596.7	0.20
March	89,033	5,312,441	89,797	1,947,817	5,332.8	48,055	48,087	1,751,173	1,729,127	164,414,315	450,141.9	0.20
April	91,164	5,214,111	92,027	2,296,191	6,286.6	50,146	50,180	2,070,114	2,060,589	156,117,169	427,425.5	0.20
May	94,088	5,211,993	95,041	2,283,424	6,251.7	49,015	49,048	2,053,182	2,059,056	161,342,233	441,731.0	0.21
June	96,492	5,205,734	97,292	2,024,533	5,542.9	46,189	46,206	1,815,412	1,812,529	155,963,416	427,004.6	0.21
July	99,710	5,223,637	100,524	2,161,875	5,918.9	49,330	49,408	1,924,339	1,912,134	161,568,268	442,349.8	0.21
August	101,763	5,221,894	102,633	1,706,543	4,672.3	38,435	38,463	1,511,392	1,502,508	161,610,996	442,466.8	0.22
September	104,412	5,215,944	105,272	1,830,745	5,012.3	43,154	43,187	1,623,496	1,612,066	156,283,032	427,879.6	0.22
October	107,764	5,254,354	108,724	1,978,401	5,416.6	46,439	46,482	1,740,238	1,727,663	162,602,021	445,180.1	0.23
November	110,591	5,247,911	111,405	1,594,888	4,366.6	35,762	35,783	1,391,072	1,402,276	157,212,007	430,423.0	0.23
December	112,039	5,373,061	112,776	1,271,712	3,481.8	28,880	28,894	1,110,778	1,092,858	162,419,938	444,681.6	0.23
<i>2020</i>												
January	111,893	5,259,449	112,719	1,134,449	3,106.0	25,203	25,239	989,880	976,916	162,724,489	445,515.4	0.23
February	108,285	5,252,961	109,051	869,543	2,380.7	20,032	20,048	767,825	756,142	152,125,581	416,497.1	0.22
March	102,787	5,251,492	104,028	1,370,581	3,752.4	30,512	30,520	1,216,389	1,163,453	162,553,946	445,048.4	0.21
April	95,026	5,298,169	95,834	1,217,451	3,333.2	30,145	30,151	1,081,170	1,085,533	158,709,018	434,521.6	0.19
May	92,744	5,293,064	93,643	1,014,837	2,778.5	22,515	22,527	904,118	909,428	163,826,174	448,531.6	0.19
June	92,991	5,285,120	94,191	1,041,530	2,851.6	20,721	20,735	933,159	930,617	158,335,539	433,499.1	0.19
July	93,905	5,326,175	95,125	931,027	2,549.0	17,549	17,555	833,146	834,243	164,801,989	451,203.3	0.19
August	94,440	5,325,535	95,166	637,628	1,745.7	13,629	13,633	565,701	562,634	164,812,478	451,232.0	0.19
September	96,405	5,320,247	96,929	466,059	1,276.0	11,171	11,174	420,793	418,333	159,403,146	436,422.0	0.19
October	98,170	5,358,904	98,998	361,365	989.4	9,299	9,307	335,779	334,756	165,861,675	454,104.5	0.19
November	99,004	5,350,616	99,888	237,706	650.8	7,549	7,556	226,524	224,666	160,308,637	438,901.1	0.19
December	99,522	5,470,746	100,127	75,194	205.9	4,796	4,800	74,941	74,617	165,524,336	453,180.9	0.19

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Prevalent Valsartan episodes</i>												
2014												
January	3,819	4,531,255	3,819	2,297,106	6,289.1	53,236	53,496	2,106,816	2,192,878	140,156,968	383,728.9	0.20
February	7,128	4,525,425	7,128	1,897,903	5,196.2	46,270	46,431	1,732,275	1,805,430	126,514,507	346,377.8	0.20
March	10,885	4,524,556	10,967	2,263,477	6,197.1	51,813	52,252	2,073,631	2,175,017	140,036,195	383,398.2	0.20
April	14,951	4,551,212	15,070	2,750,430	7,530.3	61,760	61,886	2,533,776	2,656,744	136,259,621	373,058.5	0.20
May	18,939	4,549,461	19,193	2,804,635	7,678.7	58,449	59,022	2,582,133	2,706,068	140,812,634	385,524.0	0.20
June	22,137	4,543,585	22,413	2,707,073	7,411.6	59,124	59,337	2,487,110	2,614,045	136,112,338	372,655.3	0.20
July	24,768	4,567,206	25,093	2,503,130	6,853.2	55,662	55,778	2,302,424	2,401,388	141,244,393	386,706.1	0.20
August	26,684	4,566,372	27,051	1,983,422	5,430.3	45,217	45,323	1,816,688	1,869,355	141,287,064	386,822.9	0.20
September	28,708	4,560,192	29,135	2,213,913	6,061.4	48,426	48,717	2,025,851	2,124,567	136,611,694	374,022.4	0.20
October	30,938	4,603,390	31,425	2,435,115	6,667.0	53,900	54,005	2,231,457	2,336,362	142,414,439	389,909.5	0.20
November	32,667	4,596,452	33,087	2,083,744	5,705.0	46,163	46,881	1,906,278	2,014,268	137,689,334	376,972.9	0.20
December	34,330	4,690,727	34,756	1,983,664	5,431.0	46,281	46,530	1,811,521	1,895,159	142,159,405	389,211.2	0.20
2015												
January	35,822	4,630,053	36,323	2,036,141	5,574.7	48,345	48,529	1,860,428	1,928,971	143,195,395	392,047.6	0.20
February	36,904	4,622,633	37,346	1,767,430	4,839.0	41,168	41,306	1,609,715	1,679,852	128,891,444	352,885.5	0.20
March	38,314	4,608,204	38,862	2,122,131	5,810.1	47,312	47,928	1,937,265	2,029,077	142,621,979	390,477.7	0.20
April	40,115	4,649,181	40,729	2,654,672	7,268.1	58,268	58,518	2,434,203	2,510,052	139,200,373	381,109.9	0.20
May	42,152	4,646,557	42,759	2,528,776	6,923.4	51,696	51,933	2,315,238	2,407,472	143,820,934	393,760.3	0.20
June	43,834	4,639,786	44,400	2,376,497	6,506.5	50,116	50,284	2,174,381	2,247,519	139,000,288	380,562.0	0.20
July	45,241	4,670,939	45,864	2,164,450	5,925.9	46,295	46,424	1,976,676	2,060,651	144,470,455	395,538.5	0.20
August	46,264	4,668,567	46,863	1,836,333	5,027.6	38,202	38,439	1,675,820	1,762,568	144,458,311	395,505.3	0.20
September	47,420	4,661,777	48,034	2,032,290	5,564.1	44,410	44,594	1,847,925	1,934,522	139,666,252	382,385.4	0.20
October	48,792	4,702,725	49,437	2,162,883	5,921.7	46,992	47,251	1,969,310	2,054,595	145,490,180	398,330.4	0.20
November	50,013	4,694,981	50,593	1,904,846	5,215.2	39,253	39,413	1,731,223	1,840,768	140,653,325	385,087.8	0.20
December	51,193	4,787,323	51,692	1,812,756	4,963.1	39,055	39,399	1,646,955	1,714,172	145,235,622	397,633.5	0.20

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2016</i>												
January	52,223	4,728,935	52,778	1,823,382	4,992.1	40,626	40,863	1,656,883	1,715,816	146,290,949	400,522.8	0.20
February	53,047	4,722,828	53,555	1,552,199	4,249.7	33,054	33,169	1,402,657	1,456,394	136,754,625	374,413.8	0.20
March	53,964	4,721,494	54,600	1,910,943	5,231.9	41,148	41,318	1,735,028	1,815,672	146,130,012	400,082.2	0.20
April	55,218	4,763,745	55,899	2,297,994	6,291.6	45,876	46,103	2,093,029	2,174,516	142,710,057	390,718.8	0.20
May	56,809	4,761,475	57,548	2,319,009	6,349.1	47,018	47,251	2,116,668	2,201,447	147,398,347	403,554.7	0.20
June	58,115	4,755,765	58,797	2,018,434	5,526.2	39,042	39,378	1,831,796	1,909,788	142,485,590	390,104.3	0.20
July	59,015	4,789,659	59,654	1,716,019	4,698.2	34,730	34,995	1,550,724	1,637,098	148,216,944	405,795.9	0.20
August	59,951	4,789,879	60,644	1,685,473	4,614.6	34,466	34,640	1,521,667	1,601,957	148,205,722	405,765.2	0.20
September	60,799	4,784,732	61,443	1,613,503	4,417.5	33,037	33,225	1,450,666	1,513,087	143,351,972	392,476.3	0.20
October	61,813	4,827,419	62,468	1,757,693	4,812.3	36,637	36,799	1,580,519	1,650,470	149,343,093	408,879.1	0.20
November	62,898	4,821,453	63,546	1,701,555	4,658.6	36,928	37,083	1,531,750	1,607,771	144,440,669	395,457.0	0.20
December	63,818	4,912,146	64,403	1,472,880	4,032.5	30,800	30,848	1,317,102	1,395,634	149,183,800	408,443.0	0.20
<i>2017</i>												
January	64,645	4,857,234	65,288	1,503,650	4,116.8	30,542	30,680	1,346,103	1,406,852	150,243,342	411,343.9	0.20
February	65,239	4,851,354	65,767	1,316,947	3,605.6	29,050	29,101	1,177,538	1,234,683	135,630,146	371,335.1	0.20
March	66,044	4,850,455	66,705	1,477,366	4,044.8	32,122	32,267	1,316,920	1,380,496	150,130,789	411,035.7	0.20
April	67,082	4,891,602	67,794	1,872,998	5,128.0	39,557	39,724	1,685,451	1,818,290	146,479,408	401,038.8	0.20
May	69,398	4,889,743	70,180	2,476,071	6,779.1	65,285	65,674	2,250,790	2,903,242	151,368,663	414,424.8	0.20
June	71,544	4,884,152	72,285	2,537,831	6,948.2	73,899	74,202	2,325,735	3,252,974	146,327,826	400,623.8	0.20
July	73,037	4,921,394	73,695	1,874,401	5,131.8	40,748	40,887	1,690,761	2,193,820	152,222,136	416,761.5	0.20
August	74,303	4,919,729	75,038	1,690,572	4,628.5	38,263	38,366	1,517,068	1,928,653	152,243,200	416,819.2	0.21
September	75,195	4,914,078	75,917	1,447,355	3,962.6	33,118	33,250	1,285,363	1,552,176	147,221,835	403,071.4	0.21
October	76,297	4,958,836	77,019	1,516,151	4,151.0	34,251	34,456	1,344,384	1,602,904	153,436,270	420,085.6	0.21
November	77,485	4,952,572	78,220	1,435,033	3,928.9	32,758	32,892	1,270,456	1,519,401	148,367,001	406,206.7	0.21
December	78,406	5,042,972	79,003	1,248,806	3,419.0	27,632	27,707	1,099,190	1,315,948	153,189,380	419,409.7	0.21

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2018</i>												
January	79,418	4,992,613	80,163	1,292,081	3,537.5	29,935	30,319	1,134,538	1,365,135	154,431,922	422,811.6	0.21
February	80,155	4,985,838	80,771	1,099,901	3,011.4	24,872	24,929	962,099	1,157,302	139,376,482	381,592.0	0.21
March	81,018	4,984,546	81,763	1,217,666	3,333.8	27,793	27,852	1,061,119	1,290,042	154,273,374	422,377.5	0.21
April	82,238	5,049,616	83,085	1,336,431	3,658.9	28,626	28,671	1,160,963	1,408,978	151,180,465	413,909.6	0.21
May	83,959	5,031,719	84,821	1,306,416	3,576.8	26,586	26,792	1,128,295	1,371,951	155,771,715	426,479.7	0.21
June	85,128	5,025,754	85,932	1,199,509	3,284.1	25,936	25,986	1,037,708	1,280,493	150,569,752	412,237.5	0.21
July	84,476	5,248,659	84,878	755,262	2,067.8	17,061	17,168	667,305	851,701	161,952,925	443,402.9	0.20
August	81,827	5,248,206	82,146	619,567	1,696.3	15,972	15,987	560,192	732,432	162,396,364	444,617.0	0.19
September	63,594	5,235,591	63,928	669,291	1,832.4	17,184	17,290	608,214	775,774	156,845,789	429,420.4	0.15
October	50,461	5,283,080	50,842	851,074	2,330.1	20,996	21,038	770,898	992,452	163,464,170	447,540.5	0.12
November	40,018	5,278,165	40,324	802,573	2,197.3	21,470	21,672	729,241	967,344	158,110,407	432,882.7	0.09
December	35,772	5,429,046	36,028	660,429	1,808.2	18,248	18,454	597,213	780,786	163,374,287	447,294.4	0.08
<i>2019</i>												
January	35,303	5,316,623	35,628	713,966	1,954.7	18,419	18,565	648,976	853,792	164,467,330	450,287.0	0.08
February	35,209	5,311,853	35,465	645,684	1,767.8	17,901	17,934	584,656	768,498	148,509,460	406,596.7	0.08
March	35,637	5,312,441	35,943	752,483	2,060.2	24,649	24,685	682,682	890,915	164,414,315	450,141.9	0.08
April	36,234	5,214,111	36,612	899,885	2,463.8	24,882	25,065	817,228	1,071,964	156,117,169	427,425.5	0.08
May	37,076	5,211,993	37,424	896,557	2,454.6	23,465	23,583	815,346	1,074,766	161,342,233	441,731.0	0.08
June	37,799	5,205,734	38,118	780,313	2,136.4	21,072	21,192	699,711	900,467	155,963,416	427,004.6	0.08
July	38,724	5,223,637	39,031	807,873	2,211.8	21,995	22,128	730,063	948,124	161,568,268	442,349.8	0.08
August	39,312	5,221,894	39,654	656,954	1,798.6	18,341	18,380	586,652	779,044	161,610,996	442,466.8	0.08
September	40,061	5,215,944	40,399	702,383	1,923.0	19,905	19,947	631,522	846,193	156,283,032	427,879.6	0.08
October	40,883	5,254,354	41,231	712,607	1,951.0	20,668	20,728	637,082	854,790	162,602,021	445,180.1	0.09
November	41,758	5,247,911	42,101	638,541	1,748.2	17,967	18,044	571,466	776,408	157,212,007	430,423.0	0.09
December	42,382	5,373,061	42,702	551,468	1,509.8	15,888	15,921	489,231	654,711	162,419,938	444,681.6	0.09

Table 2g. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2020</i>												
January	43,037	5,259,449	43,381	589,395	1,613.7	21,041	21,084	524,074	696,348	162,724,489	445,515.4	0.09
February	43,294	5,252,961	43,629	520,062	1,423.9	17,114	17,176	463,814	617,210	152,125,581	416,497.1	0.09
March	43,133	5,251,492	43,553	527,722	1,444.8	14,616	14,701	468,311	605,685	162,553,946	445,048.4	0.09
April	42,314	5,298,169	42,638	377,624	1,033.9	10,560	10,597	333,011	422,568	158,709,018	434,521.6	0.09
May	41,713	5,293,064	42,094	390,880	1,070.2	10,489	10,557	350,176	438,038	163,826,174	448,531.6	0.08
June	41,672	5,285,120	42,163	422,044	1,155.5	9,834	9,876	378,147	483,329	158,335,539	433,499.1	0.08
July	41,934	5,326,175	42,462	375,417	1,027.8	8,724	8,770	337,551	431,231	164,801,989	451,203.3	0.08
August	42,273	5,325,535	42,591	278,993	763.8	7,518	7,551	249,574	326,956	164,812,478	451,232.0	0.09
September	43,109	5,320,247	43,349	199,918	547.3	6,111	6,118	180,288	242,878	159,403,146	436,422.0	0.09
October	43,946	5,358,904	44,286	159,213	435.9	5,234	5,245	146,929	196,595	165,861,675	454,104.5	0.09
November	44,484	5,350,616	44,900	109,518	299.8	4,158	4,167	103,091	139,861	160,308,637	438,901.1	0.09
December	44,987	5,470,746	45,243	36,328	99.5	2,538	2,544	36,118	49,232	165,524,336	453,180.9	0.09

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year month divided by all ARB episodes in the same year month

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
<i>Prevalent ARB episodes</i>												
2014												
Q1: January - March	54,914	4,546,590	55,372	37,256,092	102,001.6	923,037	927,500	34,602,771	35,911,767	406,707,670	1,113,504.9	1.00
Q2: April - June	114,158	4,568,552	120,171	45,483,231	124,526.3	1,044,921	1,050,120	42,357,577	43,963,675	413,184,593	1,131,237.8	1.00
Q3: July - September	150,137	4,582,849	161,083	38,158,677	104,472.8	911,244	916,606	35,455,331	36,804,162	419,143,151	1,147,551.4	1.00
Q4: October - December	178,745	4,717,888	191,653	37,150,128	101,711.5	892,085	897,497	34,485,156	35,784,386	422,263,178	1,156,093.6	1.00
2015												
Q1: January - March	201,443	4,645,087	215,509	34,740,160	95,113.4	840,703	845,756	32,238,700	33,450,466	414,708,818	1,135,410.9	1.00
Q2: April - June	229,564	4,665,610	247,449	43,760,126	119,808.7	979,883	985,023	40,729,569	42,143,869	422,021,595	1,155,432.2	1.00
Q3: July - September	248,563	4,685,143	265,688	35,017,998	95,874.1	814,383	818,414	32,465,086	33,708,247	428,595,018	1,173,429.2	1.00
Q4: October - December	267,267	4,814,313	284,391	35,110,040	96,126.1	806,241	809,476	32,561,096	33,755,483	431,379,127	1,181,051.7	1.00
2016												
Q1: January - March	283,919	4,744,390	300,263	32,765,458	89,706.9	784,638	788,696	30,400,487	31,486,526	429,175,586	1,175,018.7	1.00
Q2: April - June	305,285	4,780,488	326,244	40,768,171	111,617.2	900,384	905,306	37,912,732	39,300,640	432,593,994	1,184,377.8	1.00
Q3: July - September	319,444	4,805,865	338,239	32,411,054	88,736.6	754,478	759,050	30,000,850	31,133,818	439,774,638	1,204,037.3	1.00
Q4: October - December	334,190	4,937,562	353,096	32,377,372	88,644.4	746,776	750,426	29,933,979	31,149,727	442,967,562	1,212,779.1	1.00
2017												
Q1: January - March	347,294	4,873,160	365,370	29,803,045	81,596.3	704,148	707,665	27,558,455	28,575,784	436,004,277	1,193,714.7	1.00
Q2: April - June	366,734	4,907,954	389,891	38,214,363	104,625.2	879,136	883,203	35,472,811	38,246,696	444,175,897	1,216,087.3	1.00
Q3: July - September	379,943	4,936,446	400,030	30,224,337	82,749.7	709,817	713,385	27,914,778	29,969,403	451,687,171	1,236,652.1	1.00
Q4: October - December	392,877	5,069,943	413,146	29,501,892	80,771.8	689,281	693,100	27,219,530	28,819,311	454,992,651	1,245,702.0	1.00
2018												
Q1: January - March	404,990	5,009,440	424,837	27,639,434	75,672.6	667,078	670,387	25,520,486	26,931,007	448,081,778	1,226,781.0	1.00
Q2: April - June	422,988	5,065,453	447,525	33,910,758	92,842.6	765,143	768,975	31,454,373	33,270,973	457,521,932	1,252,626.8	1.00
Q3: July - September	437,247	5,266,838	458,178	27,195,891	74,458.3	640,112	643,228	24,969,852	26,249,013	481,195,078	1,317,440.3	1.00
Q4: October - December	449,564	5,455,499	471,270	25,872,866	70,836.0	605,223	607,627	23,647,530	25,054,559	484,948,864	1,327,717.6	1.00
2019												
Q1: January - March	460,691	5,335,318	482,120	22,860,346	62,588.2	544,276	546,516	20,835,681	22,141,577	477,391,105	1,307,025.6	1.00
Q2: April - June	478,088	5,230,849	504,333	27,175,124	74,401.4	613,632	616,341	24,833,890	26,472,943	473,422,818	1,296,161.0	1.00
Q3: July - September	489,191	5,238,298	513,728	20,884,803	57,179.5	487,159	489,209	18,906,858	20,359,680	479,462,296	1,312,696.2	1.00
Q4: October - December	501,616	5,398,988	525,674	19,141,352	52,406.2	454,252	455,960	17,249,107	18,546,341	482,233,966	1,320,284.6	1.00

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
ARB												
<i>2020</i>												
Q1: January - March	511,647	5,274,664	538,871	16,150,878	44,218.7	394,532	395,928	14,435,141	15,507,577	477,404,016	1,307,061.0	1.00
Q2: April - June	513,494	5,314,163	542,300	12,809,766	35,071.2	290,747	291,448	11,430,862	12,234,253	480,870,731	1,316,552.3	1.00
Q3: July - September	519,384	5,342,071	543,608	8,837,170	24,194.9	195,206	195,841	7,936,948	8,540,664	489,017,613	1,338,857.3	1.00
Q4: October - December	532,972	5,497,712	557,026	2,924,857	8,007.8	97,781	98,052	2,767,697	2,997,464	491,694,648	1,346,186.6	1.00
Candesartan												
<i>Prevalent Candesartan episodes</i>												
<i>2014</i>												
Q1: January - March	10,846	4,546,590	10,933	7,299,606	19,985.2	183,865	185,559	6,774,798	7,162,004	406,707,670	1,113,504.9	0.20
Q2: April - June	22,382	4,568,552	23,507	8,661,630	23,714.3	209,510	211,722	8,039,235	8,555,877	413,184,593	1,131,237.8	0.20
Q3: July - September	29,672	4,582,849	31,781	7,711,198	21,112.1	195,087	197,841	7,164,327	7,631,183	419,143,151	1,147,551.4	0.20
Q4: October - December	35,570	4,717,888	38,014	7,559,738	20,697.4	187,205	189,089	6,999,780	7,436,491	422,263,178	1,156,093.6	0.20
<i>2015</i>												
Q1: January - March	39,995	4,645,087	42,688	6,796,553	18,607.9	176,586	178,604	6,296,075	6,694,987	414,708,818	1,135,410.9	0.20
Q2: April - June	45,744	4,665,610	49,188	8,749,988	23,956.2	204,851	207,302	8,136,305	8,606,623	422,021,595	1,155,432.2	0.20
Q3: July - September	49,530	4,685,143	52,825	6,850,837	18,756.6	167,173	169,395	6,327,686	6,752,498	428,595,018	1,173,429.2	0.20
Q4: October - December	53,287	4,814,313	56,684	7,120,270	19,494.2	163,966	165,052	6,591,768	6,994,155	431,379,127	1,181,051.7	0.20
<i>2016</i>												
Q1: January - March	56,690	4,744,390	59,816	6,621,769	18,129.4	167,993	169,843	6,135,816	6,495,998	429,175,586	1,175,018.7	0.20
Q2: April - June	61,086	4,780,488	65,011	8,110,769	22,206.1	187,843	189,619	7,524,756	7,992,089	432,593,994	1,184,377.8	0.20
Q3: July - September	63,799	4,805,865	67,267	6,389,125	17,492.5	150,438	152,356	5,903,429	6,259,517	439,774,638	1,204,037.3	0.20
Q4: October - December	66,717	4,937,562	70,342	6,626,314	18,141.9	161,767	163,473	6,110,154	6,531,635	442,967,562	1,212,779.1	0.20
<i>2017</i>												
Q1: January - March	69,484	4,873,160	72,927	6,009,986	16,454.4	144,053	145,950	5,540,518	5,907,516	436,004,277	1,193,714.7	0.20
Q2: April - June	72,977	4,907,954	77,529	7,410,326	20,288.4	167,206	168,782	6,843,773	7,231,897	444,175,897	1,216,087.3	0.20
Q3: July - September	75,541	4,936,446	79,341	5,887,854	16,120.1	142,492	144,160	5,405,056	5,741,562	451,687,171	1,236,652.1	0.20
Q4: October - December	78,425	5,069,943	82,272	6,121,702	16,760.3	145,690	147,244	5,626,061	5,962,044	454,992,651	1,245,702.0	0.20
<i>2018</i>												
Q1: January - March	80,991	5,009,440	84,796	5,682,532	15,557.9	142,716	144,169	5,214,680	5,491,028	448,081,778	1,226,781.0	0.20
Q2: April - June	84,761	5,065,453	89,478	6,900,790	18,893.3	156,690	158,206	6,339,619	6,747,530	457,521,932	1,252,626.8	0.20
Q3: July - September	98,995	5,266,838	103,266	11,909,874	32,607.5	414,906	418,778	11,036,249	11,651,793	481,195,078	1,317,440.3	0.23
Q4: October - December	105,584	5,455,499	110,376	7,506,832	20,552.6	182,422	183,786	6,869,292	7,235,581	484,948,864	1,327,717.6	0.23

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Candesartan												
<i>2019</i>												
Q1: January - March	112,104	5,335,318	116,983	7,216,731	19,758.3	188,218	189,628	6,601,235	6,971,571	477,391,105	1,307,025.6	0.24
Q2: April - June	122,660	5,230,849	128,687	9,090,480	24,888.4	224,045	225,459	8,313,099	8,753,800	473,422,818	1,296,161.0	0.26
Q3: July - September	135,075	5,238,298	140,925	8,603,462	23,555.0	223,686	224,990	7,818,659	8,313,434	479,462,296	1,312,696.2	0.27
Q4: October - December	153,425	5,398,988	159,552	9,607,007	26,302.6	267,874	269,314	8,723,889	9,293,347	482,233,966	1,320,284.6	0.30
<i>2020</i>												
Q1: January - March	180,889	5,274,664	188,369	10,694,133	29,278.9	323,910	325,485	9,667,818	10,525,788	477,404,016	1,307,061.0	0.35
Q2: April - June	183,144	5,314,163	192,317	4,955,026	13,566.1	122,859	123,325	4,425,250	4,745,517	480,870,731	1,316,552.3	0.35
Q3: July - September	182,660	5,342,071	190,564	3,261,062	8,928.3	76,196	76,623	2,931,463	3,159,877	489,017,613	1,338,857.3	0.35
Q4: October - December	187,835	5,497,712	195,731	1,132,046	3,099.4	39,696	39,863	1,066,035	1,142,391	491,694,648	1,346,186.6	0.35
Irbesartan												
<i>Prevalent Irbesartan episodes</i>												
<i>2014</i>												
Q1: January - March	10,024	4,546,590	10,105	6,678,916	18,285.9	157,959	158,570	6,153,132	6,379,673	406,707,670	1,113,504.9	0.18
Q2: April - June	20,959	4,568,552	22,073	8,238,588	22,556.0	183,981	184,623	7,629,470	7,905,071	413,184,593	1,131,237.8	0.18
Q3: July - September	27,211	4,582,849	29,322	6,579,081	18,012.5	147,291	148,125	6,061,494	6,282,586	419,143,151	1,147,551.4	0.18
Q4: October - December	32,116	4,717,888	34,543	6,372,997	17,448.3	148,347	149,115	5,863,126	6,061,130	422,263,178	1,156,093.6	0.18
<i>2015</i>												
Q1: January - March	36,042	4,645,087	38,537	5,949,401	16,288.6	139,541	140,369	5,484,690	5,663,888	414,708,818	1,135,410.9	0.18
Q2: April - June	40,687	4,665,610	44,036	7,605,997	20,824.1	165,365	166,246	7,031,208	7,265,092	422,021,595	1,155,432.2	0.18
Q3: July - September	43,844	4,685,143	46,978	6,049,835	16,563.5	136,812	137,317	5,573,711	5,759,457	428,595,018	1,173,429.2	0.18
Q4: October - December	46,794	4,814,313	49,853	5,778,748	15,821.3	128,505	129,094	5,311,033	5,490,466	431,379,127	1,181,051.7	0.18
<i>2016</i>												
Q1: January - March	49,209	4,744,390	52,107	5,359,342	14,673.1	122,886	123,537	4,928,892	5,101,990	429,175,586	1,175,018.7	0.17
Q2: April - June	52,516	4,780,488	56,316	6,987,955	19,132.0	147,570	148,412	6,450,765	6,672,031	432,593,994	1,184,377.8	0.17
Q3: July - September	54,736	4,805,865	58,005	5,342,373	14,626.6	120,169	120,892	4,900,494	5,077,991	439,774,638	1,204,037.3	0.17
Q4: October - December	56,814	4,937,562	60,157	5,222,933	14,299.6	112,446	113,213	4,778,163	4,976,310	442,967,562	1,212,779.1	0.17
<i>2017</i>												
Q1: January - March	58,657	4,873,160	61,941	4,897,583	13,408.9	111,764	112,050	4,478,351	4,637,801	436,004,277	1,193,714.7	0.17
Q2: April - June	61,148	4,907,954	65,095	5,967,991	16,339.5	122,598	123,119	5,481,235	5,706,521	444,175,897	1,216,087.3	0.17
Q3: July - September	62,816	4,936,446	66,205	4,738,898	12,974.4	104,814	105,426	4,333,697	4,506,993	451,687,171	1,236,652.1	0.17
Q4: October - December	64,593	5,069,943	67,999	4,660,668	12,760.2	104,922	105,445	4,251,271	4,423,918	454,992,651	1,245,702.0	0.16

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Irbesartan												
<i>2018</i>												
Q1: January - March	66,051	5,009,440	69,398	4,325,672	11,843.0	98,914	99,265	3,942,922	4,102,622	448,081,778	1,226,781.0	0.16
Q2: April - June	68,267	5,065,453	72,298	5,196,564	14,227.4	109,478	109,910	4,756,459	4,953,228	457,521,932	1,252,626.8	0.16
Q3: July - September	73,460	5,266,838	76,951	6,042,907	16,544.6	164,920	165,435	5,541,132	5,746,094	481,195,078	1,317,440.3	0.17
Q4: October - December	76,012	5,455,499	79,705	4,430,102	12,129.0	97,340	97,704	4,017,507	4,181,465	484,948,864	1,327,717.6	0.17
<i>2019</i>												
Q1: January - March	78,299	5,335,318	81,855	3,938,483	10,783.0	94,760	94,969	3,559,557	3,718,528	477,391,105	1,307,025.6	0.17
Q2: April - June	82,403	5,230,849	86,834	5,076,700	13,899.2	110,627	111,082	4,606,981	4,831,031	473,422,818	1,296,161.0	0.17
Q3: July - September	86,543	5,238,298	90,712	4,283,367	11,727.2	98,038	98,307	3,850,203	4,081,942	479,462,296	1,312,696.2	0.18
Q4: October - December	91,131	5,398,988	95,401	3,988,395	10,919.6	95,137	95,542	3,565,386	3,730,642	482,233,966	1,320,284.6	0.18
<i>2020</i>												
Q1: January - March	102,963	5,274,664	107,536	5,337,336	14,612.8	155,672	156,115	4,785,926	4,938,744	477,404,016	1,307,061.0	0.20
Q2: April - June	103,286	5,314,163	108,765	2,579,224	7,061.5	58,394	58,502	2,286,253	2,421,697	480,870,731	1,316,552.3	0.20
Q3: July - September	100,856	5,342,071	105,457	1,650,673	4,519.3	34,240	34,318	1,468,842	1,562,020	489,017,613	1,338,857.3	0.19
Q4: October - December	101,396	5,497,712	106,125	527,819	1,445.1	16,705	16,737	500,129	543,458	491,694,648	1,346,186.6	0.19
Losartan												
<i>Prevalent Losartan episodes</i>												
<i>2014</i>												
Q1: January - March	6,790	4,546,590	6,850	4,397,623	12,040.0	111,849	112,512	4,039,291	4,254,514	406,707,670	1,113,504.9	0.12
Q2: April - June	14,387	4,568,552	15,146	5,376,241	14,719.3	113,476	114,105	4,942,080	5,163,066	413,184,593	1,131,237.8	0.13
Q3: July - September	19,186	4,582,849	20,567	4,645,493	12,718.7	103,937	104,392	4,258,238	4,472,576	419,143,151	1,147,551.4	0.13
Q4: October - December	22,794	4,717,888	24,446	4,392,898	12,027.1	97,688	98,399	4,027,713	4,234,910	422,263,178	1,156,093.6	0.13
<i>2015</i>												
Q1: January - March	25,473	4,645,087	27,194	4,077,604	11,163.9	94,951	95,751	3,738,115	3,955,961	414,708,818	1,135,410.9	0.13
Q2: April - June	28,879	4,665,610	31,104	5,049,546	13,824.9	103,313	103,778	4,635,295	4,863,114	422,021,595	1,155,432.2	0.13
Q3: July - September	31,181	4,685,143	33,301	4,131,660	11,311.9	90,314	90,698	3,779,930	3,988,839	428,595,018	1,173,429.2	0.13
Q4: October - December	33,282	4,814,313	35,302	3,843,009	10,521.6	84,100	84,490	3,507,086	3,702,588	431,379,127	1,181,051.7	0.12
<i>2016</i>												
Q1: January - March	35,084	4,744,390	37,025	3,624,414	9,923.1	81,275	81,975	3,306,084	3,478,437	429,175,586	1,175,018.7	0.12
Q2: April - June	37,556	4,780,488	40,108	4,577,333	12,532.1	95,074	95,875	4,193,785	4,441,312	432,593,994	1,184,377.8	0.12
Q3: July - September	39,204	4,805,865	41,520	3,726,578	10,202.8	80,555	80,960	3,391,390	3,579,158	439,774,638	1,204,037.3	0.12
Q4: October - December	40,755	4,937,562	42,982	3,378,534	9,249.9	70,677	71,100	3,064,384	3,259,497	442,967,562	1,212,779.1	0.12

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Losartan												
<i>2017</i>												
Q1: January - March	41,954	4,873,160	44,062	3,083,601	8,442.4	69,026	69,169	2,792,492	2,922,531	436,004,277	1,193,714.7	0.12
Q2: April - June	43,983	4,907,954	46,734	3,937,385	10,780.0	80,370	80,799	3,565,114	3,790,205	444,175,897	1,216,087.3	0.12
Q3: July - September	45,370	4,936,446	47,779	3,071,637	8,409.7	64,767	65,012	2,764,167	2,934,741	451,687,171	1,236,652.1	0.12
Q4: October - December	46,743	5,069,943	49,084	2,867,754	7,851.5	59,092	59,664	2,563,344	2,711,644	454,992,651	1,245,702.0	0.12
<i>2018</i>												
Q1: January - March	47,952	5,009,440	50,246	2,633,995	7,211.5	55,402	55,673	2,352,015	2,475,567	448,081,778	1,226,781.0	0.12
Q2: April - June	49,906	5,065,453	52,823	3,283,366	8,989.4	65,970	66,473	2,931,799	3,112,925	457,521,932	1,252,626.8	0.12
Q3: July - September	53,746	5,266,838	56,278	3,358,716	9,195.7	86,359	86,795	2,966,467	3,139,965	481,195,078	1,317,440.3	0.12
Q4: October - December	55,530	5,455,499	58,126	2,389,313	6,541.6	51,851	52,124	2,082,203	2,211,720	484,948,864	1,327,717.6	0.12
<i>2019</i>												
Q1: January - March	56,335	5,335,318	58,749	1,857,617	5,085.9	39,219	39,441	1,600,230	1,712,661	477,391,105	1,307,025.6	0.12
Q2: April - June	56,637	5,230,849	59,748	2,297,674	6,290.7	45,704	45,849	2,000,781	2,134,276	473,422,818	1,296,161.0	0.12
Q3: July - September	50,771	5,238,298	53,023	1,506,752	4,125.3	31,494	31,646	1,298,464	1,397,535	479,462,296	1,312,696.2	0.10
Q4: October - December	45,471	5,398,988	47,531	1,284,815	3,517.6	27,589	27,689	1,128,454	1,240,530	482,233,966	1,320,284.6	0.09
<i>2020</i>												
Q1: January - March	37,043	5,274,664	38,886	1,598,154	4,375.5	43,375	43,473	1,432,904	1,562,309	477,404,016	1,307,061.0	0.07
Q2: April - June	33,798	5,314,163	35,659	1,073,130	2,938.1	25,923	25,998	958,644	1,044,033	480,870,731	1,316,552.3	0.07
Q3: July - September	33,818	5,342,071	35,421	678,697	1,858.2	14,605	14,675	606,799	660,787	489,017,613	1,338,857.3	0.07
Q4: October - December	34,998	5,497,712	36,549	224,012	613.3	7,132	7,168	210,623	227,703	491,694,648	1,346,186.6	0.07
Olmesartan												
<i>Prevalent Olmesartan episodes</i>												
<i>2014</i>												
Q1: January - March	6,756	4,546,590	6,815	4,367,977	11,958.9	111,648	111,745	4,033,875	4,064,479	406,707,670	1,113,504.9	0.12
Q2: April - June	13,640	4,568,552	14,343	5,088,015	13,930.2	121,583	121,612	4,703,694	4,729,354	413,184,593	1,131,237.8	0.12
Q3: July - September	17,971	4,582,849	19,069	4,292,582	11,752.4	106,211	106,244	3,955,238	3,968,396	419,143,151	1,147,551.4	0.12
Q4: October - December	21,597	4,717,888	22,982	4,289,085	11,742.9	103,839	103,866	3,942,823	3,971,324	422,263,178	1,156,093.6	0.12
<i>2015</i>												
Q1: January - March	24,679	4,645,087	26,243	4,092,659	11,205.1	94,182	94,222	3,756,847	3,802,410	414,708,818	1,135,410.9	0.12
Q2: April - June	28,304	4,665,610	30,205	4,847,146	13,270.8	112,254	112,289	4,453,947	4,503,351	422,021,595	1,155,432.2	0.12
Q3: July - September	30,858	4,685,143	32,771	4,014,745	10,991.8	89,932	89,951	3,673,387	3,704,215	428,595,018	1,173,429.2	0.12
Q4: October - December	33,608	4,814,313	35,628	4,325,487	11,842.5	98,715	98,752	3,960,916	3,995,636	431,379,127	1,181,051.7	0.13

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Olmesartan												
<i>2016</i>												
Q1: January - March	36,297	4,744,390	38,307	4,097,297	11,217.8	95,224	95,262	3,747,128	3,777,016	429,175,586	1,175,018.7	0.13
Q2: April - June	39,627	4,780,488	42,033	4,817,320	13,189.1	107,306	107,497	4,409,663	4,451,721	432,593,994	1,184,377.8	0.13
Q3: July - September	41,622	4,805,865	44,041	3,919,138	10,730.0	87,812	87,930	3,561,823	3,590,554	439,774,638	1,204,037.3	0.13
Q4: October - December	43,855	4,937,562	46,277	3,957,252	10,834.4	86,817	86,854	3,589,068	3,607,799	442,967,562	1,212,779.1	0.13
<i>2017</i>												
Q1: January - March	45,822	4,873,160	48,195	3,546,949	9,711.0	77,062	77,099	3,201,403	3,234,791	436,004,277	1,193,714.7	0.13
Q2: April - June	47,923	4,907,954	50,794	3,892,839	10,658.0	80,866	80,903	3,514,669	3,552,454	444,175,897	1,216,087.3	0.13
Q3: July - September	49,098	4,936,446	51,805	3,194,723	8,746.7	67,577	67,692	2,857,651	2,883,781	451,687,171	1,236,652.1	0.13
Q4: October - December	50,317	5,069,943	53,017	3,227,587	8,836.7	67,633	67,698	2,880,156	2,915,478	454,992,651	1,245,702.0	0.13
<i>2018</i>												
Q1: January - March	51,598	5,009,440	54,276	2,975,546	8,146.6	65,092	65,136	2,642,848	2,680,382	448,081,778	1,226,781.0	0.13
Q2: April - June	53,667	5,065,453	56,722	3,268,857	8,949.6	66,063	66,134	2,901,322	2,955,593	457,521,932	1,252,626.8	0.13
Q3: July - September	57,155	5,266,838	59,999	3,370,911	9,229.1	86,186	86,266	2,965,544	3,016,631	481,195,078	1,317,440.3	0.13
Q4: October - December	59,077	5,455,499	62,037	2,635,755	7,216.3	53,328	53,360	2,286,310	2,349,968	484,948,864	1,327,717.6	0.13
<i>2019</i>												
Q1: January - March	60,966	5,335,318	63,922	2,195,106	6,009.9	45,821	45,860	1,867,471	1,927,367	477,391,105	1,307,025.6	0.13
Q2: April - June	61,961	5,230,849	65,075	2,006,882	5,494.5	39,559	39,605	1,702,465	1,781,042	473,422,818	1,296,161.0	0.13
Q3: July - September	57,425	5,238,298	60,393	1,476,195	4,041.6	28,851	28,876	1,248,289	1,306,455	479,462,296	1,312,696.2	0.12
Q4: October - December	46,359	5,398,988	48,304	1,310,930	3,589.1	26,581	26,603	1,117,902	1,159,789	482,233,966	1,320,284.6	0.09
<i>2020</i>												
Q1: January - March	39,269	5,274,664	41,202	1,073,549	2,939.2	24,282	24,297	926,916	930,003	477,404,016	1,307,061.0	0.08
Q2: April - June	29,234	5,314,163	31,057	1,062,045	2,907.7	23,831	23,835	941,578	959,498	480,870,731	1,316,552.3	0.06
Q3: July - September	27,336	5,342,071	28,833	660,980	1,809.7	14,298	14,298	585,523	595,532	489,017,613	1,338,857.3	0.05
Q4: October - December	28,636	5,497,712	30,225	215,781	590.8	6,705	6,710	201,711	205,151	491,694,648	1,346,186.6	0.05
Telmisartan												
<i>Prevalent Telmisartan episodes</i>												
<i>2014</i>												
Q1: January - March	10,093	4,546,590	10,180	6,425,636	17,592.4	146,465	146,513	5,942,032	6,019,568	406,707,670	1,113,504.9	0.18
Q2: April - June	20,682	4,568,552	21,746	7,802,861	21,363.1	167,284	167,601	7,238,833	7,304,096	413,184,593	1,131,237.8	0.18
Q3: July - September	26,945	4,582,849	28,877	6,373,283	17,449.1	144,925	145,030	5,887,933	5,957,927	419,143,151	1,147,551.4	0.18
Q4: October - December	31,665	4,717,888	33,911	6,140,383	16,811.5	140,669	140,821	5,672,457	5,679,306	422,263,178	1,156,093.6	0.18

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Telmisartan												
<i>2015</i>												
Q1: January - March	35,558	4,645,087	38,070	5,973,310	16,354.0	132,224	132,414	5,508,790	5,544,163	414,708,818	1,135,410.9	0.18
Q2: April - June	40,706	4,665,610	43,869	7,534,960	20,629.6	154,629	154,828	6,973,107	7,018,603	422,021,595	1,155,432.2	0.18
Q3: July - September	43,801	4,685,143	46,813	5,859,459	16,042.3	128,304	128,348	5,394,320	5,409,695	428,595,018	1,173,429.2	0.18
Q4: October - December	47,039	4,814,313	50,028	5,945,179	16,277.0	128,740	128,810	5,472,611	5,454,914	431,379,127	1,181,051.7	0.18
<i>2016</i>												
Q1: January - March	49,984	4,744,390	52,834	5,575,237	15,264.2	126,914	126,987	5,135,803	5,154,359	429,175,586	1,175,018.7	0.18
Q2: April - June	53,722	4,780,488	57,460	6,958,923	19,052.5	143,125	143,286	6,423,012	6,440,033	432,593,994	1,184,377.8	0.18
Q3: July - September	56,156	4,805,865	59,472	5,615,403	15,374.1	130,296	130,423	5,160,330	5,176,496	439,774,638	1,204,037.3	0.18
Q4: October - December	58,813	4,937,562	62,149	5,691,219	15,581.7	129,432	129,482	5,222,580	5,219,575	442,967,562	1,212,779.1	0.18
<i>2017</i>												
Q1: January - March	61,191	4,873,160	64,311	5,270,109	14,428.8	119,343	119,407	4,839,829	4,817,103	436,004,277	1,193,714.7	0.18
Q2: April - June	64,953	4,907,954	69,044	6,693,423	18,325.6	139,970	140,115	6,155,419	6,154,797	444,175,897	1,216,087.3	0.18
Q3: July - September	67,124	4,936,446	70,622	5,212,143	14,270.1	113,578	113,676	4,768,221	4,771,208	451,687,171	1,236,652.1	0.18
Q4: October - December	69,282	5,069,943	72,876	5,058,008	13,848.1	110,350	110,419	4,612,679	4,628,689	454,992,651	1,245,702.0	0.18
<i>2018</i>												
Q1: January - March	71,537	5,009,440	74,911	4,698,906	12,864.9	102,492	102,561	4,273,962	4,262,736	448,081,778	1,226,781.0	0.18
Q2: April - June	75,295	5,065,453	79,711	6,012,189	16,460.5	125,777	125,908	5,486,525	5,485,594	457,521,932	1,252,626.8	0.18
Q3: July - September	84,560	5,266,838	88,438	8,029,459	21,983.5	228,502	228,617	7,326,852	7,275,802	481,195,078	1,317,440.3	0.19
Q4: October - December	89,178	5,455,499	93,264	5,591,018	15,307.4	121,964	122,025	5,041,487	5,022,488	484,948,864	1,327,717.6	0.20
<i>2019</i>												
Q1: January - March	93,390	5,335,318	97,720	5,091,466	13,939.7	118,370	118,463	4,578,003	4,516,554	477,391,105	1,307,025.6	0.20
Q2: April - June	100,477	5,230,849	105,722	6,604,148	18,081.2	145,350	145,434	5,938,708	5,932,174	473,422,818	1,296,161.0	0.21
Q3: July - September	108,699	5,238,298	113,751	5,699,163	15,603.5	130,919	131,058	5,059,227	5,026,708	479,462,296	1,312,696.2	0.22
Q4: October - December	116,629	5,398,988	121,518	4,845,001	13,264.9	111,081	111,159	4,242,088	4,222,797	482,233,966	1,320,284.6	0.23
<i>2020</i>												
Q1: January - March	117,437	5,274,664	123,049	3,374,573	9,239.1	75,747	75,807	2,974,094	2,896,511	477,404,016	1,307,061.0	0.23
Q2: April - June	101,756	5,314,163	107,595	3,273,818	8,963.2	73,381	73,413	2,918,447	2,925,578	480,870,731	1,316,552.3	0.20
Q3: July - September	99,889	5,342,071	104,800	2,034,714	5,570.7	42,349	42,362	1,819,640	1,815,211	489,017,613	1,338,857.3	0.19
Q4: October - December	103,483	5,497,712	108,425	674,265	1,846.0	21,644	21,663	637,244	634,039	491,694,648	1,346,186.6	0.19

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
<i>Prevalent Valsartan episodes</i>												
2014												
Q1: January - March	10,912	4,546,590	10,995	6,458,486	17,682.4	151,319	152,179	5,912,722	6,173,325	406,707,670	1,113,504.9	0.20
Q2: April - June	23,112	4,568,552	24,300	8,262,138	22,620.5	179,333	180,245	7,603,019	7,976,858	413,184,593	1,131,237.8	0.20
Q3: July - September	30,285	4,582,849	32,486	6,700,465	18,344.9	149,305	149,818	6,144,963	6,395,310	419,143,151	1,147,551.4	0.20
Q4: October - December	36,094	4,717,888	38,701	6,502,523	17,802.9	146,344	147,416	5,949,256	6,245,788	422,263,178	1,156,093.6	0.20
2015												
Q1: January - March	40,539	4,645,087	43,447	5,925,702	16,223.7	136,825	137,763	5,407,408	5,637,900	414,708,818	1,135,410.9	0.20
Q2: April - June	45,991	4,665,610	49,591	7,559,945	20,698.0	160,080	160,735	6,923,822	7,165,043	422,021,595	1,155,432.2	0.20
Q3: July - September	49,769	4,685,143	53,221	6,033,073	16,517.7	128,907	129,457	5,500,421	5,757,741	428,595,018	1,173,429.2	0.20
Q4: October - December	53,425	4,814,313	56,845	5,880,485	16,099.9	125,300	126,063	5,347,488	5,609,536	431,379,127	1,181,051.7	0.20
2016												
Q1: January - March	56,563	4,744,390	59,860	5,286,524	14,473.7	114,828	115,350	4,794,568	4,987,882	429,175,586	1,175,018.7	0.20
Q2: April - June	60,586	4,780,488	64,814	6,635,437	18,166.8	131,936	132,732	6,041,493	6,285,751	432,593,994	1,184,377.8	0.20
Q3: July - September	63,300	4,805,865	67,036	5,014,995	13,730.3	102,233	102,860	4,523,057	4,752,142	439,774,638	1,204,037.3	0.20
Q4: October - December	66,321	4,937,562	70,030	4,932,128	13,503.4	104,365	104,730	4,429,371	4,653,875	442,967,562	1,212,779.1	0.20
2017												
Q1: January - March	68,926	4,873,160	72,377	4,297,963	11,767.2	91,714	92,048	3,840,561	4,022,031	436,004,277	1,193,714.7	0.20
Q2: April - June	74,336	4,907,954	78,944	6,886,900	18,855.3	178,741	179,600	6,261,976	7,974,506	444,175,897	1,216,087.3	0.20
Q3: July - September	78,167	4,936,446	82,175	5,012,328	13,723.0	112,129	112,503	4,493,192	5,674,649	451,687,171	1,236,652.1	0.21
Q4: October - December	81,313	5,069,943	85,400	4,199,990	11,498.9	94,641	95,055	3,714,030	4,438,252	454,992,651	1,245,702.0	0.21
2018												
Q1: January - March	84,315	5,009,440	88,386	3,609,648	9,882.7	82,600	83,100	3,157,756	3,812,479	448,081,778	1,226,781.0	0.21
Q2: April - June	88,348	5,065,453	93,345	3,842,356	10,519.8	81,148	81,449	3,326,966	4,061,422	457,521,932	1,252,626.8	0.21
Q3: July - September	86,203	5,266,838	88,210	2,044,120	5,596.5	50,217	50,445	1,835,711	2,359,906	481,195,078	1,317,440.3	0.19
Q4: October - December	52,819	5,455,499	54,701	2,314,076	6,335.6	60,714	61,164	2,097,352	2,740,582	484,948,864	1,327,717.6	0.12
2019												
Q1: January - March	37,916	5,335,318	39,587	2,112,133	5,782.7	60,969	61,184	1,916,314	2,513,205	477,391,105	1,307,025.6	0.08
Q2: April - June	39,585	5,230,849	41,678	2,576,755	7,054.8	69,419	69,840	2,332,285	3,047,197	473,422,818	1,296,161.0	0.08
Q3: July - September	41,807	5,238,298	43,708	2,167,210	5,933.5	60,241	60,455	1,948,237	2,573,360	479,462,296	1,312,696.2	0.09
Q4: October - December	44,099	5,398,988	46,013	1,902,616	5,209.1	54,523	54,693	1,697,779	2,285,909	482,233,966	1,320,284.6	0.09

Table 2h. Summary of Prevalent Angiotensin Receptor Blocker (ARB)-Containing Product Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database between January 1, 2014 and December 31, 2020 by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²	Proportion of All ARB Use ³
Valsartan												
<i>2020</i>												
Q1: January - March	46,047	5,274,664	48,232	1,637,179	4,482.4	52,771	52,961	1,456,199	1,919,242	477,404,016	1,307,061.0	0.09
Q2: April - June	44,947	5,314,163	47,287	1,190,548	3,259.5	30,883	31,030	1,061,334	1,343,935	480,870,731	1,316,552.3	0.09
Q3: July - September	44,647	5,342,071	46,671	854,328	2,339.0	22,353	22,439	767,413	1,001,066	489,017,613	1,338,857.3	0.09
Q4: October - December	46,622	5,497,712	48,684	305,059	835.2	11,930	11,956	286,138	385,688	491,694,648	1,346,186.6	0.09

¹Total number of users by year quarter may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple ARB episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

³Proportion of ARB use estimated as number of episodes for each individual ARB in given year quarter divided by all ARB episodes in the same year quarter

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014												
Candesartan	-	-	-	-	0.18	0.20	0.13	0.14	0.18	0.14	0.17	0.16
Irbesartan	0.06	0.23	0.13	0.14	-	-	-	-	0.12	0.06	0.11	0.14
Losartan	0.18	0.20	0.11	0.16	0.06	0.03	0.09	0.04	-	-	-	-
Olmesartan	0.47	0.48	0.26	0.22	0.18	0.37	0.35	0.07	0.29	0.20	0.28	0.27
Telmisartan	0.24	0.37	0.19	0.20	0.06	0.28	0.15	0.22	0.18	0.23	0.15	0.18
Valsartan	0.18	0.20	0.22	0.11	0.12	0.23	0.13	0.13	0.00	0.03	0.13	0.11
Non-index-defining ARB	1.12	1.48	0.91	0.85	0.59	1.11	0.82	0.60	0.77	0.63	0.82	0.87
Angiotensin-converting-enzyme inhibitors (ACEi)	4.77	4.38	3.18	3.56	4.36	3.50	2.53	2.15	3.77	2.96	2.19	1.82
Calcium channel blockers (CCB)	34.98	26.29	19.66	17.82	31.39	21.80	15.53	12.79	21.26	15.08	11.35	10.22
ACEi or CCB*	37.98	29.11	21.64	20.08	33.68	23.96	17.07	14.14	23.85	17.02	12.67	11.38
2015												
Candesartan	-	-	-	-	0.16	0.11	0.11	0.14	0.24	0.14	0.11	0.21
Irbesartan	0.13	0.16	0.11	0.15	-	-	-	-	0.13	0.07	0.03	0.16
Losartan	0.13	0.04	0.08	0.07	0.08	0.11	0.06	0.07	-	-	-	-
Olmesartan	0.33	0.29	0.27	0.34	0.19	0.25	0.22	0.15	0.19	0.19	0.23	0.19
Telmisartan	0.27	0.19	0.08	0.18	0.17	0.12	0.09	0.13	0.11	0.16	0.13	0.14
Valsartan	0.11	0.14	0.05	0.18	0.13	0.04	0.10	0.14	0.13	0.15	0.11	0.13
Non-index-defining ARB	0.96	0.82	0.59	0.92	0.71	0.63	0.57	0.64	0.76	0.68	0.61	0.81
ACEi	2.61	2.62	2.43	2.51	2.09	1.88	1.58	1.48	1.53	1.64	1.29	1.29
CCB	14.17	15.15	10.93	11.86	11.48	10.71	8.72	9.07	8.48	8.15	7.28	6.73
ACEi or CCB*	15.82	16.78	12.61	13.49	12.57	11.80	9.74	9.93	9.44	9.15	8.08	7.62
2016												
Candesartan	-	-	-	-	0.14	0.11	0.09	0.09	0.14	0.16	0.14	0.18
Irbesartan	0.11	0.12	0.08	0.07	-	-	-	-	0.14	0.11	0.08	0.09
Losartan	0.09	0.10	0.05	0.06	0.07	0.07	0.07	0.07	-	-	-	-
Olmesartan	0.22	0.31	0.25	0.19	0.17	0.18	0.18	0.13	0.20	0.25	0.16	0.14
Telmisartan	0.16	0.26	0.27	0.25	0.23	0.16	0.14	0.15	0.16	0.08	0.16	0.19
Valsartan	0.10	0.11	0.11	0.15	0.08	0.07	0.12	0.06	0.11	0.06	0.16	0.13
Non-index-defining ARB	0.66	0.87	0.74	0.71	0.67	0.59	0.58	0.50	0.71	0.64	0.69	0.72
ACEi	2.07	2.07	1.69	1.74	1.44	1.38	0.93	0.83	1.20	1.35	0.86	1.05
CCB	10.89	11.28	9.91	10.30	8.59	8.36	7.01	6.68	5.88	6.68	5.92	5.43
ACEi or CCB*	12.18	12.60	10.92	11.54	9.33	9.21	7.54	7.23	6.70	7.53	6.46	6.07

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2017												
Candesartan	-	-	-	-	0.11	0.15	0.07	0.17	0.09	0.12	0.08	0.10
Irbesartan	0.03	0.03	0.11	0.10	-	-	-	-	0.09	0.09	0.08	0.10
Losartan	0.08	0.06	0.08	0.06	0.04	0.10	0.03	0.08	-	-	-	-
Olmesartan	0.17	0.21	0.16	0.15	0.13	0.06	0.05	0.10	0.19	0.09	0.11	0.12
Telmisartan	0.19	0.27	0.14	0.19	0.15	0.21	0.13	0.07	0.21	0.12	0.12	0.13
Valsartan	0.18	0.29	0.27	0.27	0.07	0.08	0.05	0.11	0.09	0.14	0.12	0.14
Non-index-defining ARB	0.65	0.85	0.72	0.76	0.50	0.59	0.32	0.52	0.66	0.57	0.50	0.58
ACEi	1.48	1.70	1.40	1.53	0.89	1.11	1.03	0.86	0.82	0.87	0.78	0.81
CCB	9.87	10.21	8.72	9.77	7.34	6.88	6.17	6.49	5.49	5.40	4.86	4.99
ACEi or CCB*	10.83	11.24	9.63	10.74	7.80	7.57	6.84	6.98	5.97	5.99	5.37	5.43
2018												
Candesartan	-	-	-	-	0.08	0.11	0.16	0.24	0.11	0.11	0.30	0.19
Irbesartan	0.08	0.09	0.15	0.14	-	-	-	-	0.08	0.11	0.18	0.10
Losartan	0.08	0.05	0.11	0.09	0.04	0.08	0.06	0.06	-	-	-	-
Olmesartan	0.11	0.15	0.16	0.13	0.11	0.05	0.08	0.09	0.09	0.11	0.11	0.17
Telmisartan	0.23	0.20	0.35	0.31	0.08	0.08	0.11	0.17	0.13	0.16	0.25	0.23
Valsartan	0.30	0.27	0.22	0.31	0.13	0.10	0.07	0.09	0.13	0.13	0.05	0.04
Non-index-defining ARB	0.80	0.76	0.95	0.96	0.44	0.41	0.47	0.65	0.53	0.61	0.84	0.71
ACEi	1.56	1.40	1.68	1.79	0.84	0.73	0.89	0.72	0.52	0.79	0.73	0.74
CCB	9.35	9.74	10.94	11.83	6.17	5.84	6.10	6.41	5.01	5.60	4.86	5.65
ACEi or CCB*	10.29	10.63	11.96	12.97	6.63	6.28	6.64	6.82	5.31	6.11	5.30	6.14
2019												
Candesartan	-	-	-	-	0.22	0.24	0.26	1.02	4.49	2.82	6.31	8.11
Irbesartan	0.15	0.21	0.16	0.46	-	-	-	-	1.83	0.97	2.21	2.59
Losartan	0.13	0.10	0.11	0.12	0.05	0.07	0.03	0.04	-	-	-	-
Olmesartan	0.15	0.20	0.14	0.12	0.09	0.04	0.02	0.05	1.12	0.49	0.15	0.29
Telmisartan	0.32	0.39	0.33	0.69	0.24	0.20	0.29	0.51	2.44	1.57	2.63	3.28
Valsartan	0.31	0.36	0.33	0.43	0.08	0.15	0.08	0.18	0.55	0.25	0.72	0.56
Non-index-defining ARB	1.06	1.20	1.04	1.78	0.71	0.69	0.66	1.79	10.31	5.95	11.91	14.55
ACEi	1.78	1.98	1.91	2.24	0.92	0.92	0.85	0.91	1.37	0.92	0.77	0.58
CCB	11.92	13.50	12.76	15.53	5.73	6.51	5.78	6.30	4.60	4.14	3.15	2.01
ACEi or CCB*	13.16	14.74	13.96	16.89	6.32	7.05	6.32	6.85	5.46	4.73	3.66	2.34

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020												
Candesartan	-	-	-	-	2.72	1.27	0.43	1.06	2.56	0.21	0.12	0.09
Irbesartan	3.78	0.77	0.21	0.16	-	-	-	-	1.29	0.10	0.03	0.04
Losartan	0.83	0.38	0.08	0.08	0.14	0.08	0.07	0.32	-	-	-	-
Olmesartan	0.29	0.26	0.15	0.13	0.06	0.12	0.15	0.18	0.08	0.03	0.03	0.03
Telmisartan	0.93	0.57	0.34	0.39	0.41	0.39	0.28	0.49	0.37	0.06	0.05	0.11
Valsartan	0.73	0.28	0.33	0.48	0.25	0.08	0.11	0.23	0.17	0.01	0.02	0.05
Non-index-defining ARB	6.47	2.23	1.09	1.24	3.54	1.91	1.03	2.27	4.33	0.40	0.25	0.31
ACEi	4.12	2.13	1.58	1.95	1.36	0.84	0.52	0.59	0.54	0.22	0.23	0.36
CCB	16.23	12.94	11.74	15.02	6.82	5.04	4.70	5.32	1.75	2.09	2.33	2.85
ACEi or CCB*	18.81	14.28	12.72	16.20	7.64	5.54	5.00	5.63	2.11	2.23	2.48	3.07

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi or CCB in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter

²A dash represents an invalid value, such as a switching analysis with itself or for a year-quarter extending past the study period.

*ACEi or CCB: only ACEi or only CCB

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014												
Candesartan	0.71	0.43	0.28	0.36	0.47	0.23	0.37	0.25	0.12	0.31	0.24	0.22
Irbesartan	0.24	0.28	0.28	0.18	0.18	0.17	0.13	0.25	0.41	0.14	0.04	0.09
Losartan	0.12	0.28	0.19	0.11	0.41	0.06	0.09	0.20	0.18	0.11	0.06	0.11
Olmesartan	-	-	-	-	0.53	0.65	0.35	0.51	0.35	0.43	0.30	0.18
Telmisartan	0.24	0.37	0.30	0.54	-	-	-	-	0.24	0.17	0.26	0.16
Valsartan	0.47	0.34	0.43	0.22	0.29	0.48	0.30	0.23	-	-	-	-
Non-index-defining ARB	1.77	1.65	1.49	1.41	1.77	1.59	1.21	1.44	1.30	1.14	0.89	0.76
ACEi	6.30	6.20	5.28	4.10	5.77	5.15	3.60	3.40	4.53	3.59	3.01	3.00
CCB	39.98	28.40	19.36	16.98	32.27	23.99	16.39	15.48	33.39	22.74	17.22	14.18
ACEi or CCB*	44.05	32.47	22.50	19.25	35.98	27.63	18.69	17.61	36.33	25.38	19.21	16.14
2015												
Candesartan	0.35	0.34	0.34	0.29	0.19	0.19	0.23	0.16	0.17	0.29	0.11	0.12
Irbesartan	0.11	0.12	0.13	0.15	0.11	0.22	0.11	0.04	0.09	0.07	0.04	0.08
Losartan	0.16	0.10	0.11	0.09	0.09	0.11	0.03	0.14	0.09	0.04	0.03	0.04
Olmesartan	-	-	-	-	0.32	0.38	0.31	0.39	0.30	0.25	0.27	0.22
Telmisartan	0.36	0.49	0.27	0.29	-	-	-	-	0.13	0.21	0.19	0.13
Valsartan	0.25	0.32	0.23	0.24	0.27	0.18	0.14	0.27	-	-	-	-
Non-index-defining ARB	1.20	1.34	1.03	1.07	0.96	1.10	0.80	1.01	0.78	0.82	0.64	0.59
ACEi	3.12	3.75	2.90	2.92	2.42	2.53	2.13	2.22	2.37	2.49	1.88	1.84
CCB	15.22	14.74	11.56	11.96	12.04	12.00	9.92	10.46	12.18	12.65	10.34	10.40
ACEi or CCB*	17.16	16.99	13.24	13.73	13.48	13.70	11.24	12.10	13.63	14.26	11.53	11.43
2016												
Candesartan	0.34	0.30	0.26	0.35	0.14	0.27	0.26	0.20	0.13	0.20	0.21	0.10
Irbesartan	0.15	0.18	0.14	0.10	0.20	0.19	0.08	0.14	0.07	0.09	0.03	0.05
Losartan	0.14	0.08	0.09	0.06	0.10	0.06	0.16	0.08	0.08	0.05	0.06	0.03
Olmesartan	-	-	-	-	0.37	0.37	0.27	0.25	0.33	0.21	0.21	0.13
Telmisartan	0.28	0.32	0.33	0.47	-	-	-	-	0.20	0.15	0.25	0.15
Valsartan	0.21	0.24	0.17	0.21	0.20	0.18	0.17	0.12	-	-	-	-
Non-index-defining ARB	1.11	1.09	0.98	1.18	1.01	1.04	0.91	0.79	0.77	0.66	0.74	0.47
ACEi	2.66	2.70	2.16	2.04	2.12	2.10	1.84	1.55	1.81	1.85	1.17	1.51
CCB	11.28	11.54	9.58	10.11	9.79	10.24	8.75	9.12	9.90	10.43	8.65	9.21
ACEi or CCB*	13.00	13.23	10.83	11.29	11.02	11.64	9.87	10.06	10.96	11.63	9.40	10.22

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2017												
Candesartan	0.30	0.34	0.32	0.26	0.19	0.18	0.18	0.15	0.12	0.14	0.08	0.19
Irbesartan	0.14	0.10	0.08	0.09	0.16	0.09	0.08	0.08	0.04	0.08	0.04	0.06
Losartan	0.09	0.11	0.07	0.07	0.08	0.03	0.08	0.09	0.03	0.07	0.05	0.05
Olmesartan	-	-	-	-	0.24	0.19	0.21	0.18	0.10	0.14	0.11	0.12
Telmisartan	0.34	0.40	0.32	0.29	-	-	-	-	0.21	0.18	0.19	0.19
Valsartan	0.18	0.23	0.24	0.19	0.09	0.24	0.34	0.22	-	-	-	-
Non-index-defining ARB	1.04	1.19	1.01	0.90	0.74	0.74	0.87	0.71	0.50	0.62	0.48	0.59
ACEi	1.93	2.25	1.64	1.47	1.60	1.61	1.35	1.46	1.35	1.50	1.88	1.93
CCB	9.33	8.89	7.54	7.62	8.88	8.47	7.84	8.32	8.96	9.57	9.02	9.00
ACEi or CCB*	10.32	10.14	8.37	8.43	9.91	9.44	8.74	9.22	9.71	10.59	10.31	10.34
2018												
Candesartan	0.20	0.25	0.31	0.37	0.14	0.22	0.40	0.66	0.13	0.14	42.60	1.32
Irbesartan	0.08	0.12	0.10	0.08	0.07	0.12	0.16	0.30	0.07	0.07	15.54	0.48
Losartan	0.06	0.08	0.06	0.09	0.06	0.09	0.13	0.34	0.04	0.10	9.59	0.29
Olmesartan	-	-	-	-	0.21	0.16	0.15	0.35	0.09	0.11	7.33	0.31
Telmisartan	0.35	0.28	0.38	0.44	-	-	-	-	0.24	0.23	26.16	0.78
Valsartan	0.22	0.22	0.04	0.06	0.15	0.22	0.09	0.24	-	-	-	-
Non-index-defining ARB	0.91	0.94	0.87	1.03	0.62	0.78	0.92	1.86	0.57	0.65	98.81	2.97
ACEi	1.42	1.52	1.13	1.11	1.45	1.52	1.38	1.64	1.80	1.85	3.98	0.80
CCB	7.13	7.67	6.15	6.91	8.38	10.11	8.79	9.88	9.02	8.96	4.63	2.53
ACEi or CCB*	7.86	8.50	6.70	7.57	9.19	10.94	9.64	10.93	10.29	10.28	7.55	3.08
2019												
Candesartan	0.40	6.62	9.41	10.26	0.94	0.52	0.50	4.94	0.40	0.27	0.22	0.55
Irbesartan	0.14	2.55	3.42	2.36	0.44	0.13	0.13	1.20	0.11	0.11	0.05	0.18
Losartan	0.08	0.86	0.58	0.21	0.20	0.06	0.07	0.13	0.05	0.02	0.04	0.03
Olmesartan	-	-	-	-	0.47	0.16	0.12	0.15	0.12	0.06	0.05	0.03
Telmisartan	0.35	5.46	8.02	4.53	-	-	-	-	0.27	0.20	0.18	0.25
Valsartan	0.08	0.88	1.00	0.51	0.20	0.15	0.26	0.34	-	-	-	-
Non-index-defining ARB	1.04	16.25	22.13	17.41	2.23	1.00	1.04	6.73	0.94	0.64	0.52	1.01
ACEi	1.19	2.05	1.13	0.84	1.69	1.65	1.55	1.92	0.70	0.82	0.95	0.88
CCB	6.47	5.55	2.94	2.71	8.93	9.89	11.11	10.26	2.67	2.98	3.01	2.88
ACEi or CCB*	7.14	6.75	3.50	3.12	9.92	10.96	12.02	11.47	3.21	3.69	3.79	3.54

Table 3a. Proportion of Switching for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020												
Candesartan	9.92	1.29	0.12	0.13	22.47	0.82	0.34	0.35	2.26	0.53	0.16	0.12
Irbesartan	3.13	0.24	0.04	0.03	10.67	0.26	0.07	0.09	0.95	0.19	0.04	0.02
Losartan	0.40	0.08	0.03	0.04	1.50	0.12	0.03	0.07	0.18	0.02	0.02	0.01
Olmesartan	-	-	-	-	0.63	0.08	0.08	0.14	0.07	0.03	0.02	0.02
Telmisartan	1.58	0.48	0.08	0.09	-	-	-	-	0.35	0.20	0.08	0.07
Valsartan	0.40	0.07	0.02	0.03	0.82	0.09	0.09	0.16	-	-	-	-
Non-index-defining ARB	14.74	2.06	0.29	0.32	35.38	1.34	0.59	0.79	3.72	0.90	0.32	0.23
ACEi	1.29	0.29	0.24	0.33	3.96	0.94	0.90	1.15	0.88	0.65	0.66	0.75
CCB	1.77	1.69	1.91	2.35	6.60	5.13	6.17	10.04	2.73	1.88	2.17	3.07
ACEi or CCB*	2.53	1.84	2.05	2.53	9.16	5.72	6.71	10.77	3.40	2.37	2.71	3.62

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi or CCB in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter

²A dash represents an invalid value, such as a switching analysis with itself or for a year-quarter extending past the study period.

*ACEi or CCB: only ACEi or only CCB

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014												
Candesartan	-	-	-	-	0.13	0.17	0.12	0.13	0.13	0.14	0.12	0.13
Irbesartan	0.13	0.13	0.07	0.13	-	-	-	-	0.09	0.07	0.11	0.10
Losartan	0.09	0.17	0.10	0.08	0.11	0.07	0.02	0.06	-	-	-	-
Olmesartan	0.43	0.30	0.29	0.29	0.20	0.35	0.29	0.18	0.18	0.21	0.22	0.21
Telmisartan	0.20	0.20	0.15	0.11	0.07	0.18	0.17	0.14	0.05	0.17	0.14	0.13
Valsartan	0.11	0.12	0.12	0.12	0.13	0.13	0.10	0.11	0.11	0.09	0.09	0.09
Non-index-defining ARB	0.96	0.89	0.73	0.74	0.63	0.90	0.69	0.61	0.56	0.67	0.67	0.66
Angiotensin-converting-enzyme inhibitors (ACEi)	3.25	2.63	1.92	1.96	3.67	2.68	1.72	1.48	2.42	1.76	1.40	1.18
Calcium channel blockers (CCB)	44.32	29.72	21.81	18.73	48.11	32.55	22.09	18.45	29.71	20.12	14.74	11.76
ACEi or CCB*	46.09	31.28	22.95	19.86	50.19	33.87	23.04	19.22	31.15	21.32	15.51	12.48
2015												
Candesartan	-	-	-	-	0.11	0.08	0.10	0.10	0.14	0.08	0.11	0.12
Irbesartan	0.08	0.09	0.07	0.11	-	-	-	-	0.10	0.09	0.05	0.09
Losartan	0.04	0.04	0.06	0.06	0.07	0.08	0.05	0.05	-	-	-	-
Olmesartan	0.24	0.21	0.24	0.23	0.24	0.26	0.19	0.20	0.23	0.23	0.18	0.20
Telmisartan	0.16	0.15	0.08	0.13	0.14	0.16	0.09	0.10	0.13	0.16	0.11	0.10
Valsartan	0.07	0.08	0.06	0.09	0.09	0.06	0.08	0.08	0.10	0.09	0.08	0.08
Non-index-defining ARB	0.59	0.58	0.51	0.62	0.64	0.64	0.50	0.53	0.70	0.64	0.52	0.58
ACEi	1.58	1.45	1.31	1.39	1.30	1.46	1.13	1.01	0.98	1.03	0.82	0.81
CCB	15.11	16.13	12.88	12.86	15.22	15.87	13.44	12.28	10.18	10.59	8.97	8.27
ACEi or CCB*	16.01	16.99	13.62	13.66	15.87	16.63	14.07	12.80	10.76	11.16	9.42	8.78
2016												
Candesartan	-	-	-	-	0.09	0.10	0.09	0.09	0.10	0.10	0.09	0.14
Irbesartan	0.08	0.06	0.07	0.07	-	-	-	-	0.08	0.12	0.08	0.08
Losartan	0.05	0.06	0.05	0.05	0.05	0.06	0.04	0.05	-	-	-	-
Olmesartan	0.24	0.26	0.19	0.22	0.20	0.20	0.19	0.13	0.21	0.29	0.16	0.15
Telmisartan	0.17	0.16	0.15	0.18	0.16	0.13	0.15	0.14	0.13	0.11	0.12	0.14
Valsartan	0.08	0.09	0.08	0.12	0.06	0.06	0.08	0.09	0.10	0.07	0.11	0.08
Non-index-defining ARB	0.60	0.63	0.52	0.62	0.55	0.55	0.53	0.50	0.60	0.67	0.56	0.59
ACEi	1.14	1.10	0.98	0.95	0.93	0.97	0.69	0.65	0.76	0.85	0.59	0.65
CCB	11.75	12.38	10.81	10.83	10.91	12.51	10.14	9.99	7.36	8.34	7.23	6.61
ACEi or CCB*	12.38	13.01	11.35	11.43	11.38	13.01	10.50	10.30	7.77	8.82	7.55	6.98

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2017												
Candesartan	-	-	-	-	0.08	0.10	0.07	0.09	0.10	0.11	0.10	0.08
Irbesartan	0.04	0.05	0.06	0.06	-	-	-	-	0.08	0.06	0.06	0.06
Losartan	0.06	0.04	0.05	0.05	0.04	0.06	0.03	0.04	-	-	-	-
Olmesartan	0.15	0.17	0.14	0.12	0.14	0.10	0.11	0.10	0.16	0.13	0.11	0.13
Telmisartan	0.17	0.21	0.15	0.15	0.13	0.14	0.11	0.09	0.15	0.14	0.09	0.10
Valsartan	0.10	0.19	0.20	0.23	0.07	0.09	0.08	0.09	0.07	0.12	0.10	0.12
Non-index-defining ARB	0.51	0.66	0.59	0.60	0.45	0.50	0.40	0.43	0.56	0.57	0.46	0.49
ACEi	0.88	0.97	0.87	0.83	0.65	0.75	0.67	0.65	0.51	0.58	0.51	0.52
CCB	10.14	11.19	9.92	9.92	9.54	10.31	8.86	9.01	6.34	7.04	6.14	6.07
ACEi or CCB*	10.63	11.71	10.43	10.43	9.83	10.71	9.25	9.35	6.60	7.39	6.46	6.37
2018												
Candesartan	-	-	-	-	0.09	0.07	0.22	0.22	0.11	0.13	0.29	0.20
Irbesartan	0.05	0.07	0.18	0.14	-	-	-	-	0.08	0.08	0.15	0.10
Losartan	0.06	0.05	0.13	0.07	0.02	0.07	0.08	0.08	-	-	-	-
Olmesartan	0.14	0.15	0.21	0.18	0.11	0.09	0.13	0.13	0.13	0.11	0.14	0.16
Telmisartan	0.16	0.17	0.35	0.31	0.12	0.11	0.21	0.18	0.12	0.15	0.22	0.18
Valsartan	0.23	0.21	0.68	0.51	0.12	0.10	0.23	0.19	0.11	0.15	0.16	0.12
Non-index-defining ARB	0.64	0.63	1.51	1.18	0.46	0.44	0.83	0.80	0.55	0.61	0.92	0.76
ACEi	0.85	0.82	1.03	1.03	0.61	0.60	0.65	0.59	0.42	0.50	0.54	0.53
CCB	9.77	10.73	15.96	13.36	8.47	9.26	10.39	9.36	5.81	6.72	7.11	6.42
ACEi or CCB*	10.25	11.19	16.58	13.96	8.76	9.54	10.73	9.66	6.04	7.00	7.41	6.70
2019												
Candesartan	-	-	-	-	0.28	0.31	0.35	1.38	4.44	2.99	6.37	9.31
Irbesartan	0.13	0.15	0.17	0.53	-	-	-	-	1.62	1.07	2.21	2.80
Losartan	0.20	0.35	0.44	0.79	0.10	0.18	0.17	0.25	-	-	-	-
Olmesartan	0.20	0.38	0.80	0.81	0.13	0.15	0.32	0.32	1.25	0.59	0.33	0.43
Telmisartan	0.40	0.41	0.40	0.81	0.27	0.28	0.31	0.78	2.60	1.64	2.73	4.03
Valsartan	0.40	0.43	0.37	0.44	0.16	0.20	0.16	0.27	0.63	0.28	0.74	0.78
Non-index-defining ARB	1.30	1.68	2.14	3.34	0.92	1.09	1.29	2.95	10.45	6.38	12.26	17.05
ACEi	1.00	1.11	1.08	1.34	0.67	0.65	0.58	0.65	1.15	0.83	0.68	0.70
CCB	12.83	15.25	16.04	20.00	8.48	10.04	9.98	10.51	5.68	6.08	5.09	3.89
ACEi or CCB*	13.49	15.92	16.66	20.77	8.82	10.36	10.31	10.86	6.37	6.58	5.51	4.31

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Index ARB											
	Candesartan				Irbesartan				Losartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020												
Candesartan	-	-	-	-	3.95	1.81	0.67	1.55	3.42	0.47	0.21	0.15
Irbesartan	4.69	1.17	0.35	0.36	-	-	-	-	1.83	0.18	0.06	0.11
Losartan	1.68	0.87	0.33	0.22	0.51	0.36	0.19	0.41	-	-	-	-
Olmesartan	1.36	1.47	0.71	0.45	0.40	0.60	0.37	0.36	0.19	0.11	0.06	0.04
Telmisartan	2.97	2.68	0.92	0.59	1.38	1.57	0.66	0.94	0.77	0.34	0.14	0.12
Valsartan	0.90	0.42	0.36	0.46	0.31	0.21	0.19	0.34	0.30	0.06	0.06	0.07
Non-index-defining ARB	11.41	6.52	2.67	2.08	6.44	4.50	2.09	3.56	6.30	1.16	0.53	0.48
ACEi	3.76	1.39	0.91	1.05	1.30	0.62	0.45	0.44	0.63	0.21	0.18	0.20
CCB	26.74	20.57	15.15	15.48	14.22	11.63	8.86	8.33	4.31	4.37	3.39	3.29
ACEi or CCB*	29.11	21.38	15.68	16.07	15.00	11.97	9.08	8.54	4.70	4.48	3.50	3.40

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi or CCB in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter

²A dash represents an invalid value, such as a switching analysis with itself or for a year-quarter extending past the study period.

*ACEi or CCB: only ACEi or only CCB

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2014												
Candesartan	0.43	0.23	0.19	0.22	0.22	0.16	0.18	0.14	0.20	0.17	0.14	0.18
Irbesartan	0.14	0.17	0.18	0.16	0.14	0.17	0.13	0.17	0.22	0.11	0.06	0.09
Losartan	0.16	0.17	0.15	0.14	0.18	0.07	0.10	0.11	0.11	0.10	0.09	0.07
Olmesartan	-	-	-	-	0.29	0.44	0.30	0.38	0.27	0.42	0.29	0.28
Telmisartan	0.22	0.37	0.24	0.23	-	-	-	-	0.27	0.22	0.21	0.26
Valsartan	0.22	0.22	0.23	0.15	0.23	0.26	0.19	0.15	-	-	-	-
Non-index-defining ARB	1.17	1.15	0.99	0.89	1.05	1.10	0.88	0.93	1.07	1.01	0.78	0.88
ACEi	2.94	2.51	2.17	1.78	3.43	2.58	1.83	1.69	3.30	2.44	1.87	1.74
CCB	28.86	19.41	13.47	12.43	34.08	24.21	16.75	14.20	47.59	33.12	22.60	19.15
ACEi or CCB*	30.67	21.05	14.77	13.39	36.32	25.93	17.88	15.25	49.57	34.53	23.77	20.21
2015												
Candesartan	0.17	0.21	0.18	0.18	0.13	0.13	0.15	0.13	0.12	0.15	0.09	0.11
Irbesartan	0.12	0.10	0.09	0.09	0.07	0.12	0.11	0.05	0.07	0.05	0.08	0.09
Losartan	0.09	0.11	0.11	0.06	0.07	0.11	0.05	0.08	0.06	0.06	0.04	0.04
Olmesartan	-	-	-	-	0.27	0.32	0.26	0.30	0.32	0.31	0.30	0.22
Telmisartan	0.23	0.26	0.21	0.23	-	-	-	-	0.20	0.17	0.17	0.17
Valsartan	0.16	0.21	0.15	0.15	0.19	0.14	0.13	0.18	-	-	-	-
Non-index-defining ARB	0.76	0.85	0.71	0.70	0.73	0.80	0.69	0.75	0.77	0.73	0.67	0.62
ACEi	1.39	1.57	1.32	1.28	1.29	1.32	1.15	1.18	1.50	1.50	1.18	1.18
CCB	10.72	10.90	9.22	9.29	11.81	12.72	10.66	10.37	15.92	17.12	14.14	13.49
ACEi or CCB*	11.56	11.79	9.96	10.03	12.52	13.60	11.37	11.08	16.77	18.04	14.86	14.12
2016												
Candesartan	0.19	0.20	0.17	0.19	0.11	0.16	0.17	0.12	0.06	0.16	0.11	0.09
Irbesartan	0.11	0.11	0.10	0.07	0.10	0.13	0.09	0.10	0.05	0.06	0.05	0.05
Losartan	0.07	0.07	0.07	0.07	0.07	0.07	0.10	0.07	0.05	0.05	0.03	0.04
Olmesartan	-	-	-	-	0.25	0.28	0.27	0.24	0.31	0.27	0.17	0.18
Telmisartan	0.19	0.23	0.22	0.27	-	-	-	-	0.18	0.18	0.19	0.20
Valsartan	0.15	0.18	0.12	0.15	0.15	0.15	0.15	0.13	-	-	-	-
Non-index-defining ARB	0.69	0.78	0.68	0.74	0.67	0.78	0.77	0.67	0.65	0.70	0.55	0.54
ACEi	1.23	1.25	1.05	0.97	1.11	1.14	0.98	0.89	1.07	1.20	0.84	0.93
CCB	8.56	9.26	8.07	8.04	9.33	10.12	8.73	9.04	12.03	13.62	11.18	11.20
ACEi or CCB*	9.32	9.96	8.68	8.60	9.97	10.85	9.32	9.58	12.59	14.28	11.65	11.73

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2017												
Candesartan	0.18	0.21	0.24	0.18	0.12	0.12	0.14	0.12	0.10	0.10	0.08	0.11
Irbesartan	0.09	0.08	0.06	0.10	0.09	0.08	0.08	0.07	0.04	0.06	0.05	0.05
Losartan	0.07	0.07	0.06	0.06	0.04	0.05	0.05	0.06	0.04	0.06	0.05	0.04
Olmesartan	-	-	-	-	0.19	0.19	0.15	0.16	0.13	0.16	0.14	0.17
Telmisartan	0.24	0.25	0.22	0.28	-	-	-	-	0.20	0.17	0.19	0.17
Valsartan	0.14	0.14	0.15	0.15	0.11	0.19	0.21	0.17	-	-	-	-
Non-index-defining ARB	0.71	0.76	0.72	0.76	0.54	0.62	0.62	0.58	0.50	0.54	0.50	0.52
ACEi	0.96	1.06	0.79	0.82	0.84	0.94	0.77	0.84	0.81	0.90	1.00	1.04
CCB	7.66	8.03	6.88	7.08	7.84	9.03	7.93	8.12	10.49	12.19	10.54	10.59
ACEi or CCB*	8.16	8.60	7.28	7.55	8.35	9.55	8.41	8.67	10.91	12.71	11.16	11.23
2018												
Candesartan	0.17	0.17	0.29	0.30	0.12	0.16	0.40	0.63	0.10	0.14	41.61	1.73
Irbesartan	0.07	0.09	0.11	0.12	0.06	0.10	0.19	0.28	0.06	0.06	15.64	0.61
Losartan	0.05	0.06	0.09	0.07	0.06	0.06	0.15	0.27	0.05	0.09	9.18	0.39
Olmesartan	-	-	-	-	0.16	0.16	0.21	0.38	0.10	0.16	9.49	0.55
Telmisartan	0.30	0.27	0.36	0.37	-	-	-	-	0.20	0.23	27.85	1.18
Valsartan	0.14	0.15	0.18	0.16	0.14	0.18	0.36	0.43	-	-	-	-
Non-index-defining ARB	0.73	0.73	0.99	1.02	0.53	0.64	1.26	1.95	0.50	0.67	101.17	4.24
ACEi	0.83	0.85	0.65	0.63	0.79	0.80	0.89	0.88	0.98	1.05	3.50	0.53
CCB	7.15	7.58	8.02	7.55	8.11	9.89	11.57	10.43	10.19	11.22	6.15	4.21
ACEi or CCB*	7.61	8.03	8.35	7.89	8.52	10.31	12.11	10.96	10.82	11.88	8.52	4.52
2019												
Candesartan	0.31	5.40	8.13	9.43	0.84	0.39	0.54	5.06	0.51	0.40	0.32	0.62
Irbesartan	0.11	2.06	3.05	2.24	0.38	0.14	0.16	1.33	0.18	0.16	0.10	0.25
Losartan	0.07	0.76	0.63	0.28	0.17	0.25	0.22	0.50	0.09	0.07	0.07	0.12
Olmesartan	-	-	-	-	0.40	0.36	0.69	0.71	0.19	0.12	0.14	0.13
Telmisartan	0.34	4.74	7.23	4.18	-	-	-	-	0.38	0.32	0.24	0.30
Valsartan	0.14	0.81	1.05	0.62	0.34	0.26	0.26	0.45	-	-	-	-
Non-index-defining ARB	0.96	13.62	19.77	16.35	2.11	1.38	1.83	7.96	1.32	1.04	0.84	1.38
ACEi	0.69	1.39	0.93	0.73	0.97	1.00	0.88	1.22	0.42	0.48	0.49	0.47
CCB	7.06	6.82	5.01	4.93	9.51	12.16	13.58	12.97	3.97	4.55	4.22	4.46
ACEi or CCB*	7.44	7.59	5.55	5.33	10.09	12.75	14.08	13.73	4.27	4.89	4.58	4.79

Table 3b. Proportion of Switching for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Episodes by Year and Quarter^{1,2} (Switching per 1,000 ARB Episodes)

ARB Switch	Olmesartan				Telmisartan				Valsartan			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
2020												
Candesartan	9.75	1.44	0.21	0.18	22.21	1.03	0.47	0.35	2.64	0.72	0.18	0.14
Irbesartan	3.33	0.32	0.06	0.07	10.76	0.48	0.17	0.23	1.21	0.28	0.06	0.08
Losartan	0.49	0.08	0.02	0.02	1.99	0.23	0.14	0.08	0.35	0.12	0.05	0.03
Olmesartan	-	-	-	-	1.13	0.39	0.27	0.22	0.16	0.15	0.06	0.05
Telmisartan	1.70	0.51	0.13	0.13	-	-	-	-	0.47	0.40	0.10	0.08
Valsartan	0.43	0.08	0.04	0.04	1.02	0.16	0.17	0.17	-	-	-	-
Non-index-defining ARB	15.04	2.36	0.47	0.43	36.24	2.22	1.20	1.03	4.67	1.61	0.46	0.38
ACEi	1.17	0.25	0.20	0.18	3.88	0.70	0.54	0.61	0.77	0.39	0.34	0.36
CCB	3.60	3.80	3.08	2.91	9.78	10.54	8.29	9.94	4.23	3.82	3.52	3.56
ACEi or CCB*	4.31	3.93	3.18	3.01	12.20	10.95	8.58	10.31	4.72	4.07	3.78	3.80

¹We estimated proportion of switching per 1,000 ARB episodes as the number of ARB episodes that resulted in the switch from the index ARB to another ARB, ACEi or CCB in a given year and quarter divided by the total number of all ARB index episodes during the same year and quarter

²A dash represents an invalid value, such as a switching analysis with itself or for a year-quarter extending past the study period.

*ACEi or CCB: only ACEi or only CCB

**Table 4a. Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches)**

Index ARB	2014				2015				2016			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Candesartan	177.54	187.18	189.24	199.42	190.43	198.22	185.35	196.46	187.70	189.92	195.66	199.61
Irbesartan	157.84	153.72	150.60	139.43	153.43	140.96	144.60	143.83	147.53	137.69	135.13	125.33
Losartan	112.05	108.83	114.54	115.92	115.92	112.04	121.93	113.88	107.81	115.93	118.35	112.67
Olmesartan	208.75	211.36	208.21	201.85	209.95	211.80	206.49	205.08	207.26	204.70	201.35	208.47
Telmisartan	173.45	178.90	169.05	182.39	165.65	166.52	170.81	175.89	177.54	178.71	182.17	179.07
Valsartan	170.38	160.01	168.36	160.99	164.63	170.46	170.81	164.85	172.17	173.04	167.34	174.85

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi, or CCB divided by the total number of switches for all index ARBs.

**Table 4a. Proportion of Total Switches for Incident Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switching per 1,000 ARB Switches)**

Index ARB	2017				2018				2019				2020			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Candesartan	193.28	202.63	193.44	206.68	207.30	198.59	86.83	249.90	229.30	217.33	188.05	214.87	228.00	403.61	392.18	371.99
Irbesartan	140.65	136.39	133.97	135.02	131.78	116.51	47.63	132.88	114.14	105.54	87.29	98.86	99.62	182.14	170.37	167.02
Losartan	112.41	108.41	109.32	109.30	107.19	116.84	41.30	121.61	254.67	144.86	190.28	191.04	57.38	63.38	76.44	71.99
Olmesartan	198.24	195.48	181.39	171.29	167.18	169.33	52.16	154.91	135.12	311.38	316.50	234.88	156.69	96.33	66.44	61.10
Telmisartan	181.15	171.64	179.36	179.95	184.95	207.61	70.89	229.44	199.71	162.81	164.04	207.73	395.33	173.12	208.73	245.14
Valsartan	174.27	185.45	202.52	197.77	201.59	191.11	701.19	111.27	67.06	58.08	53.85	52.62	62.99	81.42	85.84	82.77

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi, or CCB divided by the total number of switches for all index ARBs.

**Table 4b. Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switches per 1,000 ARB Switches)**

Index ARB	2014				2015				2016			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Candesartan	188.72	185.32	192.41	195.98	189.40	189.31	184.07	192.43	192.98	183.55	189.74	192.62
Irbesartan	203.82	201.22	192.76	188.05	188.23	187.29	188.74	179.00	177.09	182.40	175.17	172.93
Losartan	127.12	125.71	132.28	124.46	130.01	127.92	129.19	125.28	124.74	128.35	129.15	121.91
Olmesartan	128.25	128.63	130.81	138.16	141.20	139.00	141.12	146.04	149.87	146.92	150.91	151.40
Telmisartan	150.02	155.33	153.17	154.11	151.78	154.79	156.54	159.20	158.81	156.69	161.42	164.45
Valsartan	202.06	203.77	198.56	199.23	199.37	201.69	200.34	198.03	196.51	202.09	193.61	196.70

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi, or CCB divided by the total number of switches for all index ARBs.

**Table 4b. Proportion of Total Switches for Prevalent Angiotensin Receptor Blockers (ARB) Treatment Episodes over all ARB Switches Reported by Year and Quarter¹
(Switches per 1,000 ARB Switches)**

Index ARB	2017				2018				2019				2020			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Candesartan	192.38	192.37	195.51	192.76	196.25	191.18	105.40	237.11	217.46	210.31	198.48	221.10	268.70	370.89	357.81	342.31
Irbesartan	177.54	173.44	170.71	171.23	166.25	161.54	67.68	163.47	144.69	137.23	122.09	126.49	140.86	218.15	217.79	227.13
Losartan	123.69	122.88	122.26	120.23	118.25	122.76	48.94	117.31	249.28	156.72	186.57	196.23	73.12	74.70	78.29	73.12
Olmesartan	155.59	147.66	144.23	147.27	151.74	143.64	55.14	139.95	125.22	255.51	267.61	200.43	130.60	84.28	71.44	65.00
Telmisartan	153.86	158.97	160.24	161.98	164.28	177.80	78.25	202.27	181.00	169.33	167.88	198.91	324.06	175.64	191.95	213.36
Valsartan	196.94	204.68	207.05	206.53	203.22	203.09	644.60	139.89	82.36	70.91	57.38	56.84	62.67	76.35	82.72	79.07

¹We estimated the proportion of total switches per 1,000 ARB switches as total switches for each index ARB to another ARB, ACEi, or CCB divided by the total number of switches for all index ARBs.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (January 28, 2022)

DP ID	Start Date¹	End Date¹
DP01	01/01/1996	12/31/2020
DP02	01/01/2000	12/31/2020
DP03	04/01/1996	12/31/2020
DP04	04/01/1995	12/31/2020

¹The start date is based on the minimum date within each DP. Data included in this report are those received and processed by January 28, 2022.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Azilsartan	
azilsartan	EDARBI
azilsartan	EDARBYCLOR
Candesartan	
candesartan	AG-CANDESARTAN
candesartan	APO-CANDESARTAN
candesartan	ATACAND
candesartan	AURO-CANDESARTAN
candesartan	BIO-CANDESARTAN
candesartan	CANDESARTAN
candesartan	CANDESARTAN CILEXETIL
candesartan	DOM-CANDESARTAN
candesartan	IPG-CANDESARTAN
candesartan	JAMP-CANDESARTAN
candesartan	MINT-CANDESARTAN
candesartan	MYLAN-CANDESARTAN
candesartan	NTP-CANDESARTAN
candesartan	PMS-CANDESARTAN
candesartan	PRIVA-CANDESARTAN
candesartan	Q-CANDESARTAN
candesartan	RIVA-CANDESARTAN
candesartan	SANDOZ CANDESARTAN
candesartan	SEPTA-CANDESARTAN
candesartan	TARO-CANDESARTAN
candesartan	TEVA-CANDESARTAN
candesartan	ZINDA-CANDESARTAN
candesartan/hydrochlorothiazide	ACCEL-CANDESARTAN/HCTZ
candesartan/hydrochlorothiazide	ACT CANDESARTAN/HCT
candesartan/hydrochlorothiazide	AG-CANDESARTAN HCT
candesartan/hydrochlorothiazide	APO-CANDESARTAN/HCTZ
candesartan/hydrochlorothiazide	ATACAND PLUS
candesartan/hydrochlorothiazide	AURO-CANDESARTAN HCT
candesartan/hydrochlorothiazide	CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE
candesartan/hydrochlorothiazide	CANDESARTAN HCT
candesartan/hydrochlorothiazide	CANDESARTAN/HCTZ
candesartan/hydrochlorothiazide	JAMP CANDESARTAN-HCT
candesartan/hydrochlorothiazide	MAR-CANDESARTAN / HCTZ
candesartan/hydrochlorothiazide	MYLAN-CANDESARTAN HCTZ
candesartan/hydrochlorothiazide	PMS-CANDESARTAN HCTZ
candesartan/hydrochlorothiazide	SANDOZ CANDESARTAN PLUS
candesartan/hydrochlorothiazide	SEPTA-CANDESARTAN HCTZ
candesartan/hydrochlorothiazide	TEVA-CANDESARTAN/HCTZ
candesartan/hydrochlorothiazide	ZINDA-CANDESARTAN/HYDROCHLOROTHIAZIDE

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Eprosartan	
eprosartan	TEVETEN
eprosartan/hydrochlorothiazide	TEVETEN PLUS
Irbesartan	
irbesartan	ACT IRBESARTAN
irbesartan	AG-IRBESARTAN
irbesartan	APO-IRBESARTAN
irbesartan	AURO-IRBESARTAN
irbesartan	AVA-IRBESARTAN
irbesartan	AVAPRO
irbesartan	BIO-IRBESARTAN
irbesartan	DOM-IRBESARTAN
irbesartan	IPG-IRBESARTAN
irbesartan	IRBESARTAN
irbesartan	JAMP-IRBESARTAN
irbesartan	MAR-IRBESARTAN
irbesartan	MINT-IRBESARTAN
irbesartan	MYLAN-IRBESARTAN
irbesartan	NTP-IRBESARTAN
irbesartan	PENDO-IRBESARTAN
irbesartan	PMS-IRBESARTAN
irbesartan	PRIVA-IRBESARTAN
irbesartan	Q-IRBESARTAN
irbesartan	RIVA-IRBESARTAN
irbesartan	SANDOZ IRBESARTAN
irbesartan	TARO-IRBESARTAN
irbesartan	TEVA-IRBESARTAN
irbesartan	VAN-IRBESARTAN
irbesartan/hydrochlorothiazide	ACT IRBESARTAN/HCT
irbesartan/hydrochlorothiazide	AG-IRBESARTAN HCTZ
irbesartan/hydrochlorothiazide	APO-IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	AURO-IRBESARTAN HCT
irbesartan/hydrochlorothiazide	AVA-IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	AVALIDE
irbesartan/hydrochlorothiazide	DOM-IRBESARTAN-HCTZ
irbesartan/hydrochlorothiazide	IRBESARTAN AND HYDROCHLOROTHIAZIDE
irbesartan/hydrochlorothiazide	IRBESARTAN/HCT
irbesartan/hydrochlorothiazide	IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	JAMP-IRBESARTAN AND HYDROCHLOROTHIAZIDE
irbesartan/hydrochlorothiazide	MINT-IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	MYLAN-IRBESARTAN HCTZ
irbesartan/hydrochlorothiazide	NTP-IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	PENDO-IRBESARTAN-HCTZ
irbesartan/hydrochlorothiazide	PMS-IRBESARTAN-HCTZ

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Irbesartan	
irbesartan/hydrochlorothiazide	RAN-IRBESARTAN HCTZ
irbesartan/hydrochlorothiazide	SANDOZ IRBESARTAN HCT
irbesartan/hydrochlorothiazide	TEVA-IRBESARTAN/HCTZ
irbesartan/hydrochlorothiazide	VAN-IRBESARTAN-HCTZ
Losartan	
losartan	ACT LOSARTAN
losartan	AG-LOSARTAN
losartan	APO-LOSARTAN
losartan	AURO-LOSARTAN
losartan	BIO-LOSARTAN
losartan	COZAAR
losartan	DOM-LOSARTAN
losartan	IPG-LOSARTAN
losartan	JAMP-LOSARTAN
losartan	LOSARTAN
losartan	LOSARTAN POTASSIUM
losartan	MAR-LOSARTAN
losartan	MINT-LOSARTAN
losartan	MYLAN-LOSARTAN
losartan	PHL-LOSARTAN
losartan	PMS-LOSARTAN
losartan	PRIVA-LOSARTAN
losartan	RAN-LOSARTAN
losartan	SANDOZ LOSARTAN
losartan	SEPTA-LOSARTAN
losartan	TEVA-LOSARTAN
losartan	VAN-LOSARTAN
losartan/hydrochlorothiazide	ACT LOSARTAN/HCT
losartan/hydrochlorothiazide	AG-LOSARTAN HCTZ
losartan/hydrochlorothiazide	APO-LOSARTAN/HCTZ
losartan/hydrochlorothiazide	AURO-LOSARTAN HCT
losartan/hydrochlorothiazide	HYZAAR
losartan/hydrochlorothiazide	HYZAAR DS
losartan/hydrochlorothiazide	JAMP-LOSARTAN HCTZ
losartan/hydrochlorothiazide	LOSARTAN HCT
losartan/hydrochlorothiazide	LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
losartan/hydrochlorothiazide	LOSARTAN/HCT
losartan/hydrochlorothiazide	LOSARTAN/HCTZ
losartan/hydrochlorothiazide	MINT-LOSARTAN/HCTZ
losartan/hydrochlorothiazide	MINT-LOSARTAN/HCTZ DS
losartan/hydrochlorothiazide	MYLAN-LOSARTAN HCTZ
losartan/hydrochlorothiazide	PMS-LOSARTAN-HCTZ
losartan/hydrochlorothiazide	RATIO-LOSARTAN HCTZ

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Losartan	
losartan/hydrochlorothiazide	SANDOZ LOSARTAN HCT
losartan/hydrochlorothiazide	SANDOZ LOSARTAN HCT DS
losartan/hydrochlorothiazide	SEPTA-LOSARTAN HCTZ
losartan/hydrochlorothiazide	TEVA-LOSARTAN/HCTZ
losartan/hydrochlorothiazide	VAN-LOSARTAN-HCTZ
Olmesartan	
olmesartan	ACH-OLMESARTAN
olmesartan	ACT OLMESARTAN
olmesartan	AG-OLMESARTAN
olmesartan	APO-OLMESARTAN
olmesartan	AURO-OLMESARTAN
olmesartan	GLN-OLMESARTAN
olmesartan	JAMP-OLMESARTAN
olmesartan	MED-OLMESARTAN
olmesartan	M-OLMESARTAN
olmesartan	NRA-OLMESARTAN
olmesartan	OLMESARTAN
olmesartan	OLMETEC
olmesartan	PMS-OLMESARTAN
olmesartan	RIVA-OLMESARTAN
olmesartan	SANDOZ OLMESARTAN
olmesartan/hydrochlorothiazide	ACH-OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	ACT OLMESARTAN HCT
olmesartan/hydrochlorothiazide	AG-OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	APO-OLMESARTAN/HCTZ
olmesartan/hydrochlorothiazide	AURO-OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	GLN-OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	JAMP-OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	OLMESARTAN MEDOXOMIL / HYDROCHLOROTHIAZIDE
olmesartan/hydrochlorothiazide	OLMETEC PLUS
olmesartan/hydrochlorothiazide	PMS-OLMESARTAN-HCTZ
olmesartan/hydrochlorothiazide	SANDOZ OLMESARTAN HCTZ
olmesartan/hydrochlorothiazide	TEVA-OLMESARTAN/HCTZ
amlodipine besylate/telmisartan]	APO-TELMISARTAN-AMLODIPINE
amlodipine besylate/telmisartan]	TWYNSTA
Telmisartan	
telmisartan	ACT TELMISARTAN
telmisartan	AG-TELMISARTAN
telmisartan	ALEMBIC-TELMISARTAN
telmisartan	APO-TELMISARTAN
telmisartan	AURO-TELMISARTAN
telmisartan	JAMP TELMISARTAN

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Telmisartan	
telmisartan	MAR-TELMISARTAN
telmisartan	MICARDIS 40MG TAB
telmisartan	MICARDIS 80MG TAB
telmisartan	MINT-TELMISARTAN
telmisartan	MYLAN-TELMISARTAN
telmisartan	NRA-TELMISARTAN
telmisartan	NTP-TELMISARTAN
telmisartan	PENDO-TELMISARTAN
telmisartan	PHARMA-TELMISARTAN
telmisartan	PMS-TELMISARTAN
telmisartan	RAN-TELMISARTAN
telmisartan	SANDOZ TELMISARTAN
telmisartan	SEPTA-TELMISARTAN
telmisartan	TELMISARTAN
telmisartan	TEVA-TELMISARTAN
telmisartan	VAN-TELMISARTAN
telmisartan/hydrochlorothiazide	ACH-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	ACT TELMISARTAN/HCT
telmisartan/hydrochlorothiazide	AG TELMISARTAN-HCT
telmisartan/hydrochlorothiazide	ALEMBIC-TELMISARTAN/HCTZ
telmisartan/hydrochlorothiazide	APO-TELMISARTAN/HCTZ
telmisartan/hydrochlorothiazide	AURO-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	HYDROCHLOROTHIAZIDE/TELMISARTAN
telmisartan/hydrochlorothiazide	JAMP TELMISARTAN-HCT
telmisartan/hydrochlorothiazide	MICARDIS PLUS
telmisartan/hydrochlorothiazide	MYLAN-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	NRA-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	NTP-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	PENDO-TELMISARTAN-HCTZ
telmisartan/hydrochlorothiazide	PMS-TELMISARTAN-HCTZ
telmisartan/hydrochlorothiazide	RAN-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	SANDOZ TELMISARTAN HCT
telmisartan/hydrochlorothiazide	TELMISARTAN/HCTZ
telmisartan/hydrochlorothiazide	TEVA-TELMISARTAN HCTZ
telmisartan/hydrochlorothiazide	VAN-TELMISARTAN-HCTZ
Valsartan	
sacubitril/valsartan	ENTRESTO
valsartan	ACT VALSARTAN
valsartan	APO-VALSARTAN
valsartan	AURO-VALSARTAN
valsartan	AVA-VALSARTAN
valsartan	DIOVAN
valsartan	DOM-VALSARTAN

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Brand Name
Valsartan	
valsartan	M-VALSARTAN
valsartan	MYLAN-VALSARTAN
valsartan	NOVO-VALSARTAN
valsartan	PMS-VALSARTAN
valsartan	Q-VALSARTAN
valsartan	RIVA-VALSARTAN
valsartan	SANDOZ VALSARTAN
valsartan	TARO-VALSARTAN
valsartan	TEVA-VALSARTAN
valsartan	VALSARTAN
valsartan/hydrochlorothiazide	APO-VALSARTAN/HCTZ
valsartan/hydrochlorothiazide	AURO-VALSARTAN HCT
valsartan/hydrochlorothiazide	AVA-VALSARTAN HCT
valsartan/hydrochlorothiazide	DIOVAN-HCT
valsartan/hydrochlorothiazide	MYLAN-VALSARTAN HCTZ
valsartan/hydrochlorothiazide	NOVO-VALSARTAN/HCTZ
valsartan/hydrochlorothiazide	PMS-VALSARTAN-HCTZ
valsartan/hydrochlorothiazide	Q-VALSARTAN HCTZ
valsartan/hydrochlorothiazide	SANDOZ VALSARTAN HCT
valsartan/hydrochlorothiazide	TEVA-VALSARTAN/HCTZ
valsartan/hydrochlorothiazide	VALSARTAN HCT
valsartan/hydrochlorothiazide	VALSARTAN-HCTZ

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
benazepril	LOTENSIN
benazepril HCl/hydrochlorothiazide	LOTENSIN HCT
benazepril hydrochloride	BENAZEPRIL
benazepril hydrochloride	LOTENSIN
benazepril hydrochloride	PMS-BENAZEPRIL
captopril	APO-CAPTO TAB
captopril	BCI CAPTOPRIL TABLETS
captopril	CAPOTEN
captopril	CAPTOPRIL
captopril	CAPTRIL
captopril	DOM-CAPTOPRIL
captopril	FTP-CAPTOPRIL
captopril	MED CAPTOPRIL
captopril	MYLAN-CAPTOPRIL
captopril	NOVO-CAPTORIL
captopril	NU-CAPTO
captopril	ORB-CAPTOPRIL
captopril	PENTA-CAPTOPRIL TABLETS
captopril	PMS-CAPTOPRIL
captopril	RATIO-CAPTOPRIL
captopril	SYN-CAPTOPRIL
captopril	TEVA-CAPTOPRIL
captopril	TRIA-CAPTOPRIL
cilazapril	APO-CILAZAPRIL
cilazapril	CILAZAPRIL
cilazapril	CO CILAZAPRIL
cilazapril	DOM-CILAZAPRIL
cilazapril	INHIBACE
cilazapril	INHIBACE TAB 1MG
cilazapril	MYLAN-CILAZAPRIL
cilazapril	NTP-CILAZAPRIL
cilazapril	PHL-CILAZAPRIL
cilazapril	PMS-CILAZAPRIL
cilazapril	TEVA-CILAZAPRIL
cilazapril/hydrochlorothiazide	APO-CILAZAPRIL/HCTZ
cilazapril/hydrochlorothiazide	INHIBACE PLUS
cilazapril/hydrochlorothiazide	TEVA-CILAZAPRIL/HCTZ
enalapril maleate	ACT ENALAPRIL
enalapril maleate	APO-ENALAPRIL
enalapril maleate	AVA-ENALAPRIL
enalapril maleate	DOM-ENALAPRIL
enalapril maleate	ENALAPRIL
enalapril maleate	JAMP ENALAPRIL
enalapril maleate	MAR-ENALAPRIL

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
enalapril maleate	MYLAN-ENALAPRIL
enalapril maleate	NTP-ENALAPRIL
enalapril maleate	NU-ENALAPRIL
enalapril maleate	NU-ENALAPRIL TABLETS
enalapril maleate	PMS-ENALAPRIL
enalapril maleate	PRO-ENALAPRIL
enalapril maleate	RAN-ENALAPRIL
enalapril maleate	RATIO-ENALAPRIL
enalapril maleate	RIVA-ENALAPRIL
enalapril maleate	SANDOZ ENALAPRIL
enalapril maleate	SIG-ENALAPRIL
enalapril maleate	TARO-ENALAPRIL
enalapril maleate	TEVA-ENALAPRIL
enalapril maleate	VASOTEC
enalapril maleate/hydrochlorothiazide	ENALAPRIL MALEATE/HCTZ
enalapril maleate/hydrochlorothiazide	ENALAPRIL/HCTZ
enalapril maleate/hydrochlorothiazide	TEVA-ENALAPRIL/HCTZ
enalapril maleate/hydrochlorothiazide	VASERETIC
enalaprilat	ENALAPRILAT INJECTION USP
enalaprilat	VASOTEC IV
fosinopril	APO-FOSINOPRIL
fosinopril	AVA-FOSINOPRIL
fosinopril	DOM-FOSINOPRIL
fosinopril	FOSINOPRIL
fosinopril	JAMP-FOSINOPRIL
fosinopril	LIN-FOSINOPRIL
fosinopril	MONOPRIL
fosinopril	MYLAN-FOSINOPRIL
fosinopril	NU-FOSINOPRIL
fosinopril	PHL-FOSINOPRIL
fosinopril	PMS-FOSINOPRIL
fosinopril	RAN-FOSINOPRIL
fosinopril	RATIO FOSINOPRIL
fosinopril	RIVA-FOSINOPRIL
fosinopril	TEVA-FOSINOPRIL
indapamide/perindopril arginine	ARCOSYL PLUS
indapamide/perindopril erbumine	APO-PERINDOPRIL-INDAPAMIDE
indapamide/perindopril erbumine	ARCOSYL PLUS LD
indapamide/perindopril erbumine	COVERSYL PLUS
indapamide/perindopril erbumine	COVERSYL PLUS HD
indapamide/perindopril erbumine	COVERSYL PLUS LD
indapamide/perindopril erbumine	MYLAN-PERINDOPRIL/INDAPAMIDE
indapamide/perindopril erbumine	PERINDOPRIL ERBUMINE/ INDAPAMIDE
indapamide/perindopril erbumine	PERINDOPRIL ERBUMINE/ INDAPAMIDE HD

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
indapamide/perindopril erbumine	SANDOZ PERINDOPRIL ERBUMINE/ INDAPAMIDE
indapamide/perindopril erbumine	SANDOZ PERINDOPRIL ERBUMINE/ INDAPAMIDE HD
indapamide/perindopril erbumine	SANDOZ PERINDOPRIL ERBUMINE/ INDAPAMIDE LD
indapamide/perindopril erbumine	TEVA-PERINDOPRIL/INDAPAMIDE
lisinopril	ACT LISINOPRIL
lisinopril	APO-LISINOPRIL
lisinopril	APO-LISINOPRIL TABLET (TYPE P)
lisinopril	AURO-LISINOPRIL
lisinopril	AVA-LISINOPRIL
lisinopril	DOM-LISINOPRIL
lisinopril	IPG-LISINOPRIL
lisinopril	JAMP-LISINOPRIL
lisinopril	LISINOPRIL
lisinopril	MAR-LISINOPRIL
lisinopril	MINT-LISINOPRIL
lisinopril	MYLAN-LISINOPRIL
lisinopril	NU-LISINOPRIL
lisinopril	PMS-LISINOPRIL
lisinopril	PRINIVIL
lisinopril	PRINIVIL / ZESTRIL
lisinopril	PRO-LISINOPRIL
lisinopril	RAN-LISINOPRIL
lisinopril	RATIO-LISINOPRIL P
lisinopril	RATIO-LISINOPRIL Z
lisinopril	RIVA-LISINOPRIL
lisinopril	SANDOZ-LISINOPRIL
lisinopril	TEVA-LISINOPRIL (TYPE P)
lisinopril	TEVA-LISINOPRIL (TYPE Z)
lisinopril	ZESTRIL
lisinopril/hydrochlorothiazide	APO-LISINOPRIL/HCTZ
lisinopril/hydrochlorothiazide	AVA-LISINOPRIL HCT
lisinopril/hydrochlorothiazide	LISINOPRIL/HCTZ (TYPE Z)
lisinopril/hydrochlorothiazide	LISINOPRIL/HCTZ (TYPE P)
lisinopril/hydrochlorothiazide	MYLAN-LISINOPRIL HCTZ
lisinopril/hydrochlorothiazide	NTP-LISINOPRIL/HCTZ (TYPE P)
lisinopril/hydrochlorothiazide	NTP-LISINOPRIL/HCTZ (TYPE Z)
lisinopril/hydrochlorothiazide	NU-LISINOPRIL/HCTZ
lisinopril/hydrochlorothiazide	PRINZIDE
lisinopril/hydrochlorothiazide	SANDOZ LISINOPRIL HCT
lisinopril/hydrochlorothiazide	TEVA-LISINOPRIL/HCTZ (TYPE P)
lisinopril/hydrochlorothiazide	TEVA-LISINOPRIL/HCTZ (TYPE Z)
lisinopril/hydrochlorothiazide	ZESTORETIC
perindopril arginine	APO-PERINDOPRIL ARGININE
perindopril arginine	ARCOSYL

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
perindopril arginine	MYLAN-PERINDOPRIL ARGININE
perindopril erbumine	AG-PERINDOPRIL
perindopril erbumine	APO-PERINDOPRIL
perindopril erbumine	AURO-PERINDOPRIL
perindopril erbumine	BIO-PERINDOPRIL
perindopril erbumine	COVERSYL
perindopril erbumine	JAMP PERINDOPRIL
perindopril erbumine	MAR-PERINDOPRIL
perindopril erbumine	MINT-PERINDOPRIL
perindopril erbumine	M-PERINDOPRIL ERBUMINE
perindopril erbumine	MYLAN-PERINDOPRIL ERBUMINE
perindopril erbumine	NRA-PERINDOPRIL
perindopril erbumine	PERINDOPRIL
perindopril erbumine	PERINDOPRIL ERBUMINE
perindopril erbumine	PMS-PERINDOPRIL
perindopril erbumine	PRIVA-PERINDOPRIL ERBUMINE
perindopril erbumine	RIVA-PERINDOPRIL
perindopril erbumine	SANDOZ PERINDOPRIL ERBUMINE
perindopril erbumine	TEVA-PERINDOPRIL
quinapril	ACCUPRIL
quinapril	ACCUPRO
quinapril	APO-QUINAPRIL
quinapril	GD-QUINAPRIL
quinapril	PMS-QUINAPRIL
quinapril	QUINAPRIL
quinapril	RAN-QUINAPRIL
quinapril/hydrochlorothiazide	ACCURETIC
quinapril/hydrochlorothiazide	APO-QUINAPRIL/HCTZ
quinapril/hydrochlorothiazide	AURO-QUINAPRIL HCTZ
quinapril/hydrochlorothiazide	GD-QUINAPRIL HCTZ
quinapril/hydrochlorothiazide	TEVA-QUINAPRIL/HCTZ
ramipril	ACH-RAMIPRIL
ramipril	ACT RAMIPRIL
ramipril	AG-RAMIPRIL
ramipril	ALTACE
ramipril	APO-RAMIPRIL
ramipril	AURO-RAMIPRIL
ramipril	AVA-RAMIPRIL
ramipril	BIO-RAMIPRIL
ramipril	DOM-RAMIPRIL
ramipril	IPG-RAMIPRIL
ramipril	JAMP-RAMIPRIL
ramipril	MAR-RAMIPRIL
ramipril	MINT-RAMIPRIL

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
ACEi	
ramipril	MYLAN-RAMIPRIL
ramipril	NRA-RAMIPRIL
ramipril	NTP-RAMIPRIL
ramipril	PHARMA-RAMIPRIL
ramipril	PMS-RAMIPRIL
ramipril	PRIVA-RAMIPRIL
ramipril	PRO-RAMIPRIL
ramipril	PRV-RAMIPRIL
ramipril	RAMACE
ramipril	RAMIPRIL
ramipril	RATIO-RAMIPRIL
ramipril	RBX-RAMIPRIL
ramipril	SANDOZ RAMIPRIL
ramipril	TARO-RAMIPRIL
ramipril	TEVA-RAMIPRIL
ramipril	VAN-RAMIPRIL
ramipril/hydrochlorothiazide	ALTACE HCT
ramipril/hydrochlorothiazide	APO-RAMIPRIL/HCTZ
ramipril/hydrochlorothiazide	PMS-RAMIPRIL-HCTZ
ramipril/hydrochlorothiazide	RAMIPRIL-HCTZ
ramipril/hydrochlorothiazide	TARO-RAMIPRIL HCTZ
ramipril/hydrochlorothiazide	TEVA-RAMIPRIL/HCTZ
trandolapril	APO-TRANDOLAPRIL
trandolapril	AURO-TRANDOLAPRIL
trandolapril	MAVIK
trandolapril	MYLAN-TRANDOLAPRIL
trandolapril	ODRIK
trandolapril	PMS-TRANDOLAPRIL
trandolapril	SANDOZ TRANDOLAPRIL
trandolapril	TEVA-TRANDOLAPRIL
trandolapril	TRANDOLAPRIL
CCB	
acetylsalicylic acid/nifedipine	ADALAT XL PLUS
aliskiren fumarate/amlodipine besylate	RASILAMLO
amlodipine	ACCEL-AMLODIPINE
amlodipine	ACT AMLODIPINE
amlodipine	AG-AMLODIPINE
amlodipine	AMLODIPINE
amlodipine	AMLODIPINE BESYLATE
amlodipine	AMLODIPINE-ODAN
amlodipine	APO-AMLODIPINE
amlodipine	AURO-AMLODIPINE
amlodipine	AVA-AMLODIPINE

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
	CCB
amlodipine	BIO-AMLODIPINE
amlodipine	DOM-AMLODIPINE
amlodipine	GD-AMLODIPINE
amlodipine	IPG-AMLODIPINE
amlodipine	JAMP-AMLODIPINE
amlodipine	M-AMLODIPINE
amlodipine	MANDA-AMLODIPINE TABLETS
amlodipine	MAR-AMLODIPINE TABLETS
amlodipine	MINT-AMLODIPINE
amlodipine	MYLAN-AMLODIPINE
amlodipine	NORVASC
amlodipine	NRA-AMLODIPINE
amlodipine	PDP-AMLODIPINE
amlodipine	PHARMA-AMLODIPINE
amlodipine	PHL-AMLODIPINE
amlodipine	PMS-AMLODIPINE
amlodipine	PMS-AMLODIPINE MESYLATE
amlodipine	PRIVA-AMLODIPINE
amlodipine	Q-AMLODIPINE
amlodipine	Q-GEN AMLODIPINE
amlodipine	RAN-AMLODIPINE
amlodipine	RATIO-AMLODIPINE
amlodipine	RIVA-AMLODIPINE
amlodipine	SANDOZ AMLODIPINE
amlodipine	SEPTA-AMLODIPINE
amlodipine	TEVA-AMLODIPINE
amlodipine	VAN-AMLODIPINE
amlodipine	ZYM-AMLODIPINE
amlodipine besylate	NORVASC
amlodipine besylate	RAN-AMLODIPINE
amlodipine besylate	RATIO-AMLODIPINE
amlodipine besylate/atorvastatin	CADUET
amlodipine besylate/atorvastatin ca	CADUET
amlodipine besylate/atorvastatin ca	GD-AMLODIPINE/ATORVASTATIN
amlodipine besylate/atorvastatin ca	MYLAN-AMLODIPINE/ATORVASTATIN
amlodipine besylate/atorvastatin ca	PENDO-AMLODIPINE-ATORVASTATIN
amlodipine besylate/atorvastatin ca	PMS-AMLODIPINE-ATORVASTATIN
amlodipine besylate/atorvastatin ca propylene glycol solvate	APO-AMLODIPINE-ATORVASTATIN
amlodipine mesylate	PMS-AMLODIPINE MESYLATE
clevipidine	CLEVIPREX
diltiazem	AA-DILTIAZ
diltiazem	ACT DILTIAZEM CD
diltiazem	ACT DILTIAZEM T
diltiazem	ALBERT DILTIAZEM CD

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
	CCB
diltiazem	ALTI-DILTIAZEM TAB
diltiazem	APO-DILTIAZ CD
diltiazem	APO-DILTIAZ INJECTABLE
diltiazem	APO-DILTIAZ SR
diltiazem	APO-DILTIAZ TZ
diltiazem	AVA-DILTIAZEM
diltiazem	CARDIZEM
diltiazem	CARDIZEM CD
diltiazem	CARDIZEM LYO-JECT
diltiazem	CARDIZEM SR
diltiazem	DILTIAZEM
diltiazem	DILTIAZEM CD
diltiazem	DILTIAZEM HCL
diltiazem	DILTIAZEM TZ
diltiazem	DILTIAZEM-SR
diltiazem	GEN-DILTIAZEM
diltiazem	GEN-DILTIAZEM SR
diltiazem	JAMP DILTIAZEM T
diltiazem	MAR-DILTIAZEM CD
diltiazem	MAR-DILTIAZEM T
diltiazem	MED DILTIAZEM
diltiazem	MED DILTIAZEM SR
diltiazem	NOVO-DILTIAZEM SR
diltiazem	NU-DILTIAZ
diltiazem	NU-DILTIAZ-CD
diltiazem	NU-DILTIAZ-SR
diltiazem	PENTA-DILTIAZEM
diltiazem	PHARMA-DILTIAZ
diltiazem	PMS-DILTIAZEM CD
diltiazem	RATIO-DILTIAZEM CD
diltiazem	SANDOZ DILTIAZEM CD
diltiazem	SANDOZ DILTIAZEM T
diltiazem	TARO-DILTIAZEM T
diltiazem	TARO-DILTIAZEM
diltiazem	TEVA-DILTIAZEM
diltiazem	TEVA-DILTIAZEM CD
diltiazem	TEVA-DILTIAZEM HCL ER CAPSULES
diltiazem	TEVA-DILTIAZEM XC
diltiazem	TIAZAC
diltiazem	TIAZAC XC
diltiazem	TRIA-DILTIAZEM
felodipine	APO-FELODIPINE
felodipine	PLENDIL
felodipine	RENEDIL

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
CCB	
felodipine	RENEDIL / PLINDIL
felodipine	RENEDIL SRT
felodipine	SANDOZ FELODIPINE
nicardipine	CARDENE
nicardipine	CARDENE (EDS)
nicardipine	CARDENE
nifedipine	ADALAT
nifedipine	ADALAT FT
nifedipine	ADALAT OROS
nifedipine	ADALAT P.A.10
nifedipine	ADALAT P.A.20
nifedipine	ADALAT XL
nifedipine	APO-NIFED PA
nifedipine	DOM-NIFEDIPINE
nifedipine	GEN NIFEDIPINE USP
nifedipine	MED NIFEDIPINE
nifedipine	MYLAN-NIFEDIPINE EXTENDED RELEASE
nifedipine	NIFEDIPINE
nifedipine	NIFEDIPINE ER
nifedipine	NIFEDIPINE PA
nifedipine	NIFEDIPINE PA 10
nifedipine	NIFEDIPINE PA 20
nifedipine	NIFEDIPINE-10
nifedipine	NOVO-NIFEDIN CAP
nifedipine	NOVO-NIFEDIN XL
nifedipine	NU-NIFED
nifedipine	NU-NIFEDIPINE-PA
nifedipine	PMS-NIFEDIPINE
nifedipine	PMS-NIFEDIPINE ER
nifedipine	SCHEINPHARM NIFEDIPINE XL
nifedipine	TARO-NIFEDIPINE
nimodipine	NIMOTOP
verapamil	ALTI-VERAPAMIL
verapamil	APO-VERAP SR
verapamil	APO-VERAP
verapamil	AVA-VERAPAMIL
verapamil	COVERA-HS
verapamil	DOM-VERAPAMIL SR
verapamil	ISOPTIN
verapamil	ISOPTIN SR
verapamil	MED VERAPAMIL
verapamil	MYLAN-VERAPAMIL
verapamil	MYLAN-VERAPAMIL SR
verapamil	NOVO-VERAMIL

Appendix C. List of Generic and Brand Names of Medical Products Used to Define Angiotensin-Converting-Enzyme Inhibitors (ACEi), Calcium Channel Blockers (CCB), and ACEi/CCB Combination Drugs in this Request

Generic Name	Brand Name
CCB	
verapamil	NOVO-VERAMIL SR
verapamil	NU-VERAP SR
verapamil	NU-VERAP
verapamil	PENTA-VERAPAMIL
verapamil	PHL-VERAPAMIL SR
verapamil	PMS-VERAPAMIL SR
verapamil	PRO-VERAPAMIL SR
verapamil	RIVA-VERAPAMIL SR
verapamil	SYN-VERAPAMIL SR
verapamil	TARO-VERAPAMIL TAB
verapamil	VERAPAMIL
verapamil	VERAPAMIL HYDROCHLORIDE USP
verapamil	VERAPAMIL HYDROCHLORIDE
verapamil	VERAPAMIL SR
verapamil	VERELAN
ACEi/CCB Combination Drugs	
amlodipine/perindopril arginine	APO-PERINDOPRIL/AMLODIPINE
amlodipine/perindopril arginine	VIACORAM
felodipine/ramipril	ALTACE PLUS FELODIPINE
trandolapril/verapamil	TARKA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Angina			
I201	Angina pectoris with documented spasm	Diagnosis	ICD-10-CA
I2080	Atypical angina	Diagnosis	ICD-10-CA
I2088	Other forms of angina pectoris	Diagnosis	ICD-10-CA
I209	Angina pectoris, unspecified	Diagnosis	ICD-10-CA
I250	Atherosclerotic cardiovascular disease, so described	Diagnosis	ICD-10-CA
I251	Atherosclerotic heart disease	Diagnosis	ICD-10-CA
I2510	Atherosclerotic heart disease of native coronary artery	Diagnosis	ICD-10-CA
I2511	Atherosclerotic heart disease of autologous vein bypass graft	Diagnosis	ICD-10-CA
I2512	Atherosclerotic heart disease of nonautologous biological bypass graft	Diagnosis	ICD-10-CA
I2513	Atherosclerotic heart disease of artery bypass graft	Diagnosis	ICD-10-CA
I2514	Atherosclerotic heart disease of unspecified type of bypass graft	Diagnosis	ICD-10-CA
I2515	Atherosclerotic heart disease of coronary artery of transplanted heart	Diagnosis	ICD-10-CA
I2519	Atherosclerotic heart disease of unspecified type of vessel, native or graft	Diagnosis	ICD-10-CA
I252	Old myocardial infarction	Diagnosis	ICD-10-CA
I253	Aneurysm of heart	Diagnosis	ICD-10-CA
I254	Coronary artery aneurysm	Diagnosis	ICD-10-CA
I255	Ischaemic cardiomyopathy	Diagnosis	ICD-10-CA
I256	Silent myocardial ischaemia	Diagnosis	ICD-10-CA
I258	Other forms of chronic ischaemic heart disease	Diagnosis	ICD-10-CA
I259	Chronic ischaemic heart disease, unspecified	Diagnosis	ICD-10-CA
Atrial Fibrillation			
I480	Atrial fibrillation	Diagnosis	ICD-10-CA
I4800	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CA
I4801	Persistent atrial fibrillation	Diagnosis	ICD-10-CA
I4802	Chronic atrial fibrillation	Diagnosis	ICD-10-CA
I481	Atrial flutter	Diagnosis	ICD-10-CA
I483	Typical atrial flutter	Diagnosis	ICD-10-CA
I484	Atypical atrial flutter	Diagnosis	ICD-10-CA
I4890	Atrial fibrillation, unspecified	Diagnosis	ICD-10-CA
I4891	Atrial flutter, unspecified	Diagnosis	ICD-10-CA
Diabetes			
E100	Type 1 diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1010	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E10100	Type 1 diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E10101	Type 1 diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1011	Type 1 diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E10110	Type 1 diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E10111	Type 1 diabetes mellitus with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1012	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E10120	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA
E10121	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1020	Type 1 diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA
E10200	Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agent	Diagnosis	ICD-10-CA
E10201	Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10202	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10203	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10204	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10209	Type 1 diabetes mellitus with incipient diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E1021	Type 1 diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E10210	Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agent	Diagnosis	ICD-10-CA
E10211	Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10212	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10213	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10214	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10219	Type 1 diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1022	Type 1 diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E10220	Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10221	Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E10222	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10223	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10224	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10229	Type 1 diabetes mellitus with end stage renal disease [ESRD], level of control unspecified	Diagnosis	ICD-10-CA
E1023	Type 1 diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1028	Type 1 diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA
E10280	Type 1 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10281	Type 1 diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10282	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10283	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10284	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10289	Type 1 diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E10290	Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10291	Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10292	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10293	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10294	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10299	Type 1 diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1030	Type 1 diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E10300	Type 1 diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10301	Type 1 diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10302	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10303	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10304	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10309	Type 1 diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1031	Type 1 diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E10310	Type 1 diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10311	Type 1 diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10312	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10313	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10314	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10319	Type 1 diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1032	Type 1 diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E10320	Type 1 diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10321	Type 1 diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10322	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10323	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10324	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10329	Type 1 diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1033	Type 1 diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E10330	Type 1 diabetes mellitus with other retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10331	Type 1 diabetes mellitus with other retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10332	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10333	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10334	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10339	Type 1 diabetes mellitus with other retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E10340	Type 1 diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10341	Type 1 diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10342	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10343	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10344	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10349	Type 1 diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1035	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E10350	Type 1 diabetes mellitus with cataract, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10351	Type 1 diabetes mellitus with cataract, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10352	Type 1 diabetes mellitus with cataract, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10353	Type 1 diabetes mellitus with cataract, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10354	Type 1 diabetes mellitus with cataract, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10359	Type 1 diabetes mellitus with cataract, level of control unspecified	Diagnosis	ICD-10-CA
E1036	Type 1 diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1038	Type 1 diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E10380	Type 1 diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10381	Type 1 diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10382	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10383	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10384	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10389	Type 1 diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA
E10390	Type 1 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10391	Type 1 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10392	Type 1 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10393	Type 1 diabetes mellitus with ophthalmic complication,unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10394	Type 1 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10399	Type 1 diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1040	Type 1 diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E10400	Type 1 diabetes mellitus with mononeuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10401	Type 1 diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10402	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10403	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10404	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10409	Type 1 diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1041	Type 1 diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA
E10410	Type 1 diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10411	Type 1 diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10412	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10413	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10414	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10419	Type 1 diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1042	Type 1 diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA
E10420	Type 1 diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10421	Type 1 diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10422	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10423	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10424	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10429	Type 1 diabetes mellitus with autonomic neuropathy, level of control unspecified	Diagnosis	ICD-10-CA
E10480	Type 1 diabetes mellitus with other specified neurological complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10481	Type 1 diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10482	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10483	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10484	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10489	Type 1 diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E10490	Type 1 diabetes mellitus with neuropathy unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10491	Type 1 diabetes mellitus with neuropathy unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10492	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10493	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10494	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10499	Type 1 diabetes mellitus with neuropathy unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1050	Type 1 diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA
E10500	Type 1 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10501	Type 1 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10502	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10503	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10504	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10509	Type 1 diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1051	Type 1 diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA
E10510	Type 1 diabetes mellitus with peripheral angiopathy with gangrene adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10511	Type 1 diabetes mellitus with peripheral angiopathy with gangrene adequately controlled with insulin	Diagnosis	ICD-10-CA
E10512	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10513	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10514	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10519	Type 1 diabetes mellitus with peripheral angiopathy with gangrene level of control unspecified	Diagnosis	ICD-10-CA
E1052	Type 1 diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E10580	Type 1 diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10581	Type 1 diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10582	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10583	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10584	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10589	Type 1 diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E10590	Type 1 diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10591	Type 1 diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10592	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10593	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10594	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10599	Type 1 diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1060	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E10600	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10601	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10602	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10603	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10604	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10609	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1061	Type 1 diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E10610	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10611	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10612	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10613	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10614	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10619	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1062	Type 1 diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E10620	Type 1 diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10621	Type 1 diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10622	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10623	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10624	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10629	Type 1 diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1063	Type 1 diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E10630	Type 1 diabetes mellitus with hypoglycemia adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10631	Type 1 diabetes mellitus with hypoglycemia adequately controlled with insulin	Diagnosis	ICD-10-CA
E10632	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10633	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10634	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10639	Type 1 diabetes mellitus with hypoglycemia level of control unspecified	Diagnosis	ICD-10-CA
E1064	Type 1 diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA
E1068	Type 1 diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E10680	Type 1 diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10681	Type 1 diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10682	Type 1 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10683	Type 1 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10684	Type 1 diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10689	Type 1 diabetes mellitus with other specified complication level of control unspecified	Diagnosis	ICD-10-CA
E1070	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic)	Diagnosis	ICD-10-CA
E10700	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10701	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E10702	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10703	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10704	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10709	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1071	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1078	Type 1 diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E10780	Type 1 diabetes mellitus with other specified multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10781	Type 1 diabetes mellitus with other specified multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10782	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10783	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10784	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10789	Type 1 diabetes mellitus with other specified multiple complications, level of control unspecified	Diagnosis	ICD-10-CA
E109	Type 1 diabetes mellitus without (mention of) complication	Diagnosis	ICD-10-CA
E10900	Type 1 diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10901	Type 1 diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10902	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10903	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10904	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10909	Type 1 diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
E110	Type 2 diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1100	Type 2 diabetes mellitus with hyperosmolarity (without coma)	Diagnosis	ICD-10-CA
E1101	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CA
E1110	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E11100	Type 2 diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E11101	Type 2 diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1111	Type 2 diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E11110	Type 2 diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E11111	Type 2 diabetes mellitus with lactic acidosis (alone) with coma	Diagnosis	ICD-10-CA
E1112	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E11120	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11121	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1120	Type 2 diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA
E11200	Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11201	Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11202	Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11203	Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11204	Type 2 diabetes mellitus with incipient diabetics nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11209	Type 2 diabetes mellitus with incipient diabetics nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1121	Type 2 diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E11210	Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11211	Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11212	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11213	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11214	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11219	Type 2 diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1122	Type 2 diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E11220	Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11221	Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E11222	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11223	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11224	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11229	Type 2 diabetes mellitus with end-stage renal disease [ESRD] ,level of control unspecified	Diagnosis	ICD-10-CA
E1123	Type 2 diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1128	Type 2 diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA
E11280	Type 2 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11281	Type 2 diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11282	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11283	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11284	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11289	Type 2 diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E11290	Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11291	Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11292	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11293	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11294	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11299	Type 2 diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1130	Type 2 diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E11300	Type 2 diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11301	Type 2 diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11302	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11303	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11304	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11309	Type 2 diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1131	Type 2 diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E11310	Type 2 diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11311	Type 2 diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11312	Type 2 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11313	Type 2 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11314	Type 2 diabetes mellitus with preproliferative retinopathy inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11319	Type 2 diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1132	Type 2 diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E11320	Type 2 diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11321	Type 2 diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11322	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11323	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11324	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11329	Type 2 diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1133	Type 2 diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E11330	Type 2 diabetes mellitus with other retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11331	Type 2 diabetes mellitus with other retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11332	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11333	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11334	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11339	Type 2 diabetes mellitus with other retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E11340	Type 2 diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11341	Type 2 diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11342	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11343	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11344	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11349	Type 2 diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1135	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E11350	Type 2 diabetes mellitus with cataract, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11351	Type 2 diabetes mellitus with cataract, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11352	Type 2 diabetes mellitus with cataract, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11353	Type 2 diabetes mellitus with cataract, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11354	Type 2 diabetes mellitus with cataract, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11359	Type 2 diabetes mellitus with cataract, level of control unspecified	Diagnosis	ICD-10-CA
E1136	Type 2 diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1138	Type 2 diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E11380	Type 2 diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11381	Type 2 diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11382	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11383	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11384	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11389	Type 2 diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA
E11390	Type 2 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11391	Type 2 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11392	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11393	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11394	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11399	Type 2 diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1140	Type 2 diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E11400	Type 2 diabetes mellitus with mononeuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11401	Type 2 diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11402	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11403	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11404	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11409	Type 2 diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1141	Type 2 diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA
E11410	Type 2 diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11411	Type 2 diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11412	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11413	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11414	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11419	Type 2 diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1142	Type 2 diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA
E11420	Type 2 diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11421	Type 2 diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11422	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11423	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11424	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11429	Type 2 diabetes mellitus with autonomic neuropathy level of control unspecified	Diagnosis	ICD-10-CA
E11480	Type 2 diabetes mellitus with other specified neurological complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11481	Type 2 diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11482	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11483	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11484	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11489	Type 2 diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E11490	Type 2 diabetes mellitus with neurological complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11491	Type 2 diabetes mellitus with neurological complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11492	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11493	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11494	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11499	Type 2 diabetes mellitus with neurological complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1150	Type 2 diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA
E11500	Type 2 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11501	Type 2 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11502	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11503	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11504	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11509	Type 2 diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1151	Type 2 diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA
E11510	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11511	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11512	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11513	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11514	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11519	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, level of control unspecified	Diagnosis	ICD-10-CA
E1152	Type 2 diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E11580	Type 2 diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11581	Type 2 diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11582	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11583	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11584	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11589	Type 2 diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E11590	Type 2 diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11591	Type 2 diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11592	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11593	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11594	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11599	Type 2 diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1160	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E11600	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet and oral agents	Diagnosis	ICD-10-CA
E11601	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11602	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11603	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11604	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11609	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1161	Type 2 diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E11610	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11611	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11612	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11613	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11614	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11619	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1162	Type 2 diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E11620	Type 2 diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11621	Type 2 diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11622	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11623	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11624	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11629	Type 2 diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1163	Type 2 diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E11630	Type 2 diabetes mellitus with hypoglycemia adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11631	Type 2 diabetes mellitus with hypoglycemia adequately controlled with insulin	Diagnosis	ICD-10-CA
E11632	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11633	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11634	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11639	Type 2 diabetes mellitus with hypoglycemia level of control unspecified	Diagnosis	ICD-10-CA
E1164	Type 2 diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA
E1168	Type 2 diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E11680	Type 2 diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11681	Type 2 diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11682	Type 2 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11683	Type 2 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11684	Type 2 diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11689	Type 2 diabetes mellitus with other specified complication level of control unspecified	Diagnosis	ICD-10-CA
E1170	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic)	Diagnosis	ICD-10-CA
E11700	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11701	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E11702	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11703	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11704	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11709	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1171	Type 2 diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1178	Type 2 diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E11780	Type 2 diabetes mellitus with other multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11781	Type 2 diabetes mellitus with other multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11782	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11783	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11784	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11789	Type 2 diabetes mellitus with other multiple complications, level of control unspecified	Diagnosis	ICD-10-CA
E119	Type 2 diabetes mellitus without (mention of) complications	Diagnosis	ICD-10-CA
E11900	Type 2 diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11901	Type 2 diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11902	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11903	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11904	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11909	Type 2 diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
E130	Other specified diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1300	Other specified diabetes mellitus with hyperosmolarity (without coma)	Diagnosis	ICD-10-CA
E1301	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CA
E1310	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E13100	Other specified diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E13101	Other specified diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1311	Other specified diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E13110	Other specified diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E13111	Other specified diabetes mellitus with lactic acidosis (alone) with coma	Diagnosis	ICD-10-CA
E1312	Other specified diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E13120	Other specified diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA
E13121	Other specified diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1320	Other specified diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA
E13200	Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13201	Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13202	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13203	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13204	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13209	Other specified diabetes mellitus with incipient diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1321	Other specified diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E13210	Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13211	Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13212	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13213	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13214	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13219	Other specified diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1322	Other specified diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E13220	Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13221	Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E13222	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13223	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13224	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13229	Other specified diabetes mellitus with end-stage renal disease [ESRD], level of control unspecified	Diagnosis	ICD-10-CA
E1323	Other specified diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1328	Other specified diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13280	Other specified diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13281	Other specified diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13282	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13283	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13284	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13289	Other specified diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E13290	Other specified diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13291	Other specified diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13292	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13293	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13294	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13299	Other specified diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1330	Other specified diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E13300	Other specified diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13301	Other specified diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13302	Other specified diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13303	Other specified diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13304	Other specified diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13309	Other specified diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1331	Other specified diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E13310	Other specified diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13311	Other specified diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13312	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13313	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13314	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13319	Other specified diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1332	Other specified diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E13320	Other specified diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13321	Other specified diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13322	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13323	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13324	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13329	Other specified diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1333	Other specified diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E13330	Other specified diabetes mellitus with other retinopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13331	Other specified diabetes mellitus with other retinopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13332	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13333	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13334	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13339	Other specified diabetes mellitus with other retinopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E13340	Other specified diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13341	Other specified diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13342	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13343	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13344	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13349	Other specified diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1335	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E13350	Other specified diabetes mellitus with cataract adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13351	Other specified diabetes mellitus with cataract adequately controlled with insulin	Diagnosis	ICD-10-CA
E13352	Other specified diabetes mellitus with cataract inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13353	Other specified diabetes mellitus with cataract inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13354	Other specified diabetes mellitus with cataract inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13359	Other specified diabetes mellitus with cataract level of control unspecified	Diagnosis	ICD-10-CA
E1336	Other specified diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1338	Other specified diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E13380	Other specified diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13381	Other specified diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13382	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet and oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13383	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet and oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13384	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13389	Other specified diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA
E13390	Other specified diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13391	Other specified diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13392	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13393	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13394	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13399	Other specified diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1340	Other specified diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E13400	Other specified diabetes mellitus with mononeuropathy NEC, adequately controlled with diet and oral agents	Diagnosis	ICD-10-CA
E13401	Other specified diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13402	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13403	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13404	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13409	Other specified diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1341	Other specified diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA
E13410	Other specified diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13411	Other specified diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13412	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13413	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13414	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13419	Other specified diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1342	Other specified diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA
E13420	Other specified diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13421	Other specified diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13422	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13423	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13424	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13429	Other specified diabetes mellitus with autonomic neuropathy, level of control unspecified	Diagnosis	ICD-10-CA
E13480	Other specified diabetes mellitus with other specified neurological complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13481	Other specified diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13482	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13483	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13484	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13489	Other specified diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E13490	Other specified diabetes mellitus with neurological complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13491	Other specified diabetes mellitus with neurological complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13492	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13493	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13494	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13499	Other specified diabetes mellitus with neurological complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1350	Other specified diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA
E13500	Other specified diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13501	Other specified diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13502	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13503	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13504	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13509	Other specified diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1351	Other specified diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA
E13510	Other specified diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13511	Other specified diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13512	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13513	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13514	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13519	Other specified diabetes mellitus with peripheral angiopathy with gangrene, level of control unspecified	Diagnosis	ICD-10-CA
E1352	Other specified diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E13580	Other specified diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13581	Other specified diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13582	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13583	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13584	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13589	Other specified diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E13590	Other specified diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13591	Other specified diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13592	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13593	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13594	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13599	Other specified diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1360	Other specified diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E13600	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13601	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13602	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13603	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13604	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13609	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1361	Other specified diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E13610	Other specified diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13611	Other specified diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13612	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13613	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13614	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13619	Other specified diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1362	Other specified diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E13620	Other specified diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13621	Other specified diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13622	Other specified diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13623	Other specified diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13624	Other specified diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13629	Other specified diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1363	Other specified diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E13630	Other specified diabetes mellitus with hypoglycemia, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13631	Other specified diabetes mellitus with hypoglycemia, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13632	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13633	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13634	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13639	Other specified diabetes mellitus with hypoglycemia, level of control unspecified	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E1364	Other specified diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA
E1368	Other specified diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E13680	Other specified diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13681	Other specified diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13682	Other specified diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13683	Other specified diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13684	Other specified diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13689	Other specified diabetes mellitus with other specified complication, level of control unspecified	Diagnosis	ICD-10-CA
E1370	Other specified diabetes mellitus with foot ulcer (angiopathic) (neuropathic)	Diagnosis	ICD-10-CA
E13700	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13701	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E13702	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13703	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13704	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13709	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1371	Other specified diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1378	Other specified diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E13780	Other specified diabetes mellitus with other specified multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13781	Other specified diabetes mellitus with other specified multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13782	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13783	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13784	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13789	Other specified diabetes mellitus with other specified multiple complications, level of control unspecified	Diagnosis	ICD-10-CA
E139	Other specified diabetes mellitus without (mention of) complication	Diagnosis	ICD-10-CA
E13900	Other specified diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13901	Other specified diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13902	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13903	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13904	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13909	Other specified diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
Heart Failure			
I09.9	Rheumatic Heart Disease, unspecified (Rheumatic: carditis; Heart Failure)	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I11	Hypertensive heart disease	Diagnosis	ICD-10-CA
I13	Hypertensive heart and renal disease	Diagnosis	ICD-10-CA
I500	Congestive heart failure	Diagnosis	ICD-10-CA
I501	Left ventricular failure	Diagnosis	ICD-10-CA
I509	Heart failure, unspecified	Diagnosis	ICD-10-CA
Hyperlipidemia			
E780	Pure hypercholesterolaemia	Diagnosis	ICD-10-CA
E781	Pure hyperglyceridaemia	Diagnosis	ICD-10-CA
E782	Mixed hyperlipidaemia	Diagnosis	ICD-10-CA
E783	Hyperchylomicronaemia	Diagnosis	ICD-10-CA
E784	Other hyperlipidaemia	Diagnosis	ICD-10-CA
E785	Hyperlipidaemia, unspecified	Diagnosis	ICD-10-CA
E786	Lipoprotein deficiency	Diagnosis	ICD-10-CA
E788	Other disorders of lipoprotein metabolism	Diagnosis	ICD-10-CA
E789	Disorder of lipoprotein metabolism, unspecified	Diagnosis	ICD-10-CA
272	Disorders of lipid metabolism (e.g., hypercholesterolemia, lipoprotein disorders)	Diagnosis	ICD-9-CM
Hypertension			
I100	Benign hypertension	Diagnosis	ICD-10-CA
I101	Malignant hypertension	Diagnosis	ICD-10-CA
I11	Hypertensive heart disease	Diagnosis	ICD-10-CA
I12	Hypertensive renal disease	Diagnosis	ICD-10-CA
I13	Hypertensive heart and renal disease	Diagnosis	ICD-10-CA
I1500	Renovascular hypertension, benign or unspecified	Diagnosis	ICD-10-CA
I1501	Renovascular hypertension, malignant	Diagnosis	ICD-10-CA
I1510	Hypertension secondary to other renal disorders, benign or unspecified	Diagnosis	ICD-10-CA
I1511	Hypertension secondary to other renal disorders, malignant	Diagnosis	ICD-10-CA
I1520	Hypertension secondary to endocrine disorders, benign or unspecified	Diagnosis	ICD-10-CA
I1521	Hypertension secondary to endocrine disorders, malignant	Diagnosis	ICD-10-CA
I1580	Other secondary hypertension, benign or unspecified	Diagnosis	ICD-10-CA
I1581	Other secondary hypertension, malignant	Diagnosis	ICD-10-CA
I1590	Secondary hypertension, benign or unspecified	Diagnosis	ICD-10-CA
I1591	Secondary hypertension, unspecified, malignant	Diagnosis	ICD-10-CA
I674	Hypertensive encephalopathy	Diagnosis	ICD-10-CA
362	Hypertensive retinopathy and other retinal diseases not specifically listed	Diagnosis	ICD-9-CM
Myocardial Infarction			
I210	Acute transmural myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I211	Acute transmural myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I212	Acute transmural myocardial infarction of other sites	Diagnosis	ICD-10-CA
I213	Acute transmural myocardial infarction of unspecified site	Diagnosis	ICD-10-CA
I214	Acute subendocardial myocardial infarction	Diagnosis	ICD-10-CA
I2140	Acute subendocardial myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I2141	Acute subendocardial myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I2142	Acute subendocardial myocardial infarction of other sites	Diagnosis	ICD-10-CA
I2149	Acute subendocardial myocardial infarction, unspecified site	Diagnosis	ICD-10-CA
I219	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CA
I220	Subsequent myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I221	Subsequent myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I228	Subsequent myocardial infarction of other sites	Diagnosis	ICD-10-CA
I229	Subsequent myocardial infarction of unspecified site	Diagnosis	ICD-10-CA
Renal Disorders			
M321	Systemic lupus erythematosus with organ or system involvement	Diagnosis	ICD-10-CA
M350	Sicca syndrome	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N000	Acute nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N001	Acute nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N002	Acute nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N003	Acute nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N004	Acute nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N005	Acute nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N006	Acute nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N007	Acute nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N008	Acute nephritic syndrome, other	Diagnosis	ICD-10-CA
N009	Acute nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N010	Rapidly progressive nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N011	Rapidly progressive nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N012	Rapidly progressive nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N013	Rapidly progressive nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N014	Rapidly progressive nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N015	Rapidly progressive nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N016	Rapidly progressive nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N017	Rapidly progressive nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N018	Rapidly progressive nephritic syndrome, other	Diagnosis	ICD-10-CA
N019	Rapidly progressive nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N020	Recurrent and persistent haematuria, minor glomerular abnormality	Diagnosis	ICD-10-CA
N021	Recurrent and persistent haematuria, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N022	Recurrent and persistent haematuria, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N023	Recurrent and persistent haematuria, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N024	Recurrent and persistent haematuria, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N025	Recurrent and persistent haematuria, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N026	Recurrent and persistent haematuria, dense deposit disease	Diagnosis	ICD-10-CA
N027	Recurrent and persistent haematuria, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N028	Recurrent and persistent haematuria, other	Diagnosis	ICD-10-CA
N029	Recurrent and persistent haematuria, unspecified	Diagnosis	ICD-10-CA
N030	Chronic nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N031	Chronic nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N032	Chronic nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N033	Chronic nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N034	Chronic nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N035	Chronic nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N036	Chronic nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N037	Chronic nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N038	Chronic nephritic syndrome, other	Diagnosis	ICD-10-CA
N039	Chronic nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N040	Nephrotic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N041	Nephrotic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N042	Nephrotic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N043	Nephrotic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N044	Nephrotic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N045	Nephrotic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N046	Nephrotic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N047	Nephrotic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N048	Nephrotic syndrome, other	Diagnosis	ICD-10-CA
N049	Nephrotic syndrome, unspecified	Diagnosis	ICD-10-CA
N050	Unspecified nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N051	Unspecified nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N052	Unspecified nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N053	Unspecified nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N054	Unspecified nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N055	Unspecified nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N056	Unspecified nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N057	Unspecified nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N058	Unspecified nephritic syndrome, other	Diagnosis	ICD-10-CA
N059	Unspecified nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N070	Hereditary nephropathy, not elsewhere classified, minor glomerular abnormality	Diagnosis	ICD-10-CA
N071	Hereditary nephropathy, not elsewhere classified, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N072	Hereditary nephropathy, not elsewhere classified, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N073	Hereditary nephropathy, not elsewhere classified, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N074	Hereditary nephropathy, not elsewhere classified, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N075	Hereditary nephropathy, not elsewhere classified, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N076	Hereditary nephropathy, not elsewhere classified, dense deposit disease	Diagnosis	ICD-10-CA
N077	Hereditary nephropathy, not elsewhere classified, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N078	Hereditary nephropathy, not elsewhere classified, other	Diagnosis	ICD-10-CA
N079	Hereditary nephropathy, not elsewhere classified, unspecified	Diagnosis	ICD-10-CA
N080	Glomerular disorders in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N081	Glomerular disorders in neoplastic diseases	Diagnosis	ICD-10-CA
N082	Glomerular disorders in blood diseases and disorders involving the immune mechanism	Diagnosis	ICD-10-CA
N083	Glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N0831	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 1	Diagnosis	ICD-10-CA
N0832	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 2	Diagnosis	ICD-10-CA
N0833	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 3	Diagnosis	ICD-10-CA
N0834	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 4	Diagnosis	ICD-10-CA
N0835	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 5	Diagnosis	ICD-10-CA
N0838	Other glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N0839	Unspecified glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N084	Glomerular disorders in other endocrine, nutritional and metabolic diseases	Diagnosis	ICD-10-CA
N085	Glomerular disorders in systemic connective tissue disorders	Diagnosis	ICD-10-CA
N088	Glomerular disorders in other diseases classified elsewhere	Diagnosis	ICD-10-CA
N110	Nonobstructive reflux-associated chronic pyelonephritis	Diagnosis	ICD-10-CA
N111	Chronic obstructive pyelonephritis	Diagnosis	ICD-10-CA
N118	Other chronic tubulo-interstitial nephritis	Diagnosis	ICD-10-CA
N119	Chronic tubulo-interstitial nephritis, unspecified	Diagnosis	ICD-10-CA
N12	Tubulo-interstitial nephritis, not specified as acute or chronic	Diagnosis	ICD-10-CA
N130	Hydronephrosis with ureteropelvic junction obstruction	Diagnosis	ICD-10-CA
N131	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CA
N132	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CA
N133	Other and unspecified hydronephrosis	Diagnosis	ICD-10-CA
N134	Hydroureter	Diagnosis	ICD-10-CA
N135	Kinking and stricture of ureter without hydronephrosis	Diagnosis	ICD-10-CA
N136	Pyonephrosis	Diagnosis	ICD-10-CA
N137	Vesicoureteral-reflux-associated uropathy	Diagnosis	ICD-10-CA
N138	Other obstructive and reflux uropathy	Diagnosis	ICD-10-CA
N139	Obstructive and reflux uropathy, unspecified	Diagnosis	ICD-10-CA
N140	Analgesic nephropathy	Diagnosis	ICD-10-CA
N141	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CA
N142	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CA
N143	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CA
N144	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CA
N150	Balkan nephropathy	Diagnosis	ICD-10-CA
N151	Renal and perinephric abscess	Diagnosis	ICD-10-CA
N158	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CA
N159	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CA
N160	Renal tubulo-interstitial disorders in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N161	Renal tubulo-interstitial disorders in neoplastic diseases	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N162	Renal tubulo-interstitial disorders in blood diseases and disorders involving the immune mechanism	Diagnosis	ICD-10-CA
N163	Renal tubulo-interstitial disorders in metabolic diseases	Diagnosis	ICD-10-CA
N164	Renal tubulo-interstitial disorders in systemic connective tissue disorders	Diagnosis	ICD-10-CA
N165	Renal tubulo-interstitial disorders in transplant rejection	Diagnosis	ICD-10-CA
N168	Renal tubulo-interstitial disorders in other diseases classified elsewhere	Diagnosis	ICD-10-CA
N170	Acute renal failure with tubular necrosis	Diagnosis	ICD-10-CA
N171	Acute renal failure with acute cortical necrosis	Diagnosis	ICD-10-CA
N172	Acute renal failure with medullary necrosis	Diagnosis	ICD-10-CA
N178	Other acute renal failure	Diagnosis	ICD-10-CA
N179	Acute renal failure, unspecified	Diagnosis	ICD-10-CA
N180	End-stage renal disease	Diagnosis	ICD-10-CA
N181	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CA
N182	Chronic kidney disease, stage 2	Diagnosis	ICD-10-CA
N183	Chronic kidney disease, stage 3	Diagnosis	ICD-10-CA
N184	Chronic kidney disease, stage 4	Diagnosis	ICD-10-CA
N185	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CA
N188	Other chronic renal failure	Diagnosis	ICD-10-CA
N189	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CA
N19	Unspecified kidney failure	Diagnosis	ICD-10-CA
N250	Renal osteodystrophy	Diagnosis	ICD-10-CA
N251	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CA
N258	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CA
N259	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CA
N280	Ischaemia and infarction of kidney	Diagnosis	ICD-10-CA
N281	Cyst of kidney, acquired	Diagnosis	ICD-10-CA
N2880	Hypertrophy of kidney	Diagnosis	ICD-10-CA
N2881	Megaloureter	Diagnosis	ICD-10-CA
N2882	Nephroptosis	Diagnosis	ICD-10-CA
N2883	Pyelitis cystica	Diagnosis	ICD-10-CA
N2884	Pyeloureteritis cystica	Diagnosis	ICD-10-CA
N2885	Ureteritis cystica	Diagnosis	ICD-10-CA
N2888	Other specified disorders of kidney and ureter	Diagnosis	ICD-10-CA
N289	Disorder of kidney and ureter, unspecified	Diagnosis	ICD-10-CA
N290	Late syphilis of kidney	Diagnosis	ICD-10-CA
N291	Other disorders of kidney and ureter in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N298	Other disorders of kidney and ureter in other diseases classified elsewhere	Diagnosis	ICD-10-CA
588.81	Secondary Hyperparathyroidism (of renal origin)	Diagnosis	ICD-9-CM
590.8	Pyelonephritis, unspecified	Diagnosis	ICD-9-CM
590.80	Other pyelonephritis or pyonephrosis not specified as acute or chronic	Diagnosis	ICD-9-CM
590.81	Pyelitis or pyelonephritis in diseases classified elsewhere	Diagnosis	ICD-9-CM
590.9	Infection of kidney, unspecified	Diagnosis	ICD-9-CM
593.0	Nephroptosis	Diagnosis	ICD-9-CM
593.2	Cyst of kidney, acquired	Diagnosis	ICD-9-CM
593.3	Stricture or kinking of ureter	Diagnosis	ICD-9-CM
593.6	Postural proteinuria	Diagnosis	ICD-9-CM
593.82	Ureteral fistula	Diagnosis	ICD-9-CM
599.7	Hematuria	Diagnosis	ICD-9-CM
599.70	Hematuria, unspecified	Diagnosis	ICD-9-CM
599.71	Gross hematuria	Diagnosis	ICD-9-CM
Stroke			
I600	Subarachnoid haemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CA
I601	Subarachnoid haemorrhage from middle cerebral artery	Diagnosis	ICD-10-CA
I602	Subarachnoid haemorrhage from anterior communicating artery	Diagnosis	ICD-10-CA
I603	Subarachnoid haemorrhage from posterior communicating artery	Diagnosis	ICD-10-CA

Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I604	Subarachnoid haemorrhage from basilar artery	Diagnosis	ICD-10-CA
I605	Subarachnoid haemorrhage from vertebral artery	Diagnosis	ICD-10-CA
I606	Subarachnoid haemorrhage from other intracranial arteries	Diagnosis	ICD-10-CA
I607	Subarachnoid haemorrhage from intracranial artery, unspecified	Diagnosis	ICD-10-CA
I608	Other subarachnoid haemorrhage	Diagnosis	ICD-10-CA
I609	Subarachnoid haemorrhage, unspecified	Diagnosis	ICD-10-CA
I610	Intracerebral haemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CA
I611	Intracerebral haemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CA
I612	Intracerebral haemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CA
I613	Intracerebral haemorrhage in brain stem	Diagnosis	ICD-10-CA
I614	Intracerebral haemorrhage in cerebellum	Diagnosis	ICD-10-CA
I615	Intracerebral haemorrhage, intraventricular	Diagnosis	ICD-10-CA
I616	Intracerebral haemorrhage, multiple localized	Diagnosis	ICD-10-CA
I618	Other intracerebral haemorrhage	Diagnosis	ICD-10-CA
I619	Intracerebral haemorrhage, unspecified	Diagnosis	ICD-10-CA
I620	Subdural haemorrhage (acute)(nontraumatic)	Diagnosis	ICD-10-CA
I621	Nontraumatic extradural haemorrhage	Diagnosis	ICD-10-CA
I629	Intracranial haemorrhage (nontraumatic), unspecified	Diagnosis	ICD-10-CA
I630	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CA
I631	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CA
I632	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CA
I633	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CA
I634	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CA
I635	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CA
I636	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CA
I638	Other cerebral infarction	Diagnosis	ICD-10-CA
I639	Cerebral infarction, unspecified	Diagnosis	ICD-10-CA
I64	Stroke, not specified as haemorrhage or infarction	Diagnosis	ICD-10-CA
I650	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CA
I651	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CA
I652	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CA
I653	Occlusion and stenosis of multiple and bilateral precerebral arteries	Diagnosis	ICD-10-CA
I658	Occlusion and stenosis of other precerebral artery	Diagnosis	ICD-10-CA
I659	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CA
I660	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CA
I661	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CA
I662	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CA
I663	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CA
I664	Occlusion and stenosis of multiple and bilateral cerebral arteries	Diagnosis	ICD-10-CA
I668	Occlusion and stenosis of other cerebral artery	Diagnosis	ICD-10-CA
I669	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CA
I670	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CA
I671	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CA
I672	Cerebral atherosclerosis	Diagnosis	ICD-10-CA
432	Other and unspecified intracranial hemorrhage	Diagnosis	ICD-9-CM
432.0	Nontraumatic extradural hemorrhage	Diagnosis	ICD-9-CM
432.1	Subdural hemorrhage	Diagnosis	ICD-9-CM
432.9	Unspecified intracerebral hemorrhage	Diagnosis	ICD-9-CM
435	Transient cerebral ischemia	Diagnosis	ICD-9-CM
435.0	Basil artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.2	Subclavian steal syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

Query period: January 1, 2014 - December 31, 2020
Coverage requirement: Medical & drug
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Enrollment gap: 45 days
Age groups: 18-44, 45-64, 65+ years
Sex groups: Male, Female
Censor output categorization: 1-183, 184-365, 366-730, 731+ days
Stratified output: Age group
 Year*month
 Year*quarter
Envelope macro: No reclassification
Freeze data: No
Additional programming: Episodes that cross multiple quarters will be counted in each quarter
 (reuses custom programming from cder_mpl1p_wp044)

Notes: Stockpile by custom-defined generic name

		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4
Drug/Exposure	Exposure	All ARB Incident Cohort	Candesartan	Irbesartan	Losartan
		Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Candesartan	Irbesartan	Losartan
	Care Setting	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4
		All ARB Incident Cohort	Candesartan	Irbesartan	Losartan
Drug/Exposure	Incident with respect to:	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)
	Washout (days)	183 days	183 days	183 days	183 days
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	30 days	30 days	30 days	30 days
	Exposure Extension Period	30 days	30 days	30 days	30 days
	Minimum Episode Duration	1 day	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A	N/A
	Prevalent Cohort creation?	Yes	Yes	Yes	Yes

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4
		All ARB Incident Cohort	Candesartan	Irbesartan	Losartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	Yes	Yes	Yes	Yes
	Covariates	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1
		All ARB Incident Cohort	Candesartan exposure with irbesartan switch	Irbesartan exposure with candesartan switch	Losartan exposure with candesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2
Multiple Events		Candesartan exposure with losartan switch	Irbesartan exposure with losartan switch	Losartan exposure with irbesartan switch
	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3
Multiple Events		Candesartan exposure with olmesartan switch	Irbesartan exposure with olmesartan switch	Losartan exposure with olmesartan switch
	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4
Multiple Events		Candesartan exposure with telmisartan switch	Irbesartan exposure with telmisartan switch	Losartan exposure with telmisartan switch
	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5
Multiple Events		Candesartan exposure with valsartan switch	Irbesartan exposure with valsartan switch	Losartan exposure with valsartan switch
	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6
		Candesartan exposure with any ARB switch (except candesartan)	Irbesartan exposure with any ARB switch (except irbesartan)	Losartan exposure with any ARB switch (except losartan)
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7
Multiple Events		Candesartan exposure with ACEi or CCB switch	Irbesartan exposure with ACEi or CCB switch	Losartan exposure with ACEi or CCB switch
	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8
		Candesartan exposure with any ACEi switch	Irbesartan exposure with any ACEi switch	Losartan exposure with any ACEi switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9
		Candesartan exposure with any CCB switch	Irbesartan exposure with any CCB switch	Losartan exposure with any CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 5	Primary Cohort 6	Primary Cohort 7
		Olmesartan	Telmisartan	Valsartan
Drug/Exposure	Exposure	Olmesartan	Telmisartan	Valsartan
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)	Any ARB (Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan)
	Washout (days)	183 days	183 days	183 days
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	30 days	30 days	30 days
	Exposure Extension Period	30 days	30 days	30 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A
	Prevalent Cohort creation?	Yes	Yes	Yes

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Primary Cohort 5	Primary Cohort 6	Primary Cohort 7
		Olmesartan	Telmisartan	Valsartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	Yes	Yes	Yes
	Covariates	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	(-183, 0)	(-183, 0)	(-183, 0)

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 1	Multiple Events Group 1	Multiple Events Group 1
		Olmesartan exposure with candesartan switch	Telmisartan exposure with candesartan switch	Valsartan exposure with candesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 2	Multiple Events Group 2	Multiple Events Group 2
		Olmesartan exposure with irbesartan switch	Telmisartan exposure with irbesartan switch	Valsartan exposure with irbesartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 3	Multiple Events Group 3	Multiple Events Group 3
		Olmesartan exposure with losartan switch	Telmisartan exposure with losartan switch	Valsartan exposure with losartan switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 4	Multiple Events Group 4	Multiple Events Group 4
		Olmesartan exposure with telmisartan switch	Telmisartan exposure with olmesartan switch	Valsartan exposure with olmesartan switch
		(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
		First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
		N/A	N/A	N/A
		N/A	N/A	N/A
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 5	Multiple Events Group 5	Multiple Events Group 5
		Olmesartan exposure with valsartan switch	Telmisartan exposure with valsartan switch	Valsartan exposure with telmisartan switch
		(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
Multiple Events	Observation window around primary episode			
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 6	Multiple Events Group 6	Multiple Events Group 6
		Olmesartan exposure with any ARB switch (except olmesartan)	Telmisartan exposure with any ARB switch (except telmisartan)	Valsartan exposure with any ARB switch (except valsartan)
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 7	Multiple Events Group 7	Multiple Events Group 7
		Olmesartan exposure with ACEi or CCB switch	Telmisartan exposure with ACEi or CCB switch	Valsartan exposure with ACEi or CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 8	Multiple Events Group 8	Multiple Events Group 8
		Olmesartan exposure with any ACEi switch	Telmisartan exposure with any ACEi switch	Valsartan exposure with any ACEi switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix E. Specifications Defining Parameters for this Request (Incident and Prevalent Cohorts) (Continued)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Multiple Events Group 9	Multiple Events Group 9	Multiple Events Group 9
		Olmesartan exposure with any CCB switch	Telmisartan exposure with any CCB switch	Valsartan exposure with any CCB switch
Multiple Events	Observation window around primary episode	(episode start, episode end)	(episode start, episode end)	(episode start, episode end)
	Secondary episode to use for time metrics	First occurrence of secondary episode	First occurrence of secondary episode	First occurrence of secondary episode
	Minimum cutoff to be considered adherent	N/A	N/A	N/A
	Categories for length of primary episode	N/A	N/A	N/A

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Secondary Cohort 1	Secondary Cohort 2	Secondary Cohort 3	Secondary Cohort 4
		Azilsartan	Candesartan	Eprosartan	Irbesartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No	No
	Covariates	N/A	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A	N/A

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

This request estimates the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Secondary Cohort 5	Secondary Cohort 6	Secondary Cohort 7	Secondary Cohort 8
		Losartan	Olmesartan	Telmisartan	Valsartan
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No	No
	Covariates	N/A	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A	N/A

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 10.1.1, to estimate the proportion of individual angiotensin receptor blocker (ARB)-containing product use and the proportion of patients who switched from a primary ARB to another individual ARB over time.

		Secondary Cohort 9	Secondary Cohort 10	Secondary Cohort 11
		ACE inhibitors	CCB	Combinations
Drug/Exposure	Exposure	Angiotensin-converting-enzyme inhibitors (ACEi) (forced days supply of 1 day)	Calcium channel blockers (CCB) (forced days supply of 1 day)	ACEi/CCB combination drugs (forced days supply of 1 day)
	Care Setting	N/A	N/A	N/A
	Incident with respect to:	N/A	N/A	N/A
	Washout (days)	N/A	N/A	N/A
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	0 days	0 days	0 days
	Exposure Extension Period	0 days	0 days	0 days
	Minimum Episode Duration	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day
	Intention-to-Treat Days	N/A	N/A	N/A
	Prevalent Cohort creation?	No	No	No

Appendix F. Specifications Defining Parameters for this Request (Cohorts used to Define Switches)

		Secondary Cohort 9	Secondary Cohort 10	Secondary Cohort 11
		ACE inhibitors	CCB	Combinations
Stockpiling	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap
Baseline Covariates	Output Baseline Table?	No	No	No
	Covariates	N/A	N/A	N/A
	Care Setting/PDX	N/A	N/A	N/A
	Covariate evaluation window (days)	N/A	N/A	N/A